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 Bovine viral diarrhea virus (BVDV) and bovine respiratory syncytial virus 
(BRSV) infections contribute to the bovine respiratory disease complex (BRDC), which 
is a multi-factorial disorder involving co-infections of viruses and bacteria including 
mycoplasma. BRDC causes great economic losses to the United States feedlot industry. 
BVDV infection induces immunosuppression in infected animals. BVDV Npro binds and 
degrades the transcription factor interferon regulatory factor-3 (IRF-3) and effectively 
blocks type I interferon (type I IFN) expression in host cells. BRSV nonstructural 
proteins, NS1 and NS2, block activation of IRF-3. In calves, concurrent infection with 
BVDV and BRSV resulted in more severe clinical signs of disease and extensive lung 
lesions than infection with either virus alone. The objective of this study was to extend 
the understanding of the role of the Npro of noncytopathic BVDV-2 (pestivirus B) on type 
I IFN pathway signaling in bovine turbinate (BT) cells during single and co-infection 
with BRSV. 
Based on real-time quantitative-reverse transcription-polymerase chain reaction, 
the BVDV-2 mutant with dysfunctional Npro (BVDV2-E) significantly up-regulated 
protein kinase R (PKR), TANK-Binding Kinase 1, IRF-3, IRF-7, and interferon-β (IFN-
β) mRNAs compared to BVDV-2 wild-type (BVDV2-wt) and BRSV in single and co-
infected BT cells. BRSV-infected cells expressed significantly up-regulated PKR, IRF-3, 
 
 
IRF-7, and IFN-β mRNAs, whereas BVDV2-wt, but not BVDV2-E, abolished this up-
regulation in co-infection. No significant differences were observed in mitochondrial 
antiviral signaling, Nuclear Factor-κB (NF-κB), and NIMA-Interacting 1 mRNAs. A 
dual-luciferase reporter assay showed that BVDV2-wt significantly increased NF-κB 
activity compared to BVDV2-E, while BVDV2-E significantly increased IFN-β activity 
compared to BVDV2-wt. BT cells infected with BVDV2-E produced more IRF-3 protein 
compared to cells infected with BRSV or BVDV2-wt. The BRSV titer and RNA levels 
significantly increased in cells co-infected with BRSV/BVDV2-wt compared to cells co-
infected with BRSV/BVDV2-E or infected with BRSV alone. BVDV2-E single and co-
infected cells synthesized type I IFN significantly higher than BVDV2-wt single and co-
infected BT cells. These findings are useful in defining the role of the intact BVDV-2 
Npro on type I IFN pathway signaling and support the understanding of the mechanism 
underlying the synergistic action of BVDV2-wt and BRSV inhibition of type I IFN. The 
inhibition of BRSV-induced signals by BVDV augments BRSV infection.
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INTRODUCTION 
Bovine viral diarrhea virus (BVDV) is a significant pathogen of cattle worldwide 
and an endemic virus in North America causing continuous economic losses to the cattle 
industry primarily due to decreased reproductive performance. BVDV infections are 
associated with gastrointestinal, respiratory, and reproductive diseases and because of its 
ability to cross the placenta during early pregnancy, it can result in the birth of 
persistently infected (PI) calves. BVDV Npro prevents the production of type I interferon 
α/β (type I IFN) by suppressing levels of interferon regulatory factor-3 (IRF-3) to avoid 
host antiviral responses (Hilton et al., 2006; Horscroft et al., 2005). Bovine respiratory 
syncytial virus (BRSV) is the major cause of pneumonia in calves, especially during the 
first year of life but reinfection can occur at any age. Nonstructural proteins, NS1 and 
NS2, of BRSV block activation of IRF-3. 
BVDV and BRSV infections contribute to the bovine respiratory disease complex 
(BRDC), which has a major negative impact on animal well-being. Concurrent infection 
with BVDV and BRSV in cattle causes more severe respiratory tract disease compared to 
single infection with either virus alone (Brodersen and Kelling, 1998). Type I IFN 
activates many genes that transcribe new proteins that inhibit virus replication. Viruses 
can interfere with components of the type I IFN induction and signaling pathway to 
subvert the innate immune system. We recently determined that enhancement of BRSV 
replication by BVDV co-infection was associated with BVDV Npro antagonism of type I 
IFN production (Alkheraif et al., 2017).  
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Type I IFN induction is mediated by IFN regulatory factors that are transmitted 
via a pathway dependent upon intracellular receptors known as retinoic acid-inducible 
gene (RIG)-like receptors (RLR), located in the cell cytoplasm. These receptors bind viral 
dsRNA resulting in activation of type I IFN induction cell signals, including 
mitochondrial antiviral signaling (MAVS), TANK-Binding Kinase 1 (TBK-1), protein 
kinase R (PKR), interferon regulatory factor-3 (IRF-3), IRF-7, and Nuclear Factor-κB 
(NF-κB). These signals activate transcription and play key roles among numerous adaptor 
molecules in complex pathways that culminate in the production of type I IFN (Peterhans 
and Schweizer, 2013). The interaction of viral dsRNA and RLRs induces interaction with 
their adaptor protein, MAVS, activating TBK-1, which induces the phosphorylation of 
IRF-3 and IRF-7. Homodimers and heterodimers of IRF-3/7 translocate to the nucleus to 
activate the transcription of type I IFN genes. 
The effects of BVDV Npro on type I IFN pathway signaling in cells infected with 
BVDV or co-infected with BVDV and another viral pathogen, such as BRSV, has not 
been previously studied. In this study, we hypothesized that BVDV-2 Npro enhances 
virulence and modulates host cell innate immune responses which augment BRSV 
replication during co-infection with BVDV. Our main objectives were: 
1. To characterize the effects of BVDV Npro on type I IFN induction cell signals in 
IFN antagonism during BVDV infections. These cell signals include MAVS, PKR, 
TBK-1, IRF-3, IRF-7, IFN, NF-κB and NIMA-Interacting 1 (PIN-1). 
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2. To identify BVDV immunomodulatory proteins and host cell responses which are 
important to increased virulence of BRSV and the effects of BVDV Npro on type I 
IFN cell signaling in IFN antagonism and enhancement of BRSV replication 
during co-infections with BVDV. 
To elucidate the BRSV effects and the role of BVDV Npro on these type I IFN 
induction cell signals and the mechanisms by which BVDV infection enhances the effects 
of BRSV infection, we propose to characterize type I IFN pathway signaling in bovine 
turbinate (BT) cells infected with BRSV, BVDV-2 wild-type (BVDV2-wt), or BVDV-2 
mutant with dysfunctional Npro (BVDV2-E) or co-infected with BRSV/BVDV2-wt or 
BRSV/BVDV2-E. To evaluate the mRNA levels of the cell signals, total RNA was 
extracted from these infected and co-infected BT cells and real-time quantitative-reverse 
transcription-polymerase chain reaction (Q-RT-PCR) was performed. The results were 
normalized against two reference genes, glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and bovine ribosomal protein S18 (RPS18). IFN-β and NF-kB activities were 
determined using a Dual-luciferase reporter assay. Synthesized type I IFN and IRF-3 
protein production were evaluated. 
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CHAPTER 1: 
LITERATURE REVIEW 
Bovine Viral Diarrhea Virus (BVDV) 
Bovine viral diarrhea virus (BVDV) is a member of the genus Pestivirus within 
the family Flaviviridae. The genus Pestivirus also includes classical swine fever virus 
(CSFV, pestivirus C) and border disease virus (pestivirus D) of sheep (Simmonds et al., 
2017; Smith et al., 2017; Wengler, 1991). BVDV is commonly associated with cattle, but 
infection has also been reported in pigs (Liess and Moennig, 1990; Løken, 1995), deer 
(Frölich and Hofmann, 1995; Raizman et al., 2009), other domesticated and exotic 
ungulates including sheep (Løken, 1995; Silveira et al., 2018), and new world camelids 
(Belknap et al., 2000), such as alpacas (Topliff et al., 2009). BVDV was first identified in 
New York State from cattle with gastroenteritis, diarrhea, and abortion (Olafson et al., 
1946). BVDV infection is endemic and causes economic loss. In BVDV infected herds, 
60-85% of the cattle are antibody positive and 1-2% of the cattle are persistently-infected 
(PI). Persistently-infected animals are the common source of the virus and spread the 
virus by direct contact to other susceptible animals (Houe, 1999). Estimates of economic 
losses due to BVDV vary depending on the immune status of the animal and the 
virulence of the infecting virus strains. Annual losses due to BVDV are estimated at $20 
per calving due to a low-virulent BVDV strain with an estimated annual incidence of 
acute infections of 34%. Annual losses are estimated at $75 per calving due to a high-
virulent BVDV strain at the same incidence of infection (Houe, 1999). BVDV infection 
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in dairies decreases milk production, reproductive performance and growth while 
increasing occurrence of other diseases and mortality among calves. At the national level, 
it is estimated that the losses in dairies due to BVDV infection range between $10 and 
$40 per calving (Houe, 2003). The mortality rates associated with infectious disease are 
significantly higher in feedlot cattle positive for BVDV-1 (Booker et al., 2008).  
BVDV Types and Genome 
BVDV isolates belong to one of two species, pestivirus A (bovine viral diarrhea 
virus 1, BVDV-1) or pestivirus B (BVDV-2), within the genus Pestivirus. Within each 
BVDV species, there are two biotypes, cytopathic (cp) and noncytopathic (ncp), based on 
their effects in cell culture (Mendez et al., 1998). The genus Pestivirus has four species, 
pestivirus A, B, C, and D, but it has been recently proposed to create seven new species 
in addition to the current four species. The new designation includes pestivirus E, F, G, 
H, I, J, and K (Smith et al., 2017). There are currently more than thirty BVDV genomes 
that have been completely sequenced. Recently in Italy, Colitti et al., 2018 sequenced the 
complete genome of ncp BVDV-2 strain CN10.2015.821, which was isolated from a PI 
calf (Colitti et al., 2018). BVDV species are designated based on sequence differences of 
the 5’ untranslated region (UTR). Antigenic and pathological differences exist between 
BVDV-1 and BVDV-2 species (Ridpath et al., 1994). Monoclonal antibodies specific for 
BVDV-2 demonstrated no or weak cross-reaction with BVDV-1 (Deregt et al., 1998). In 
the 5’ UTR, two nucleotide substitutions were identified distinguishing between eight 
isolates of low and high virulence BVDV-2. A cytosine at position 219 and a uracil at 
position 278 was present in the low virulence isolates, while the opposite was observed in 
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the high virulence isolates (Topliff and Kelling, 1998). Cp strains of BVDV induce 
apoptosis of cells in vitro, whereas ncp strains do not (Hoff and Donis, 1997; Yamane et 
al., 2006). Viral proteins of ncp BVDV protect cells from induction of apoptosis by other 
factors, such as synthetic molecules or other viral infections. Ncp BVDV strains decrease 
type I interferon (type I IFN) in vitro more effectively than cp strains (Schweizer and 
Peterhans, 2001). Unlike cp BVDV strains, ncp BVDV strains may cause persistent 
infection in calves that get infected early in gestation. These PI calves will be 
immunotolerant and shed virus throughout their lifetime (Bolin et al., 1990).  
BVDV has a single-stranded, positive-sense RNA genome of approximately 12.5 
kilobases (kb). It consists of a large open reading frame (ORF) with a UTR on both the 5’ 
and 3’ ends (Ridpath and Bolin, 1995). The BVDV viral proteins from 5’ to 3’ are: Npro – 
C – Erns – E1 – E2 – P7 – NS2 – NS3 – NS4A – NS4B – NS5A – NS5B (Collett et al., 
1991; Tautz et al., 2015). The BVDV genome encodes four structural (C, Erns, E1, and 
E2) and eight non-structural (Npro, P7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) 
proteins (Collett et al., 1988; Donis et al., 1988; Meyers and Thiel, 1996; Thiel et al., 
1991). The main differences in genomic organization between ncp and cp BVDV are 
rearrangements in the NS2/NS3 region of the genome. By a variety of mechanisms, such 
as cellular RNA insertions, cp BVDV arises by RNA recombination of ncp BVDV (Qi et 
al., 1992; Ridpath and Bolin, 1995; Tautz et al., 1994). Unlike in cp BVDV, the 
NS2/NS3 region is not cleaved in ncp BVDV (Greiser-Wilke et al., 1992). The soluble 
form of the envelope glycoprotein Erns of pestivirus degrades immunostimulatory viral 
single- and double-stranded RNA and inhibits ss- and dsRNA-induced type I IFN 
synthesis (Lussi and Schweizer, 2016). 
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Npro of BVDV and Host Interferon 
 The autoprotease, Npro, is a NS protein that has proteolytic properties and cleaves 
itself from the capsid protein between Cys168 and Ser169 of the polyprotein (Stark et al., 
1993). Only pestiviruses within the family Flaviviridae have a NS protein at the N-
terminus of the polyprotein. The essential amino acids for the proteolytic activity of Npro 
are Cys69, His49, and Glu22 (Rumenapf et al., 1998). Viruses can be attenuated by deleting 
or mutating the Npro (Tratschin et al., 1998). The growth kinetics of a BVDV chimeric 
virus in which the Npro region was replaced with the hepatitis C virus (genus Hepacivirus 
in the family Flaviviridae) NS3 gene, resulting in the Npro enzymatic activity with a 
serine protease, were similar to the wild-type BVDV. However, the growth kinetics and 
replication of an Npro-null BVDV virus (entire Npro region deleted) were much lower than 
the wild-type BVDV, but still viable (Lai et al., 2000). A ncp BVDV, attenuated by 
deleting Npro, showed reduced virulence in experimentally infected calves compared to 
wild-type BVDV, however, no difference in type I IFN induction was observed 
(Henningson et al., 2009).  
Interferons (IFNs), inducible cytokines, are a major component of innate 
immunity and a bridge between innate and adaptive immunity. They are produced by 
almost every type of nucleated cell, especially immunological cells including B and T 
cells. There are three types of IFNs classified as type I, including subtypes α and β, type 
II, including subtype γ, and type III, including subtype λ. Type I IFN is the innate 
immune response to viral infection or dsRNA exposure of cells and activates cellular 
factors to degrade viral RNA and shut down viral mRNA synthesis (Bautista et al., 2005; 
Castelli et al., 1997). Type I IFN has control effects on viral infection through its action 
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on cells to assist in the production and activation of constitutively expressed cellular 
protein kinase R (PKR) (Clemens and Elia, 1997; Wang et al., 2003). In addition, type I 
IFN controls some cellular functions such as inducing dendritic cell (DC) differentiation 
and stimulating proliferation and class switching of B cells (Jego et al., 2003; Litinskiy et 
al., 2002; Paquette et al., 2002; Tough, 2004). Type I IFN also stimulates the motility, 
differentiation, and cross-priming of T cells, enhances the cytotoxicity of natural killer 
(NK) cells, stimulates the production of inflammatory cytokines or nitric oxide, and 
affects the capacity of type II IFN to activate phagocytes (Biron, 2001; Bogdan, 2000; 
Foster et al., 2004; García-Sastre and Biron, 2006; Le Bon et al., 2003; Rogge et al., 
1998; Sato et al., 2001). DC, NK, and T helper1 (Th1) cells produce type II IFN. Unlike 
type I IFN, type II IFN is not directly inducible by viral infection (Munder et al., 1998). 
The first characterization of type III IFN (IFN-λ) was in 2002 with similar activity to, but 
independent of, type I IFN. In several human cell lines and tissues, type III IFN RNA, 
like type I IFN RNA, was inducible by viral infection (Kotenko et al., 2003). Type III 
IFN also has antiviral activity in viral infected animals preventing them from sickness 
and weight loss (Bartlett et al., 2005).  
In both BVDV and CSFV, the amino-terminal cysteine protease, Npro, prevents 
the production of type I IFN by suppressing levels of interferon regulatory factor-3 (IRF-
3) to avoid host antiviral responses (Horscroft et al., 2005). Even though IRF-3 can be 
relocated from the cytoplasm to the nucleus in BVDV-infected cells, Npro blocks IRF-3 
protein binding to DNA and directs the degradation of the protein IRF-3 by proteasomes, 
but not IRF-3 mRNA. The autoprotease activity of Npro is not required for IFN inhibition 
(Hilton et al., 2006; Seago et al., 2007). Infection of cells with ncp BVDV having a 
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functional Npro interferes with type I IFN production in vitro, while in vivo BVDV 
induces a sustained IFN (alpha, beta, and gamma) production in postnatal animals 
(Charleston et al., 2002). 
Many studies have evaluated the role of Npro on evasion of the innate immune 
response of host cells infected with CSFV or BVDV. Host cells produce type I IFN in 
response to viral infection, and macrophages are important IFN producers (Roberts et al., 
1979). Studies using polyinosinic-polycytidylic acid (poly I:C), a synthetic dsRNA that 
induces IFN, have shown a novel function of Npro against the cellular innate immune 
system. Wild-type CSFV protects macrophages and the porcine kidney cells, PK-15, 
stimulated with poly I:C from poly I:C-induced apoptosis and prevents poly I:C-induced 
type I IFN production; in contrast, Npro-deleted mutants did not (Ruggli et al., 2003). 
Preventing type I IFN production requires the presence of BVDV Npro in cell culture. 
Infection of DCs, a major link between innate and adaptive immunity, with cp and ncp 
Npro-deleted CSFV mutants resulted in increased type I IFN production and DC 
maturation with decreased replication of these mutants (Bauhofer et al., 2005). In 
macrophages, monocytes, DCs, and calf testicle cells in vitro, type I IFN production was 
induced in cp BVDV infection; however, in ncp BVDV infection, type I IFN was 
suppressed (Adler et al., 1997; Baigent et al., 2002; Glew et al., 2003; Perler et al., 
2000). Other studies have reported that in infected cells, BVDV Npro prevented IFN-β 
mRNA production (Chen et al., 2007; Hilton et al., 2006). In pregnant cows, 
experimentally infected with ncp BVDV-2 at gestation day 75, type I IFN was increased 
and virus was cleared in approximately two weeks; however, fetuses were persistently 
infected (Smirnova et al., 2008). By antagonism of type I INF, Npro of BVDV plays a role 
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in evasion of the innate immune response. The N-terminal region of Npro is necessary for 
this antagonism. Abolition of the ability of Npro to suppress production of IFN was 
achieved by substituting amino acids E22 and H49. A mutant BVDV-1 strain NADL with 
modified Npro fused with enhanced green fluorescent protein (EGFP) showed reduced 
antagonism of type I IFN synthesis indicating that the structural integrity of the BVDV 
Npro amino terminus was important for type I IFN suppression, but not the enzymatic 
activity of the protein (Gil et al., 2006a; Alkheraif et al., 2017).  
BVDV and Innate Immunity 
Innate immunity is the first line of the host's immune system defying viral 
infection. Recombinant type I IFN inhibited CSFV replication in multiple cell lines (Xia 
et al., 2005). Viruses, intracellular pathogens, have developed mechanisms to avoid the 
innate immunity and allow virus propagation and survival. BVDV double-stranded RNA 
(dsRNA) is a trigger of the innate immune response. Cp and ncp BVDV strains have 
different effects on the cell pathways of apoptosis and type I IFN production. Cp BVDV 
produces large amounts of dsRNA during viral replication in vitro, which stimulates 
activation of transcriptional factors and increases type I IFN production, while ncp 
BVDV does not (Alexopoulou et al., 2001; Gil and Esteban, 2000; Yamane et al., 2006). 
BVDV infection in alpaca testicular (AT) cells resulted in a 3 – 4 log TCID50 decrease in 
infectivity compared to bovine cells. The limited permissiveness of BVDV infection in 
AT cells may be a result of greater type I IFN expression in the AT cells inhibiting 
replication. BVDV-1 infected alpaca cells synthesized greater levels of type I IFN 
following poly I:C stimulation compared to bovine cells (Samson et al., 2011). In 
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experimentally infected pregnant heifers, ncp BVDV-2 induces IFN-gamma (IFN-γ) 
secretion during acute infection in fetuses while the BVDV RNA concentrations were 
decreased in PI fetal blood and tissues (Smirnova et al., 2014). Between two and three 
weeks post maternal inoculation, IFN-γ mRNA was significantly elevated in fetal 
lymphatic tissues. Ncp BVDV titer in infected fetuses was reduced by the induction of 
type I IFN and IFN-γ (Hansen et al., 2015).  
Ncp BVDV prevents apoptosis to ensure its intracellular survival, while cp 
BVDV induces apoptosis to insure its spread (Grummer et al., 1998; Hoff and Donis, 
1997; Lambot et al., 1998; Schweizer and Peterhans, 1999; Zhang et al., 1996). During 
cp BVDV infection, the major population of cells undergoing apoptosis is monocytes 
(Lambot et al., 1998). NS3 protein of cp BVDV plays a role in induction of apoptosis 
initiated by caspase-8 activation (St-Louis et al., 2005). The NS3 protein of cp BVDV is 
present in its uncleaved form, NS23, in ncp BVDV. In cells stimulated with poly I:C, a 
potent inducer of apoptosis, ncp BVDV proteins were necessary to protect cells from 
apoptosis (Schweizer and Peterhans, 2001). A study examining the role of BVDV dsRNA 
showed that ncp BVDV suppressed apoptosis by inhibiting two dsRNA reactive cellular 
factors, dsRNA-dependent protein kinase R (PKR) and 2',5'-oligoadenylate synthetase 1 
(OAS 1). PKR regulates RNA translation in the cell by inactivating the RNA translation 
factor, eIF2, through phosphorylation (Chawla-Sarkar et al., 2003; Yamane et al., 2006). 
In cp BVDV infection in vitro, initiation of apoptosis was correlated with the inhibition 
of the anti-apoptotic Bcl-2 protein, induction of the expression of caspase-12, and a 
decrease in intracellular glutathione levels (Jordan et al., 2002). Ncp BVDV upregulates 
Bcl-2 anti-apoptosis protein and TNF-α (Bendfeldt et al., 2003; Yamane et al., 2005).  
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Cp BVDV-1 significantly up-regulated the radiation-inducible immediate-early 
response protein (IER3) and A20 (TNFAIP3), which may lead to blocking the NF-κB 
pathway. This possible blocking of NF-κB signaling pathway could partly explain the 
immunosuppression observed in cattle during BVDV infection (Villalba et al., 2016). 
Prostaglandin A1 (PGA1) is capable of blocking the replication of CSFV and a wide 
variety of RNA and DNA viruses. A recent study reported that PGA1 in MDBK cells 
inhibits the replication of BVDV. PGA1 activity is attributed to the induction of heat 
shock proteins, HSP-70, and a mechanism targeting the small ribosomal subunit (40S) 
and the eukaryotic initiation factors eIF3s (Caldas et al., 2018; Tsukimoto et al., 2015). 
In enteric infection of neonatal calves, BVDV had direct and indirect roles. Host 
immunosuppression caused by BVDV enhances other infections. Calves with concurrent 
infection with BVDV and bovine rotavirus (BRV) had more severe enteric infection 
(villus atrophy and submucosal inflammation) than calves infected with either virus alone 
(Kelling et al., 2002a). 
BVDV Infections 
 BVDV infections range from subclinical to highly fatal clinical forms, which 
depend on host immune status, pregnancy status, fetal gestational age, and the influence 
of concurrent environmental stress factors. BVDV can cause a variety of syndromes 
including subclinical infections, clinical BVDV with enteric or respiratory disease, 
hemorrhagic syndrome, reproductive failure, congenital defects, persistent infection, and 
mucosal disease (Ames, 1986; Baker, 1995; Brownlie, 1990a; Brownlie, 1990b). 
Ruminant fetuses (calves and lambs) are very susceptible to transplacental BVDV 
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infection since they are agammaglobulinemic, immunologically immature, and have 
many immature organ systems with undifferentiated cells. BVDV can cause early 
embryonic death, abortion, stillbirth, malformation, congenital defects in the central 
nervous and ocular systems of fetuses, immunotolerance, and birth of seropositive 
animals (Done et al., 1980; Kirkbride, 1992). Newborn calves and lambs can have low 
birth weights, may be weak, persistently viremic, and immunologically tolerant following 
exposure of the dam with ncp BVDV during gestation (Done et al., 1980; Hewicker-
Trautwein and Trautwein, 1994; Osburn and Castrucci, 1991). 
Approximately 70-90% of BVDV infections are subclinical (Ames, 1986). 
Subclinically-infected dairy cows may exhibit a decrease in milk yield with more severe 
respiratory disease in their calves (Moerman et al., 1994). During acute experimental 
clinical infection with BVDV-1, calves developed leukopenia, high fever, increased 
respiratory rates, viremia, and infection of the thymus (Kelling et al., 2005). Calves 
acutely infected with BVDV developed mild clinical signs, including varying degrees of 
fever and anorexia, and lymphoid depletion in Peyer’s patch. BVDV and its specific 
antigen were detected with high concentrations in the thymus, Peyer’s patch, mesenteric 
lymph node, and the bone marrow. Platelet counts were significantly reduced and may 
result in thrombocytopenia during infection (Marshall et al., 1996). 
Hemorrhagic syndrome is due to infections with high virulence ncp BVDV-2 
isolates. The syndrome is characterized by thrombocytopenia, hemorrhage, leukopenia, 
fever, diarrhea, and death (Carman et al., 1998; Kelling et al., 2002b; Pellerin et al., 
1994; Ridpath et al., 1994). Common clinical findings include: diarrhea with blood and 
mucous, fever, anorexia, depression, dyspnea, and continued bleeding form injection 
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sites. Pathologically, findings may include leukopenia, and thrombocytopenia, but this is 
not consistently observed in every study (Kelling et al., 2002b; Stoffregen et al., 2000). 
Changes in platelet function were seen in animals infected with BVDV-1 and BVDV-2, 
and the platelet percentage, especially with BVDV-2, was decreased over time up to 12 
DPI. Altered platelet function may be an important contributing factor for the 
hemorrhagic syndrome and for the increased virulence of some BVDV-2 isolates (Walz 
et al., 2001). 
Persistent Infection (PI) 
 Ncp BVDV strains can cross the placenta from the pregnant dam to the fetus 
(Fredriksen et al., 1999; Harding et al., 2002). Usually the fetus, infected in utero 
between 42-114 days of gestation, recognizes the viral antigens as a part of its immune 
system, and becomes persistently-infected and immunotolerant (Malmquist, 1968; 
McClurkin et al., 1984) specifically to that BVDV strain, but immunocompetent to other 
heterologous BVDV strains (Bolin et al., 1985a; Steck et al., 1980). At day 97 of 
gestation, the IFN-γ concentrations increased at the peak of viremia in the PI fetus 
(Hansen et al., 2015). PI calves are important BVDV reservoirs in the environment and 
shed BVDV lifelong, infecting healthy animals (Houe, 1995). In one recent clinical 
study, however, it was demonstrated that BVDV-1 transmission from PI neonate lamb to 
naïve sheep and cattle is limited (Evans et al., 2018). Fetal PI was identified in 0.5% of 
calves in two dairy herds (Muñoz-Zanzi et al., 2003) and 0.3% in feedlot herds 
(Loneragan et al., 2005). In recent years, it has become evident that evasion of the innate 
immune response is essential to induce and maintain persistent infection (Lussi and 
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Schweizer, 2016). PI animals often show no lesions (Liebler-Tenorio et al., 2004) and 
may not be distinguishable from other healthy calves. Some PI animals have increased 
secondary infections, growth retardation (Barber et al., 1985; Stokstad and Løken, 2002) 
and increased mortality rates particularly in the first year of life (Duffell and Harkness, 
1985; Houe, 1993). A wide spectrum of pathologic lesions in epithelial and non-epithelial 
cells may be caused by PI BVDV infections. Histopathological lesions are often rare, but 
may be seen in the kidneys, hepatic portal triads, lymphatic nodes, and mammary gland. 
PI calves also may display an abnormal hair coat and have shallow erosions, ulcers, and 
hemorrhage in the gastrointestinal tract. Oral and abomasal ulcers in cattle with PI have 
been reported (Bielefeldt-Ohmann, 1995; Shin and Acland, 2001). However, the 
architecture of lymphoid tissues and number of lymphoid cells are normal (Bielefeldt-
Ohmann, 1988). BVDV infects many cell types of most organ systems including neural, 
epithelial, and lymphoid tissues (Bielefeldt-Ohmann, 1987; Hewicker et al., 1990). In PI 
lymphoid cells, BVDV is detected in monocytes and T cells, but not in B cells (Lopez et 
al., 1993). In the central nervous system of PI calves, BVDV has been found in the 
thalamic nuclei, hippocampus, entorhinal cortex, basal nuclei, and piriform cortex 
(Montgomery, 2007). BVDV has also been detected in the epithelial and non-epithelial 
cells of the gastrointestinal tract, liver, pancreas, spleen, lymph nodes, lung, kidney, 
adrenal gland, thymus, mammary glands, macrophages, ovary, uterus, placenta, fetal 
fluids, and semen (Bielefeldt-Ohmann, 1983; Confer et al., 2005; Niskanen et al., 2002; 
Shin and Acland, 2001).  
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Mucosal Disease (MD) 
Recombination events between ncp and cp BVDV strains can generate new cp 
BVDV strains within PI animals (Becher et al., 1999; Becher et al., 2001; Bolin, 1995b; 
Ridpath and Bolin, 1995). These new cp BVDV strains superinfect PI animals causing a 
fatal disease called mucosal disease (MD). Clinical signs of MD include: fever, 
depression, anorexia, mucous nasal discharge, hemorrhage, weakness, elevated heart and 
respiratory rates, lesions in the mucosa of the digestive tract, and death (Bolin et al., 
1985b; Brownlie et al., 1984; Dabak et al., 2007). Even though MD can be seen in 
animals of all ages, it is commonly seen between 6 months and two years (Bolin, 1995b). 
There are early onset and late onset MDs, depending on the duration between 
superinfection and the development of MD. If the cp BVDV isolate is closely related to 
the ncp BVDV isolate present in the PI animal, infection with the cp isolate will result in 
a rapid, early onset MD, which can occur within two weeks post inoculation (Moennig et 
al., 1990). On the other hand, if there is less antigenic homology between ncp and cp 
isolates, a recombination event between them must occur to develop a late onset MD, 
which can occur months post inoculation (Fritzeneier et al., 1995; 1997). There are minor 
pathological differences between the two forms of MD. Vascular lesions have been 
observed in late onset MD, but were absent in early onset MD. Histological lesions are 
similar in both forms of MD, but are different in distribution. Severe depletion of Peyer’s 
patches has been observed in both courses, with a complete loss of lymphoid architecture 
in late onset MD only (Liebler-Tenorio et al., 2000).  
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BVDV Transmission and Control 
PI animals are immunotolerant to BVDV and harbor BVDV throughout their life. 
The main source of BVDV infection in herds are PI animals that shed virus in the 
environment and transmit it to healthy animals by direct contact; however, acutely 
infected animals also secrete and transmit virus, but only for a short period of time. Also, 
other species of animals infected with BVDV can transmit virus. Transmission by 
indirect contact may happen through the use of contaminated equipment, such as needles 
and gloves (Fulton et al., 2005; Houe, 1999). BVDV transmission can also occur through 
insemination with BVDV infected semen that has normal quality. Seronegative dams 
inseminated with semen from PI bulls results in poor rates of conception and may result 
in PI calves (Givens et al., 2003; Kirkland et al., 1994; Niskanen et al., 2002; Paton et 
al., 1990). Furthermore, the exchange of embryos, gametes, semen, and somatic cells 
may provide an unnatural way to transmit BVDV between herds of cattle over the world 
(Gard et al., 2007). 
Identification and elimination of PI animals and vaccination are important to 
prevent BVDV infections (Moennig et al., 2005). Quarantine of new animals and testing 
them for BVDV PI status before accepting them is very important to maintain a BVDV-
free closed herd (Brock, 2004; Kelling et al., 2000). Modified live and inactivated 
vaccines are widely used and because of the antigenic variability, contain BVDV-1 and 
BVDV-2 strains (Beer et al., 1997; Bolin, 1995a). The timing of BVDV vaccination 
depends on factors that include: immune response, crossreactivity, fetal protection, 
immunosuppression, duration of immunity, reversion to virulence, effect of maternal 
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antibody on immune responses and purity. There is no single BVDV vaccine that 
provides complete fetal protection (Kelling, 2004). 
Several methods are used to diagnose BVDV infections or to confirm vaccine 
efficacy in live animals or to identify contamination in biological products. These tests 
include: reverse transcription-polymerase chain reaction (RT-PCR), antigen detection by 
fluorescent antibody (FA) testing, enzyme-linked immunosorbent assay (ELISA), antigen 
capture ELISA (ACE), immunohistochemistry (IHC), and virus isolation (VI). Virus 
isolation is considered the best for BVDV diagnosis (Saliki and Dubovi, 2004; Sandvik, 
2005). Real-time PCR and RT-PCR are used to detect BVDV and for taxonomy (Ridpath 
and Bolin, 1998). IHC and ACE rarely miss a PI animal. They detected nearly 100% of 
PI calves. Since the tests sometimes were positive for acute infections, virus isolation or 
RT-PCR is recommended 30 days after the initial test to confirm PI infections (Cornish et 
al., 2005). A study evaluating the diagnostic proficiency of methods for the detection of 
BVDV in infected cattle using comparisons among tests and laboratories determined that 
the test that provided the greatest consistency in detecting positive animals is ACE. It 
also has a very good agreement among diagnostic laboratories (Edmondson et al., 2007). 
Antiviral targeting of virus envelope proteins is an effective strategy against viral 
infections. A multiwell antibody ELISA based on the recombinant E2 protein of BVDV 
species was developed and evaluated (Nogarol et al., 2017). In a study, chickens were 
immunized with the BVDV structural protein E2. IgY antibodies against the BVDV-E2 
protein were extracted from egg yolk and used in IgY-based ELISA and immuno-
chromatographic assays (ICA) (Zhang et al., 2016). Recent in vitro studies identified 
BVDV inhibitors using structure-based virtual screening on the BVDV structural protein 
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E2. One drug that was designed for BVDV-E2 and emerged as a specific BVDV inhibitor 
of replication is phenyl thiophene carboxamide derivative 12 (PTC12). In MDBK cells, 
PTC12 was identified as a potent inhibitor of BVDV entry (Bollini et al., 2018; Pascual 
et al., 2018). 
Bovine Respiratory Disease Complex (BRDC) 
One of the most costly diseases in the feedlot cattle industry is bovine respiratory 
disease complex (BRDC, aka shipping fever) (Snowder et al., 2006). The pathogenesis 
factors of BRDC include contributions from not only microbial pathogens but also host, 
environmental, and animal management factors. Microbial pathogens include 
Mannheimia haemolytica, Mycoplasma bovis, BVDV, bovine herpesvirus-1, BRSV, 
parainfluenza-3 virus, bovine rhinitis A and B virus, bovine coronavirus, and influenza D 
virus (Mitra et al., 2016; Ridpath, 2010). BRDC is of major economic importance to the 
global cattle industries. The United States feedlot industry estimates a loss as high as 1 
billion dollars every year because of bovine respiratory disease, loss of production, 
increased labor expenses, drug costs, and death (Fulton et al., 2002a; Sacco et al., 2014). 
BVDV is a significant contributor to BRDC. BVDV infection results in 
immunosuppression, leading to secondary infections by other pathogens, such as BRSV 
(Brodersen and Kelling, 1998; Gagea et al., 2006). BVDV potentiates the severity of 
disease in cattle when concurrently infected with other respiratory tract and 
gastrointestinal pathogens (Kelling et al., 2002a). Similarly, immunosuppression during 
BVDV infection in alpacas may contribute to secondary bacterial and viral infections 
(Topliff et al., 2017). Experimentally, calves concurrently infected with BVDV and 
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BRSV had more severe clinical signs of disease and extensive lung lesions, and shed 
virus in greater concentration for longer duration compared to calves infected with either 
virus alone (Brodersen and Kelling, 1999). BVDV plays an indirect role by causing host 
immunosuppression while BRSV acts directly causing bronchopneumonia. BVDV and 
BRSV possibly act synergistically during co-infection of calves and as a result of 
synergism, respiratory and digestive tract diseases are enhanced (Brodersen and Kelling, 
1998). BVDV strains are different in causing pneumonia. A ncp BVDV-1 (subtype Ib) 
was the predominant isolate in feedlot cattle with respiratory disease (Fulton et al., 
2002b).  
Bovine Respiratory Syncytial Virus (BRSV) 
Bovine respiratory syncytial virus (BRSV) is a member of the genus Pneumovirus 
within the family Paramyxoviridae (Murphy et al., 1995). BRSV is closely related to 
human respiratory syncytial virus (HRSV), the leading cause of severe acute lower 
respiratory tract infection in infants and children all over the world. Respiratory syncytial 
virus (RSV) is enveloped and has a single-stranded, negative-sense RNA genome of 
15,222 nucleotides encoding 11 proteins (Huang and Wertz, 1982). RSV was first 
reported in 1955 as a respiratory disease in chimpanzees (Blount et al., 1956) and called 
chimpanzee coryza agent. It was subsequently renamed RSV, due to its ability to form 
syncytia (Chanock et al., 1957). BRSV is a pathogen of the bovine respiratory system 
(Paccaud and Jacquier, 1970) and infection commonly occurs during the first year of life 
in calves, but reinfection is common and can occur at any age (Gershwin, 2012; Van der 
Poel et al., 1993). Related RSV isolates cause respiratory tract diseases in small 
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ruminants, such as sheep and goats (Mallipeddi and Samal, 1993; Oberst et al., 1993; 
Yeşilbağ and Güngör, 2009).  
The BRSV genome has 11 genes that encode for 11 mRNAs. The viral-specific 
mRNAs from BRSV-infected cells have electrophoretic mobilities similar to those of 
HRSV mRNAs. Nine proteins specific to BRSV-infected cells correspond to those of 
HRSV proteins. The BRSV viral proteins are: non-structural proteins, NS1 and NS2, 
glycoprotein (G), fusion (F), small hydrophobic (SH), nucleoprotein (N), phosphoprotein 
(P), viral RNA-dependent polymerase (L), and the matrix proteins, M, M2-1, and M2-2. 
Unlike F, N, P, and M proteins, only G glycoprotein of BRSV shows major antigenic 
differences from the G glycoprotein of HRSV (Lerch et al., 1989; Valarcher and Taylor, 
2007). The major determinants of BRSV host range are NS1 and NS2. Together, these 
proteins inhibit the phosphorylation and transcriptional activity of IRF-3 reducing type I 
IFN production by infected host cells. The SH protein is not essential for virus replication 
and exists as different forms, SHg, SHp, SH0, and SHt. The G protein is a large 
glycoprotein and is the major attachment protein. Antibodies specific to the G protein 
block cell-virus binding. The F protein mediates the cell-virus binding and is responsible 
for the fusion between the virus and the host’s cells (viral penetration) and among 
infected cells (syncytium formation). The N, P, and L proteins are nucleocapsid proteins. 
L protein is responsible for viral transcription and replication. (Bossert and Conzelmann, 
2002; Bossert et al., 2003; Guzman and Taylor, 2015; Valarcher and Taylor, 2007). It has 
been suggested that blocking the induction of host type I IFN gene expression increases 
the virulence of BRSV. Recombinant BRSV (rBRSV) lacking the NS1 or NS2 protein is 
a strong inducer of type I IFN in bovine cells compared to wild-type BRSV. The 
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replication of NS protein deletion mutants was severely attenuated in bovine cells and 
young calves because of increased type I IFN production (Valarcher et al., 2003). The 
inhibition of type I IFN production by NS proteins of BRSV in the Madin Darby Bovine 
Kidney (MDBK) cells compared to cell lines of other origins suggests an adaptation of 
the virus to host-specific antiviral responses (Schlender et al., 2000).  
The suppressor of cytokine signaling (SOCS) family utilizes a feedback loop to 
inhibit the type I IFN dependent antiviral signaling pathway. SOCS1 and SOCS3 can 
inhibit NF-κB and JNK/p38 pathways. By disrupting the JAK/STAT pathway and 
decreasing the production of IRF7, SOCS3 inhibits both the production and signal 
transduction of type I IFN (Akhtar and Benveniste, 2011). Induction of SOCS3 by some 
viruses, such as hepatitis C virus and human immunodeficiency virus 1, suggests an 
important role for SOCS3 in suppressing anti-viral signal transduction (Mahony et al., 
2016). Gene expression analysis of nasal samples from infants with severe RSV 
bronchiolitis confirmed the reduction of type I IFN gene expression (Thwaites et al., 
2018). During RSV infection, NS1 upregulates both SOCS1 and SOCS3 proteins while 
NS2 upregulates SOCS1 expression. This induced expression of SOCS1 and SOCS3 
inhibited the IFN-inducible antiviral response (Zheng et al., 2015). The BRSV genome 
encodes a SH protein, which has a viroporin activity altering host cell membrane 
permeability. It has been reported that recombinant BRSV lacking the SH gene 
(rBRSVΔSH) was attenuated and induced protective immunity in calves (Taylor et al., 
2014). In response to BRSV infection, SH inhibits NF-κB p65 phosphorylation and 
reduces the production of pro-inflammatory cytokines while rBRSVΔSH does not inhibit 
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NF-κB p65 phosphorylation leading to increased expression of pro-inflammatory 
cytokines in bovine cells (Pollock et al., 2017).  
Clinical symptoms of natural BRSV infection include: fever, cough, and increased 
respiratory rates. Lung lesions include bronchitis, bronchiolitis, fibrosis, emphysema, and 
severe edema (Bryson et al., 1983; Kimman et al., 1989). Calves experimentally infected 
with BRSV had fever, diarrhea and developed a lobular suppurative and necrotic 
bronchointerstitial pneumonia and diffuse cilia loss with mild necrosuppurative 
inflammatory changes (Brodersen and Kelling, 1998). Colostrum-fed 17- to 24-day-old 
calves experimentally infected with BRSV developed severe chronic bronchiolitis and 
bronchiolitis obliterans. Secretions filled the bronchiolar lumina and alteration of the 
ciliogenesis was observed with partial loss of cilia (Philippou et al., 2000). In calves with 
BRDC, concurrent infections with BVDV and BRSV causes more severe respiratory and 
digestive tract diseases than infections with either virus alone (Brodersen and Kelling, 
1998).  
Killed and modified live BRSV vaccines are available as part of multivalent 
products. Although there is widespread use of BRSV vaccines in calves, their efficacy is 
not optimal. Some studies have developed BRSV mutants or anti-BRSV antibodies that 
may provide protection to calves against infection. Experimentally, calves vaccinated 
with BRSV NS1- or NS2-deletion-mutants exhibited a robust BRSV-specific antibody 
(Valarcher et al., 2003). BRSV immunostimulating complexes (BRSV-ISCOMs) used in 
3 to 8-week-old calves induced BRSV-specific cellular and humoral responses and calves 
were protected from virulent BRSV infection (Hägglund et al., 2011). Furthermore, it has 
been reported that IgG purified from bovine milk binds to human RSV, which may 
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contribute to immune protection against RSV (den Hartog et al., 2014). Anti-RSV G 
monoclonal antibodies (anti-G mAbs) reduce lung inflammation and viral titers when 
evaluated using a mouse model (Caidi et al., 2018). Recently, McGill et al., 2018 
developed a mucosal nanovaccine and determined the efficacy of the vaccine against 
RSV infection. Vaccinated calves challenged with BRSV infection exhibited reduced 
lesions and decreased virus shedding compared to unvaccinated control calves, indicating 
the potential of the BRSV-F/G nanovaccine to significantly reduce the disease burden 
associated with HRSV and BRSV infections (McGill et al., 2018). 
Cellular Signal Transduction 
While BVDV and BRSV are responsible for significant economic losses in the 
cattle industry, little is known about the pathological responses of the host’s cells and the 
signaling pathways mediated by BVDV and/or BRSV infections. When cells are infected 
with a RNA virus, the viral dsRNA will be recognized by cytosolic pattern-recognition 
receptors (PRRs) which will trigger innate immune responses and activate stress 
responses. Cytosolic PRRs, called RIG-I-like receptors (RLRs), include retinoic-acid-
inducible gene I (RIG-I) and melanoma-differentiation-associated gene 5 (MDA5). The 
interaction of dsRNA and RLRs induces interaction with their adaptor protein on the 
mitochondrial membrane, mitochondrial antiviral signaling (MAVS, also known as IFN-
β-promoter stimulator 1, IPS-1/VISA/Cardif) protein. MAVS activates TANK-binding 
kinase 1 (TBK-1) which induces the phosphorylation of interferon regulatory factor 3 
(IRF-3) and IRF-7 leading to their homo- or hetero-dimerization and their translocation to 
the nucleus to activate the transcription of type I IFN genes and increase type I IFN 
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production (Fig. 1.1). Produced type I IFN binds to the type I IFN receptor on the cellular 
membrane causing a positive-feedback regulation of type I IFN genes. This binding 
activates a heterotrimeric transcriptional activator, IFN-stimulated gene factor 3 (ISGF3), 
which consists of IRF-9 and signal transducer and activator of transcription 1 (STAT1) 
and STAT2. ISGF3 increases the induction of the IRF-7 gene and subsequently increases 
the type I IFN production (Fig. 1.2). In the nucleus, the phosphorylated IRF-3 interacts 
with the cis–trans peptidylprolyl isomerase, NIMA-interacting 1 (PIN-1), which 
facilitates proteasome-dependent degradation of IRF-3 in the cytoplasm. MAVS also 
contributes in the NF-κB-activation pathway, which induces pro-inflammatory cytokine 
genes (Fig. 1.1). Double-stranded RNA-dependent protein kinase R (PKR) can detect the 
viral dsRNA and initiates antiviral stress granule (avSG) formation in the cytoplasm 
which then triggers innate immunity (Honda et al., 2005; Honda and Taniguchi, 2006; 
Onomoto et al., 2012; Yoneyama et al., 2015). 
Mitochondrial Antiviral Signaling (MAVS) 
Mitochondria have emerged as critical cellular organelles for antiviral innate 
immune signaling. This is due in large part to the innate immune signaling adaptor 
MAVS, which coordinates signals received from two independent cytosolic PRRs 
(retinoic acid-inducible gene-I, RIG-I, or melanoma differentiation-associated gene 5, 
MDA5) to induce antiviral genes. MAVS is essential for type I IFN production in viral 
infections through the IRF-3 and NF-κB pathways. Through alteration of MAVS 
expression and signaling, the host cell can control inflammation and prevent cellular 
damage (Jacobs and Coyne, 2013). The mitochondria-associated endoplasmic reticulum 
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membrane (MAM) protein Gp78 modulates type I IFN induction by both decreasing 
MAVS protein levels and by inhibiting MAVS signaling via physical interactions (Jacobs 
et al., 2014). The importance of MAVS in the type I IFN pathway was studied in 
mammalian (feline) cells. Inhibiting MAVS by using siRNA inhibited the IFN-β 
promoter activation during Sendai virus infection. In contrast, MAVS over-expression 
activated IRF-3 and NF-κB pathway signaling and induced IFN-β production (Wu et al., 
2016). Poliovirus significantly reduced the IFN-β mRNA levels. A study reported that 
MAVS was largely intact in HEC-1B cells infected with poliovirus suggesting that the 
suppression of the host type I IFN during poliovirus infection is not mediated by MAVS 
(Kotla and Gustin, 2015).  
TANK-Binding Kinase 1 (TBK-1) 
TANK-binding kinase 1 (TBK-1, also known as NF-κB-activating kinase (NAK) 
or T2K) regulates the IRF-3 and NF-κB pathways. Phosphorylated (activated) TBK-1 
phosphorylates the transcription factors IRF-3 and IRF-7 (Zhao, 2013). The NS3 protein 
of hepatitis C virus binds to TBK-1 and inhibits the interaction between TBK-1 and IRF-
3 leading to the inhibition of the cellular antiviral response (Otsuka et al., 2005). Dengue 
virus serotype 2 (DENV2) is a member of the family Flaviviridae. When HepG2 cells 
were treated with a TBK-1 inhibitor (BX795) and stimulated with poly I:C, the type I 
IFN pathway signaling was inhibited. TBK-1 inhibitor decreased the IFN-β mRNA 
expression and increased the viral mRNA expression of DENV2 (Zhang et al., 2013). 
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Interferon Regulatory Factor 3 (IRF-3) and IRF-7 
The mammalian interferon-regulatory factor (IRF) family includes nine members 
named from one to nine. They have different roles in the gene regulatory networks in the 
immune system. Interferon regulatory factor 3 (IRF-3) and IRF-7 are closely related to 
each other and are important cellular transcription factors targeting the type I IFN gene 
and increasing type I IFN production in infected cells. IRF-3 and IRF-7 monomers are 
activated into phosphorylated homo- and heterodimers and translocated to the nucleus of 
virus-infected cells (Taniguchi et al., 2001). IRF-3 is an essential antiviral signaling 
molecule and is important in IFN regulation and development of the immune system. 
IRF-3 is expressed in a variety of tissue cells, such as mature DCs. IRF-3 is found in an 
inactive cytoplasmic form and is posttranslationally-modified following virus infection 
by protein phosphorylation. This virus-dependent phosphorylation of IRF-3 alters protein 
conformation causing the translocation of IRF-3 from the cytoplasm to the nucleus. 
Phosphorylation also stimulates DNA binding with IRF-3, and increases IRF-3 
transcriptional activation and primary activation of IFN-responsive genes to produce type 
I IFN and establish early innate immunity (Gabriele and Ozato, 2007; Hiscott et al., 
1999). It was reported that the Npro protein of pestivirus prevented IFN production by 
directly interacting with the monomer and dimer forms of IRF-3 (Gottipati et al., 2016). 
In infected cells, the Npro of both BVDV and CSFV suppress IRF-3 levels by blocking 
IRF-3 binding to DNA and mediates the degradation of the protein IRF-3, but not IRF-3 
mRNA (Hilton et al., 2006; Horscroft et al., 2005; Seago et al., 2007). BVDV Npro 
interacts with IRF-3 before virus-induced phosphorylation of IRF-3 leading to 
polyubiquitination and proteasomal degradation of IRF-3 (Chen et al., 2007).  In infected 
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MDBK cells, NS1 and NS2 proteins of BRSV inhibit the phosphorylation and 
transcriptional activity of IRF-3 and IFN induction (Bossert and Conzelmann, 2002; 
Bossert et al., 2003). The production of IRF-7 in MDBK cells was induced by cp BVDV-
1 (Fredericksen et al., 2015). Both cp and ncp BVDV inhibit the full function of IRF-3 
but do not affect the nuclear uptake of IRF-7 (Baigent et al., 2004). 
NIMA-Interacting 1 (PIN-1) 
The phosphorylated IRF-3 in the nucleus interacts with the peptidylprolyl 
isomerase (cis–trans peptidylprolyl isomerase, NIMA-interacting 1, PIN-1) to terminate 
the action of IRF-3 and facilitate the IRF-3 degradation in the cytoplasm (Saitoh et al., 
2006). The role of PIN-1 during BVDV infection is not clear. It was suggested that 
BVDV Npro induces IRF-3 degradation via a PIN-1-independent mechanism (Chen et al., 
2007). 
Protein Kinase R (PKR) 
The IFN-induced double-stranded RNA-dependent protein kinase R (PKR) is a 
serine/threonine kinase and is induced by interferon (Meurs et al., 1990). PKR is a 
component of signal transduction pathways mediating cell growth control and is activated 
in response to dsRNA, viral infection, and a wide range of activators and cell stresses. 
Phosphorylated (activated) PKR can activate NF-κB, phosphorylate the alpha-subunit of 
eukaryotic translation initiation factor 2 (eIF2α), and induce apoptosis (Gabel et al., 
2006; García et al., 2006; Lee et al., 1997; Taylor et al., 2005). The multiple functions of 
PKR during viral infection include inhibiting the translation initiation and protein 
synthesis through the transcription factor eIF2α and induction of apoptosis. PKR controls 
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the activation of many transcription factors including NF-κB, p53, and STATs (Gil and 
Eseban, 2000; Pathak et al., 1988; Wong et al., 1997). PKR detects viral dsRNA and 
initiates antiviral stress granule (avSG) formation in the cytoplasm which triggers innate 
immunity. Removal of PKR diminished IFN production and enhanced viral replication 
(Onomoto et al., 2012). Type I IFN binds to type I IFN receptor on neighboring cells 
triggering a variety of genes including PKR, which can be induced by IFN treatment 
(García et al., 2007). CSFV activates PKR which phosphorylates eIF2α and inhibits 
translation in viral infected cells leading to apoptosis (Hsu et al., 2014). At 5 DPI in vivo, 
both ncp BVDV-1 and BVDV-2, increased PKR mRNA in spleen and tracheo-bronchial 
lymph nodes of infected beef calves (Palomares et al., 2013). On the other hand, unlike 
cp BVDV, ncp BVDV-1 inhibited the signaling pathway of PKR resulting in enhanced 
protein synthesis and cell survival (Gil et al., 2006b).  
Nuclear Factor-κB (NF-κB) 
The transcription factor, nuclear factor-κB (NF-κB), induces the expression of 
immune and inflammatory genes and type I IFN production. Viruses activate three main 
transcription factor complexes involved in type I IFN production: NF-κB, IRF3/IRF7 and 
ATF2/c-jun. In the cytoplasm of resting cells, NF-κB inhibitor (IκBα) holds NF-κB as an 
inactive complex. When cells are infected with viruses, NF-κB will be released and 
translocated to the nucleus inducing target genes and increasing IFN production (Taylor 
and Mossman, 2013). NF-κB signaling pathway maintains immune homeostasis in cells. 
A20 (TNFAIP3) molecule is a target ubiquitin-editing enzyme of NF-κB and a key 
regulatory factor in the immune response, hematopoietic differentiation, and 
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immunomodulation. The expression of the negative regulator of the immune response 
A20 (TNFAIP3) is mediated by the NF-κB pathway. Through NF-κB pathway, BVDV 
modulates bovine A20 activation (Fredericksen et al., 2016). In MDBK cells, cp BVDV-
1 was able to induce the production of cytokines and modulate transcriptional factors, 
including BCL3, IL-1β, IL-8, IL-15, IL-18, Mx-1, IRF-1, and IRF-7, through activating 
NF-κB. The pharmacological inhibitor of NF-κB signaling pathway (BAY-117085) 
blocks the BVDV-1 activities (Fredericksen et al., 2015). In cells infected with cp BVDV 
NADL, the Npro does not affect the NF-κB activation of gene expression (Chen et al., 
2007). A study in vitro reported that respiratory syncytial virus (RSV) is a potent 
activator of NF-κB (Jamaluddin et al., 1998). NF-κB p65 phosphorylation is a main step 
in the regulation of pro-inflammatory cytokines. In BRSV-infected bovine cells, SH 
inhibits NF-κB p65 phosphorylation and decreases pro-inflammatory cytokine production 
(Pollock et al., 2017). However, it was reported that the immediate early response 3 
(IER3) overexpression in bovine cells blocked the NF-κB pathway activity leading to 
down-regulation of interleukin-8 (IL-8) during BVDV-1 infection (Villalba et al., 2017). 
Hypothesis and Goals 
Based on our review of the literature, there is a lack of information regarding the 
type I IFN signaling pathways during BVDV infection, in particular, the effects of Npro 
on these pathways. The effect of BVDV Npro on the IFN pathway signals in cells co-
infected with BVDV and other viral pathogens, such as BRSV, has not been previously 
evaluated. This study investigates the effects of BVDV Npro during BVDV single and co-
infection with BRSV on the type I IFN pathway in BT cells infected with BRSV, 
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BVDV2-wt, or BVDV2-E or co-infected with BRSV/BVDV2-wt or BRSV/BVDV2-E. 
We hypothesized that BVDV-2 Npro enhances virulence and modulates host cell innate 
immune responses which augment BRSV replication during co-infection with BVDV. 
The long term goal of our study is to develop new strategies to control BRDC in cattle. 
Our research is centered on studying BVDV virulence determinants and mechanisms of 
enhanced disease from BRSV/BVDV2 co-infection. We proposed to undertake the study 
to identify and characterize pathogen-specific genes that inhibit immune responses. 
Specifically, we proposed to characterize the functional role of enhancement of BRSV 
replication during co-infection. The objectives include (1) characterization of the effects 
of BVDV Npro on type I IFN induction cell signals in IFN antagonism during BVDV 
infections and (2) identifying the BVDV immunomodulatory proteins and host cell 
responses which are important to increased virulence of BRSV and the effects of BVDV 
Npro on type I IFN cell signaling in IFN antagonism and enhancement of BRSV 
replication during co-infections with BVDV. The investigated cell signals are MAVS, 
PKR, TBK-1, IRF-3, IRF-7, IFN, NF-κB, and PIN-1 using real-time Q-RT-PCR for 
signal mRNA and western blotting for signal proteins (Fig. 1.3). A reporter cell line and 
Dual-luciferase reporter assays were also used in this study. 
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                                  Fig. 1.1. 
 
 
 
 
 
 
 
 
Fig. 1.1. Virus-dependent type I IFN signaling pathways. Cytosolic pattern-
recognition receptors (PRRs), called RIG-I-like receptors (RLRs), which include RIG-I 
and MDA5, recognize viral dsRNA and interacts with MAVS protein. MAVS activates 
TBK-1 which induces the phosphorylation of IRF-3 and IRF-7 leading to their 
dimerization and their translocation to the nucleus to activate the transcription of type I 
IFN genes and increase type I IFN production. Protein kinase R (PKR) detects the viral 
dsRNA and activates MAVS. MAVS also activates NF-κB. 
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                  Fig. 1.2. 
 
 
 
 
 
 
 
Fig. 1.2. Positive-feedback of type I IFN signaling. Type I IFN binds to its receptor 
activating a heterotrimeric transcriptional activator, IFN-stimulated gene factor 3 (ISGF3, 
which consists of IRF-9, and signal transducer and activator of transcription 1 (STAT1) 
and STAT2). Activated ISGF3 increases the induction of the IRF-7 gene and the 
production of the type I IFN. 
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                            Fig. 1.3. 
 
 
 
 
 
 
 
Fig. 1.3. Evaluating cellular signal expression using Real-time Q-RT-PCR or 
western blotting. Virus infection increases the transcription of numerous adaptor 
molecules producing the mRNAs of the signals in the nucleus of infected cells. The 
mRNAs can be detected and evaluated by Real-time Q-RT-PCR. The translation of 
mRNA in the cellular cytoplasm produces the signal proteins, which can be evaluated by 
western blotting. 
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ABSTRACT 
Bovine viral diarrhea virus (BVDV) infection induces immunosuppression and in 
conjunction with bovine respiratory syncytial virus (BRSV) contributes to the bovine 
respiratory disease complex. Bovine turbinate cells were single or co-infected with type 2 
BVDV wild-type (BVDV2-wt), its dysfunctional Npro mutant (BVDV2-E), and/or BRSV. 
BVDV2-E significantly up-regulated PKR, IRF-7, TBK-1, IRF-3, and IFN-β mRNAs 
based on real-time Q-RT-PCR. BRSV-infected cells expressed significantly up-regulated 
PKR, IRF-3, IRF-7, and IFN-β mRNAs, whereas BVDV2-wt, but not BVDV2-E, 
abolished this up-regulation in co-infection. No significant differences were observed in 
MAVS, NF-κB, and PIN-1 mRNAs. A dual-luciferase reporter assay showed that 
BVDV2-wt significantly increased NF-κB activity compared to BVDV2-E, while 
BVDV2-E significantly increased IFN-β activity compared to BVDV2-wt. The BRSV 
titer and RNA levels significantly increased in cells co-infected with BRSV/BVDV2-wt 
compared to cells co-infected with BRSV/BVDV2-E or infected with BRSV alone. This 
data supports the synergistic action of BVDV2-wt and BRSV inhibition of IFN-1. 
Keywords 
BVDV2 Npro; BRSV; Bovine respiratory disease complex; IFN-1 pathway signaling; 
mRNA; Viral replication. 
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1. Introduction 
Bovine viral diarrhea virus (BVDV) is a member of the genus Pestivirus within 
the Family Flaviviridae (Simmonds et al., 2017). Bovine respiratory syncytial virus 
(BRSV) is a member of the genus Pneumovirus within the Family Paramyxoviridae 
(Bunt et al., 2005). BVDV infections are commonly associated with cattle, but other 
members of the order Artiodactyla may be infected (Løken, 1995; Raizman et al., 2009; 
Topliff et al., 2009). BVDV infections are endemic in cattle in North America and cause 
significant economic losses to the cattle industry. Mortality rates associated with 
infectious disease are significantly higher in feedlot cattle seropositive for BVDV 
(Booker et al., 2008). BVDV potentiates the severity of other respiratory viral infections, 
such as BRSV (Brodersen and Kelling, 1998, 1999) or gastrointestinal pathogens, such as 
rotavirus (Kelling et al., 2002). In calves, concurrent infection with BVDV and BRSV 
caused more severe respiratory and enteric disease than infection with either virus alone 
(Brodersen and Kelling, 1998, 1999). 
BVDV1 and BVDV2 can be differentiated based on sequence differences of the 
5’ untranslated region (UTR) (Pellerin et al., 1994; Pletnev et al., 2011; Ridpath et al., 
1994). BVDV isolates can also be separated into one of two biotypes, cytopathic (cp) or 
noncytopathic (ncp), based on effects in cell culture (Meyers et al., 1996). BVDV is an 
enveloped virus with a single-stranded, positive-sense RNA genome of approximately 
12.5 kb. The genome consists of a single large open reading frame with a UTR on both 
the 5’ and 3’ ends (Collett et al., 1988a, 1988b). Pestivirus (including BVDV) proteins 
are synthesized from 5’ to 3’ as NH2–N
pro/C/Erns/E1/E2/p7/NS2/NS3/NS4A/NS4B/ 
NS5A/NS5B–COOH (Collett et al., 1991; Tautz et al., 2015). 
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Interferon (IFN), an inducible cytokine, plays a major role in host innate immune 
responses and is a bridge between innate and adaptive immunity. Synthesis and secretion 
of type I IFN α/β (IFN-1) is the first step of the innate immune response to viral infection 
or double-stranded RNA (dsRNA) exposure of cells (Bautista et al., 2005) and activates 
cellular factors to degrade viral RNA and shut down viral mRNA synthesis (Castelli et 
al., 1997). IFN-1 controls certain cellular functions such as inducing dendritic cell 
differentiation and stimulating the proliferation and class switching of B cells (Litinskiy 
et al., 2002; Paquette et al., 2002; Tough, 2004). IFN-1 also stimulates the motility, 
differentiation, and cross-priming of T cells, enhances the cytotoxicity of natural killer 
cells, and stimulates the production of inflammatory cytokines (Le Bon et al., 2003; 
Rogge et al., 1998; Sato et al., 2001).  
When cells are infected with a RNA virus, the viral dsRNA will be recognized by 
cytosolic pattern-recognition receptors (PRRs) which will trigger innate immune 
responses and activate stress responses. Cytosolic PRRs, called RIG-I-like receptors 
(RLRs), include retinoic-acid-inducible gene I (RIG-I) and melanoma-differentiation-
associated gene 5 (MDA5). The interaction of dsRNA and RLRs induces interaction with 
their adaptor protein on the mitochondrial membrane, mitochondrial antiviral signaling 
protein (MAVS, also known as IPS-1/VISA/Cardif). MAVS activates TANK-binding 
kinase 1 (TBK-1) which induces the phosphorylation of interferon regulatory factor 3 
(IRF-3) and IRF-7 leading to their homo- or hetero-dimerization and their translocation to 
the nucleus to activate the transcription of IFN-1 genes. In the nucleus, the 
phosphorylated IRF-3 interacts with the cis–trans peptidylprolyl isomerase, NIMA-
interacting 1 (PIN-1), which facilitates proteasome-dependent degradation of IRF-3 in the 
39 
 
cytoplasm. MAVS contributes in the NF-κB-activation pathway, which induces pro-
inflammatory cytokine genes (Honda and Taniguchi, 2006). Double-stranded RNA-
dependent protein kinase (PKR) can detect the viral dsRNA and initiates the antiviral 
stress granule (avSG) formation in the cytoplasm which will trigger innate immunity 
(Onomoto et al., 2012; Yoneyaman et al., 2015). 
BVDV Npro is a nonstructural protein with autoprotease activity involved in viral 
evasion of the innate immune response. Ruggli et al., 2003 demonstrated that classical 
swine fever virus (CSFV), a Pestivirus species closely related to BVDV, with a 
functional Npro prevented IFN-1 production from infected cells while the Npro-deleted 
CSFV mutant did not (Ruggli et al., 2003). BVDV Npro prevents the production of IFN-1 
by suppressing levels of IRF-3 to avoid host antiviral responses (Hilton et al., 2006; 
Horscroft et al., 2005). The ability of type 1 BVDV Npro to suppress the production of 
IFN was abolished by substituting glutamic acid with leucine at amino acid position 22 or 
histidine with valine at position 49 of the Npro protein (Gil et al., 2006a). 
This study describes the influence of type 2 BVDV-mediated IFN-1 antagonism 
on the enhancement of BRSV replication during co-infection. BVDV2 with a modified 
Npro (BVDV2-enhanced green fluorescent protein (EGFP) coding sequence, BVDV2-E) 
to render it dysfunctional in interferon inhibition (Gil et al., 2006a), BVDV2 wild-type 
(BVDV2-wt), and BRSV were used to characterize the effects of BVDV2 Npro on IFN-1 
production and its pathway signaling and on BRSV replication in vitro.  Results showed 
that BRSV replication was enhanced when co-infected with BVDV2-wt having a 
functional Npro, while BVDV2-E with a dysfunctional Npro induced IRF-3 pathway 
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signaling and higher levels of IFN-1 than BVDV2-wt and did not enhance the replication 
of BRSV during co-infection. 
2. Materials and Methods 
2.1. Cells and viruses   
Bovine turbinate (BT, National Veterinary Services Laboratory, United States 
Department of Agriculture, Ames, IA) and Madin–Darby bovine kidney (MDBK, CCL-
22, American Type Culture Collection, Manassas, VA) cells were grown in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Invitrogen, Carlsbad, CA, USA) supplemented with 
10% (v/v)  equine serum (Hyclone, Logan, UT, USA). NCL1-ISRE-Luc-Hygro cells, a 
modified bovine uterine cell line constitutively expressing an IFN response element gene 
coupled with firefly luciferase, were maintained in DMEM supplemented with 10% (v/v) 
equine serum and 300 µg/ml hygromycin (Cellgro, Manassas, VA, USA). Bovine cell 
lines were free of adventitious BVDV and BRSV.  
Ncp BVDV2 isolates used in the study were ncp NY93-wt (BVDV2-wt) (Animal, 
Plant, and Health Inspection Service, Center for Veterinary Biologics, Ames, IA) and 
NY93/c N-Npro 18 EGFP (BVDV2-E) derived from the infectious clone, NY93/c (Meyer 
et al., 2002). BVDV2-E was constructed by mutating NY93/c between Npro codons 18 
and 19 creating a NaeI restriction site. The EGFP coding region from pEGFP-N1 
(Clontech, Mountain View, CA, USA) was PCR amplified and ligated into the NaeI site. 
The field isolate, BRSV 236-652 (BRSV), was used in this study (Brodersen and Kelling, 
1998). 
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2.2. Viral stocks   
Monolayers of MDBK cells at 90% confluency were mock-infected or infected 
with each individual BVDV isolate in 162 cm2 tissue culture flasks and incubated at 37 
°C in a humidified incubator with 5% (v/v) CO2 for four days.  Following a single freeze-
thaw cycle, aliquots of mock- and BVDV-infected MDBK cell lysates were stored at –80 
ºC. Monolayers of BT cells at 90% confluency were infected with BRSV in 162 cm2 
tissue culture flasks and incubated at 33 °C in a humidified incubator with 5% (v/v) CO2 
for eight to ten days until the cells demonstrated 50% cytopathic effect. Following a 
single freeze-thaw cycle, aliquots of BRSV-infected BT cell lysates were stored at –80 
ºC. 
2.3. dsRNA stock   
 Polyriboinosinic polyribocytidylic acid (poly I:C, Amersham Biosciences, 
Piscataway, NJ, USA) was reconstituted in PBS to a stock concentration of 2 mg/ml, 
passed through a 21 gauge needle to shear the RNA, and stored in aliquots at –80 °C.  
2.4. Virus preparation for IFN-1 assay   
Virus preparation for the IFN-1 assay has been previously described (Gil et al., 
2006a). Briefly, 75 cm2 tissue culture flasks of MDBK cells at 90% confluency were 
inoculated with BVDV2-wt or BVDV2-E and incubated at 37 °C in a humidified 
incubator with 5% (v/v) CO2 for 4 days, then frozen at –80 °C. Flasks were thawed, cell 
lysates harvested and centrifuged at 2,000×g for 30 minutes at 4 °C. The clarified 
supernatant was then transferred to ultracentrifuge tubes and centrifuged at 100,000×g for 
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2 h at 4 °C. The resulting viral pellet was re-suspended in 500 µl DMEM and stored in 
aliquots at –80 °C.   
2.5. IFN-1 reporter gene assay   
MDBK (4×105) or BT cells (3×105) were seeded onto 6-well plates and grown to 
90% confluency. Cells were then infected with each pelleted virus isolate at a multiplicity 
of infection (m.o.i.) of 0.5, stimulated with poly I:C (100 µg/ml), or treated with media as 
uninfected (UI) control. Plates were incubated at 37 °C in a humidified incubator with 
5% (v/v) CO2 for 24 h, and then frozen at –80 °C. The plates were thawed and the cell 
lysate clarified by centrifugation at 2000×g for 30 minutes at 4 °C. The pH of the 
clarified supernatant was adjusted to pH 2 with 2 M HCl. After incubation at 4 °C for 24 
h, the pH of the supernatant was adjusted to pH 7 using 2 M NaOH. Each experimental 
sample (0.5 ml) was added to one well of a 12-well plate seeded with NCL1-ISRE-Luc-
Hygro cells (Gil et al., 2006a) prepared 12 h earlier by adding 1.5×105 cells per well and 
incubating at 37 ºC in a humidified incubator with 5% CO2. After addition of the 
experimental sample, the NCL1-ISRE-Luc-Hygro cells were incubated at 37 ºC in a 
humidified incubator with 5% (v/v) CO2 for 8 h, followed by cell lysis in 100 µl of 
reporter lysis buffer (Promega, Madison, WI, USA) (Gil et al., 2006a).  Each NCL1-
ISRE-Luc-Hygro cell lysate was analyzed using the firefly luciferase assay system 
(Promega) according to the manufacturer’s instructions, with sample luminescence 
measured by a FLUOStar luminometer (BMG Labtech, Offenburg, Germany). A 
standard curve using a dilution series of an IFN-1 standard was prepared and sample 
luminescence (relative light units, RLU) expressed as units of IFN-1. 
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2.6. IFN-1 inhibition assay   
MDBK cells (4×105) were seeded onto 6-well plates and grown to 90% 
confluency. Cells were then infected with BVDV2-wt or BVDV2-E at a m.o.i. of 1.2, 
stimulated with poly I:C (100 µg/ml), or treated with media as UI control. Plates were 
incubated at 37 °C for 48 h, at which time the media was replaced with fresh media 
containing poly I:C at a concentration of 50 µg/ml (Baigent et al., 2002; Gil et al., 
2006a).  Following incubation at 37 °C for 20 h, cells were harvested by a freeze-thaw 
cycle at –80 °C and pH adjusted to pH 2 for 24 h at 4 °C to inactivate virus.  The pH of 
the cell lysates was then adjusted to pH 7 and added to reporter cell plates containing 
NCL1-ISRE-Luc-Hygro cells and assayed as described previously (Gil et al., 2006a). 
2.7. BRSV growth kinetics in single and co-infected cells   
BT cells (3×105) were seeded onto individual wells of 6-well plates and incubated 
at 37 °C in a humidified incubator with 5% (v/v) CO2 until 90% confluent. Duplicate 
wells of cells were then infected with BRSV alone or co-infected with BRSV/BVDV2-wt 
or BRSV/BVDV2-E, at a m.o.i. of 0.6 and incubated at 37 °C in a humidified incubator 
with 5% (v/v) CO2 for 1.5 h with rocking.  Following adsorption, cells were washed with 
DMEM and incubated in fresh media supplemented with 5% (v/v) equine serum. Cells 
were monitored by microscopic examination and frozen at –80 °C 2, 6, 12, and 24 h post-
infection (HPI), and 2, 3, 5, 7, and 9 days post-infection (DPI). Cell lysates were thawed 
on ice and virus titers determined and viral RNA was extracted.  
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2.8. Virus titration 
Serial ten-fold dilutions (10-1 to 10-8) of virus in DMEM from each time point 
were assayed as previously described (Brodersen and Kelling, 1998). Briefly, 50 μl of 
each dilution was added to two replicates of 4 wells/dilution of a 96-well tissue culture 
plate. A 100 μl suspension of BT cells (1×104 cells per well) in DMEM supplemented 
with 3% (v/v) equine serum, 75 µg/ml Gentamicin (Sigma, St. Louis, MO, USA), and 
0.375 µg/ml Fungizone (Invitrogen) was added to each well of a 96-well tissue culture 
plate. After incubating for 7 days at 33 °C in a humidified incubator with 5% (v/v) CO2, 
cells were fixed in 20% (v/v) acetone in PBS for 15 minutes at room temperature and 
plates allowed to dry overnight.  An enzyme-linked immunosorbent assay (ELISA) 
(Brodersen and Kelling, 1998) was performed using the monoclonal antibody 8G12 
specific for BRSV F protein (Klucas and Anderson, 1988) as the primary antibody and 
biotinylated horse anti-mouse immunoglobulin (Vector Laboratories, Burlingame, CA) as 
the secondary antibody. Antibody binding was detected using streptavidin horseradish 
peroxidase (HRP) conjugate (Zymed, San Francisco, CA) and 3-amino-9-ethyl-carbazole 
(AEC). Virus titration from each time point was determined using the Reed–Muench 
method.  
2.9. BRSV RNA extraction and Real-time Q-RT-PCR 
Viral RNA was extracted from 140 µl BT cell lysate infected with BRSV alone or 
co-infected with BRSV/BVDV2-wt or BRSV/BVDV2-E from each of the nine time 
points 2, 6, 12, and 24 HPI, and 2, 3, 5, 7, and 9 DPI using the QIAamp® Viral RNA 
Mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s directions. 
Extracted RNA was stored in AVE buffer at –80 °C until used. Real-time Quantitative-
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RT-PCR (Q-RT-PCR) was performed in single wells of a 96-well plate (Bio-Rad, 
Hercules, CA, USA) in a 25 μl reaction volume using components of a commercial RT-
PCR kit (QuantiTect Probe RT-PCR kit, Qiagen). Primers and probes were purchased 
from Integrated DNA Technologies, Inc. (Coralville, IA, USA). The primers and probe 
for BRSV amplification, based on conserved regions of the N gene were: forward primer: 
5’-GCAATGCTGCAGGACTAGGTATAAT-3’; reverse primer: 5’-ACACTGTAATTG- 
ATGACCCCATTCT-3’; and probe: 5’-/5HEX/-ACCAAGACTTGTATGATGCTGCC-
AAAGCA-/31ABkFQ/-3’ (Boxus et al., 2005). The 25 μl Q-RT-PCR reaction mixture 
contained: 12.5 μl QuantiTect Probe RT-PCR Mix (2X), 1 μl of 10 µM (BRSV) forward 
primer, 1 μl of 10 µM (BRSV) reverse primer, 1 μl of 5 µM (BRSV) fluorogenic probe, 
4.25 μl of RNase-Free Water, 0.25 μl of QuantiTect RT Mix, and 5 μl of viral RNA 
sample. Both reverse transcription and PCR were carried out in the same well of a 96-
well plate using iCycler iQ™ Thermal Cycler (Real-Time PCR Detection System, Bio-
Rad). Thermocycling parameters for BRSV amplification consisted of 50 °C for 30 
minutes, 95 °C for 15 minutes, followed by 45 cycles of 94 °C for 15 seconds and 59 °C 
for 60 seconds . Fluorescence was measured following each cycle and displayed 
graphically. The iCycler iQ software (Bio-Rad) determined a quantification cycle (Cq) 
(also known as cycle threshold, Ct) value, which identified the first cycle at which the 
fluorescence was detected above the baseline for that sample or standard.  
The standard curve, Cq value vs. starting BRSV RNA amounts extracted from 
serial BRSV dilutions, was used to determine the initial starting quantity of unknown 
BRSV RNA from each time point based on the Cq values for the known BRSV 
standards. 
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2.10. Determination of two reference genes 
EXPRESS One-Step SYBR® GreenER™ Kit (Invitrogen) with a prime PCR 
Custom 96-well plate with 19 genes (Cow B96 reference plate, 20X, Bio-Rad) was used 
to determine the appropriate reference genes for BT cells. RNA samples were extracted 
from BRSV-infected BT cells at 1 or 5 DPI. Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and bovine ribosomal protein S18 (RPS18) were chosen as endogenous 
controls to normalize all gene expression results. This experiment was repeated two times 
generating similar results. 
2.11. Cellular gene mRNA extraction and Real-time Q-RT-PCR 
BT cells in 75 cm2 flasks were infected with BVDV2-wt, BVDV2-E, BRSV, 
BRSV and BVDV2-wt, or BRSV and BVDV2-E at a m.o.i. of 0.05, stimulated with poly 
I:C (100 µg/ml), or treated with media as UI control. Cells were harvested at 2 HPI, 1, 2, 
3, 5, 7, or 9 DPI by removing the media and lysing cells with RLT buffer (Qiagen). Cell 
lysates were stored at –80 °C. Total RNA was extracted using the RNeasy plus Mini kit 
(Qiagen) according to the manufacturer’s directions. This kit includes gDNA Eliminator 
Mini Spin Columns specially designed to effectively remove genomic DNA (gDNA) 
contamination. RNA was eluted and then diluted to 20 µg/µl in RNase-free water and 
stored in 0.5-ml tube aliquots at –80 °C until used. The cellular gene mRNA levels were 
quantified using Q-RT-PCR in single wells of a 96-well plate (Bio-Rad) in a 20 μl 
reaction volume using the EXPRESS One-Step SuperScript qRT-PCR kit (Invitrogen). 
The cellular genes (MAVS, PKR, TBK-1, NF-κB, IRF-3, IRF-7, IFN-β, and PIN-1) were 
detected using commercially available primer and probe sets specific for bovine genes 
(TaqMan Gene Expression Assays, Applied Biosystems, Foster City, CA, USA). The 20 
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μl Q-RT-PCR reaction mixture contained: 10 μl EXPRESS SuperScript qRNA SuperMix 
Universal, 1.6 μl of RNase-Free Water, 0.4 μl of ROX Reference Dye (25 μM), 2 μl of 
SuperScript® Reverse Transcriptase (RT), 1 μl of TaqMan Gene Expression Assays, and 
5 μl (100 ng) of the total RNA sample. Both reverse transcription and PCR were carried 
out in the same well of a 96-well plate using C1000 Touch™ Thermal Cycler (Bio-Rad). 
Thermocycling parameters for all gene amplifications consisted of 50 °C for 15 minutes, 
95 °C for 2 minutes, followed by 40 cycles of 95 °C for 15 seconds and 60 °C for 60 
seconds . Fluorescence was measured following each cycle and displayed graphically. 
The CFX Manager™ Software (Bio-Rad) determined a Cq value, which identified the 
first cycle at which the fluorescence was detected above the baseline for that sample. The 
results were normalized against two reference genes, GAPDH and RPS18, and 
represented as fold change expressed relative to UI at the 2 HPI time point using the 
∆∆Cq method (Hellemans et al., 2007). Briefly, the ∆Cq value was calculated by 
normalizing each sample to the average of GAPDH and RPS18 using the equation ∆Cq = 
Cq (target gene) – Cq ((GAPDH + RPS18) /2). Then, ∆∆Cq was calculated by 
subtracting the ∆Cq of the control (UI at 2 HPI) sample from the ∆Cq of each 
experimental and control sample using the equation ∆∆Cq =∆Cq (a normalized sample) – 
∆Cq (the control sample). Lastly, the relative values to the control sample were 
calculated by using the formula 2–(∆∆Cq), where the control sample =2–(0) =20 =1. The 
experiment was replicated independently three times resulting in a randomized complete 
block design and the averages are represented. Three PCR wells were used for a common 
sample (inter-run calibration) in every plate to normalize among the runs in multiple 
plates. Two PCR wells were used without RT, using RNase-Free Water to ensure that 
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there was no gDNA contamination. The common total RNA sample was extracted from 
BT cells incubated for 5 days using the same kit and stored in aliquots at –80 °C until 
used. 
2.12. IFN-β and NF-kB activities using a Dual-luciferase reporter assay 
BT cells (1.5×104) were seeded into seven individual wells of seven 96-well 
plates and incubated at 37 °C in a humidified incubator with 5% (v/v) CO2 for 16 h and 
then transfected with pGL4.32 [luc2P/NF-κB-RE/Hygro] Vector (Promega) or IFN-β 
plasmid (Beura et al., 2010; a kind gift provided by Dr. Fernando Osorio) (firefly) and 
control (pRL Renilla Luciferase Reporter) Vector (Promega) using ViaFect™ 
Transfection Reagent (Promega). The transfection cocktails prepared consisted of 
pGL4.32 (50 ng) with pRL-TK (2.5 ng) (20:1) or IFN-β plasmid (100 ng) with pRL-TK 
(2.5 ng) (40:1). After 24 HPI, cells were infected with BVDV2-wt, BVDV2-E, BRSV, 
BRSV and BVDV2-wt, or BRSV and BVDV2-E at a m.o.i. of 0.05, stimulated with poly 
I:C (100 µg/ml), or treated with media as UI control. Cells were harvested at 2 HPI, 1, 2, 
3, 5, 7, or 9 DPI by removing the media and lysing cells with 1X PLB (Promega). Using 
the Dual-Luciferase® Reporter Assay System (Promega), lysates were evaluated for NF-
kB or IFN-β activity. Luciferase activities were measured by using a 20/20n luminometer 
(Turner Biosystems, CA, USA) and expressed as relative luciferase units (RLU). Ratios 
were obtained by dividing the RLU for firefly luciferase activity (NF-kB or IFN-β) by 
RLU for Renilla luciferase activity (internal control) in each sample. Then, all ratios were 
divided by a UI ratio to represent the results as relative fold increases or decreases. The 
experiment was repeated three times and the graphs represent the averages. 
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2.13. Statistical analysis  
Data were analyzed using the SAS statistical software program (SAS Institute 
Inc., Cary, NC, USA). Statistical significance was evaluated using analysis of variance 
(ANOVA) for a randomized complete block experimental design, and mean comparisons 
and contrasts were used to separate treatments. Bio-Rad CFX Manager 3.1 was used to 
analyze the gene mRNA results. The mRNA results that were upregulated at least 2-fold 
were identified. A P-value less than 0.05 was considered statistically significant. 
3. Results 
3.1. Influence of type 2 BVDV Npro on the IFN-1 response of MDBK cells  
The influence of ncp BVDV2-wt and BVDV2-E (Fig. 2.1A) on the IFN-1 
response in MDBK cells was evaluated using the NCL1-ISRE-Luc-Hygro reporter cell 
line. BVDV2-wt isolate with a functional Npro was a poor inducer of IFN-1 response in 
vitro, while BVDV2-E, a mutant with a dysfunctional Npro fused with EGFP, induced a 
significant IFN-1 response. Cells infected with BVDV2-E synthesized a significantly (P 
< 0.0001) greater level of IFN-1 compared to the UI control cells and to the BVDV2-wt-
infected cells; however, cells infected with BVDV2-wt synthesized an equivalent level of 
IFN-1 compared to the UI control cells (Fig. 2.1B). The levels of IFN-1 synthesized by 
cells infected with BVDV2-E were 22 times greater than the UI control cells and 
BVDV2-wt-infected cells. MDBK cells exposed to poly I:C (positive control) 
synthesized significantly greater levels of IFN-1 compared to viral infected or UI control 
cells.  
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 BVDV2-E-infected MDBK cells produced significantly greater amounts of IFN-1 
than cells infected with BVDV2-wt, while BVDV2-wt strongly inhibited IFN-1 
production in cells stimulated with poly I:C. MDBK cells infected with BVDV2-wt  and 
stimulated 48 HPI with poly I:C for 20 h synthesized low levels of IFN-1 compared to 
BVDV2-E-infected or UI control cells. Cells infected with BVDV2-E synthesized a 
significantly greater level (P=0.023; 3.6 times) of IFN-1 than cells infected with the 
BVDV2-wt isolate (Fig. 2.1C). MDBK cells exposed to poly I:C twice (positive control) 
and UI control cells exposed to poly I:C once synthesized significantly (P < 0.0002) 
greater levels of IFN-1 compared to viral infected cells stimulated once with poly I:C.  
3.2. IFN-1 response of BT cells to BRSV, BVDV2 or BRSV/BVDV2 infections 
BT cells were used to characterize the IFN-1 response to BRSV, BVDV2 or 
BRSV/BVDV2 infections. IFN-1 inhibition was significantly greater in cells co-infected 
with BRSV/BVDV2-wt than in cells co-infected with BRSV/BVDV2-E or BRSV-
infected cells (Fig. 2.2A). BT cells infected with BVDV2-E had IFN-1 levels 2.6 times 
greater (P=0.0013) than cells infected with BVDV2-wt. Cells co-infected with 
BRSV/BVDV2-E had IFN-1 levels 2.2 times greater than cells co-infected with 
BRSV/BVDV2-wt (P=0.0012). Cells infected with BRSV alone had IFN-1 levels 2.7 
times greater than BVDV2-wt-infected cells (P=0.0013). UI control cells synthesized 
twice the amount of IFN-1 compared to cells infected with the BVDV2-wt isolate. BT 
cells exposed to poly I:C synthesized a significantly (P < 0.0001) greater amount of IFN-
1 compared to UI control cells or cells infected with either BVDV2 virus alone or co-
infected with BRSV/BVDV2. 
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3.3. BRSV titers and RNA levels in BRSV and BRSV/BVDV2 co-infected BT cells 
 BT cells infected with BRSV/BVDV2-wt, BRSV/BVDV2-E, or BRSV alone 
were assayed for BRSV infectivity at 2, 6, 12 and 24 HPI, and 2, 3, 5, 7 and 9 DPI. The 
BRSV titer was significantly (P=0.0228) greater in BT cells infected with 
BRSV/BVDV2-wt compared to other infections at 5 DPI (Fig. 2.2B). Increased BRSV 
replication did not occur in cells co-infected with BRSV/BVDV2-E compared to cells 
infected with BRSV alone. 
 BRSV RNA levels in cells co-infected with BRSV/BVDV2-wt were 2.5, 2.8, and 
2.9 copy number logs significantly (P=0.0008) greater than in cells infected with BRSV 
alone or co-infected with BRSV/BVDV2-E at 5, 7, and 9 DPI, respectively (Fig. 2.2B). 
There was no significant difference in BRSV RNA levels between cells infected with 
BRSV or co-infected with BRSV/BVDV2-E.  
3.4. BVDV2-E induces the mRNA expression of PKR and TBK-1 
Using real-time Q-RT-PCR, BT cells infected with BVDV2-E, a mutant with a 
dysfunctional Npro, significantly (P < 0.0001) increased PKR mRNA production 
compared to BVDV2-wt-infected, BRSV-infected, or UI cells. BVDV2-E-infected cells 
produced 2.2, 2.7, 9.8, 3.8, 3.1, 3.8, and 3.5 times greater levels of PKR mRNA 
compared to BVDV2-wt-infected cells at 2 HPI, 1, 2, 3, 5, 7, and 9 DPI, respectively 
(Fig. 2.3A). BT cells infected with BVDV2-wt and BRSV had similar levels of PKR 
mRNA at all time points evaluated and were increased after 2 DPI compared to UI cells. 
Cells co-infected with BRSV/BVDV2-E significantly (P < 0.0001) increased the PKR 
mRNA production compared to cells co-infected with BRSV/BVDV2-wt or UI cells. 
Cells co-infected with BRSV/BVDV2-E produced 2.0, 2.7, 7.2, 3.6, 6.0, 6.8, and 9.2 
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times greater levels of PKR mRNA compared to cells co-infected with BRSV/BVDV2-
wt at 2 HPI, 1, 2, 3, 5, 7, and 9 DPI, respectively (Fig. 2.3B). After 3 DPI, co-infection of 
cells with BRSV and BVDV2-wt decreased levels of the PKR mRNA compared to single 
infections with BVDV2-wt or BRSV. At 5, 7, and 9 DPI, BRSV reduced the PKR mRNA 
levels in cells co-infected with BVDV2-E compared to BVDV2-E-infected cells alone 
(Fig. 2.3A and 2.3B). 
TBK-1 mRNA production started to increase in BT cells infected with BVDV2-E 
2 DPI and became significantly (P < 0.01) greater than levels in BVDV2-wt-infected, 
BRSV-infected, or UI cells at 5, 7, and 9 DPI. BVDV2-E-infected cells produced 2.0, 
2.5, and 2.2 times greater levels of TBK-1 mRNA compared to BVDV2-wt-infected cells 
at 5, 7, and 9 DPI, respectively (Fig. 2.4A). No significant differences were observed in 
TBK-1 mRNA levels between BVDV2-wt-infected, BRSV-infected or UI cells. Cells co-
infected with BRSV/BVDV2-E had increased TBK-1 mRNA production two DPI and 
significantly (P < 0.01) greater TBK-1 mRNA levels 5, 7, and 9 DPI compared to cells 
co-infected with BRSV/BVDV2-wt or UI cells. Cells co-infected with BRSV/BVDV2-E 
produced 2.3, 2.1, and 2.3 times greater levels of TBK-1 mRNA compared to cells co-
infected with BRSV/BVDV2-wt at 5, 7, and 9 DPI, respectively (Fig. 2.4B). Cells co-
infected with BRSV/BVDV2-wt had TBK-1 mRNA levels similar to UI cells. At 7 and 9 
DPI, BRSV reduced the TBK-1 mRNA levels in cells co-infected with BVDV2-E 
compared to BVDV2-E-infected cells alone (Fig. 2.4A and 2.4B). 
3.5. BVDV2-E induces the mRNA expression of IRF-3 and IRF-7 
Using real-time Q-RT-PCR, BT cells infected with ncp BVDV2-E, a mutant with 
a dysfunctional Npro, significantly (P < 0.0001) increased the IRF-3 mRNA production 
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compared to BVDV2-wt-infected, BRSV-infected, or UI cells. BVDV2-E-infected cells 
produced 3.1, 3.3, 3.5, 4.6, and 4.0 times greater levels of IRF-3 mRNA compared to 
BVDV2-wt-infected cells at 2, 3, 5, 7, and 9 DPI, respectively (Fig. 2.5A). BRSV 
modestly induced IRF-3 mRNA after 3 DPI. No significant differences were detected in 
the levels of IRF-3 mRNA between cells infected with ncp BVDV2-wt compared to UI 
cells at all time points evaluated (Fig. 2.5A). Cells co-infected with BRSV/BVDV2-E 
significantly (P < 0.0001) increased the IRF-3 mRNA production compared to cells co-
infected with BRSV/BVDV2-wt or UI cells. Cells co-infected with BRSV/BVDV2-E 
produced 2.9, 3.3, 4.5, 4.2, and 4.4 times greater levels of IRF-3 mRNA compared to 
cells co-infected with BRSV/BVDV2-wt at 2, 3, 5, 7, and 9 DPI, respectively. Cells co-
infected with BRSV/BVDV2-wt had IRF-3 mRNA levels equivalent to UI cells (Fig. 
2.5B). At 7 and 9 DPI, BRSV reduced the IRF-3 mRNA levels in cells co-infected with 
BVDV2-E compared to BVDV2-E-infected cells (Fig. 2.5A and 2.5B). 
BT cells infected with BVDV2-E had significantly (P < 0.0001) increased IRF-7 
mRNA production compared to BVDV2-wt-infected, BRSV-infected, or UI cells. 
BVDV2-E-infected cells produced 5.9, 5.9, 13.8, 3.9, 2.6, 3.2, and 4.0 times greater 
levels of IRF-7 mRNA compared to BVDV2-wt-infected cells at 2 HPI, 1, 2, 3, 5, 7, and 
9 DPI, respectively. Compared to UI cells, BT cells infected with BVDV2-wt or BRSV 
produced greater levels of IRF-7 mRNA after 2 DPI. BVDV2-wt and BRSV induced 
similar levels of IRF-7 mRNA (Fig. 2.6A). Cells co-infected with BRSV/BVDV2-E had 
significantly (P < 0.0001) increased IRF-7 mRNA production compared to cells co-
infected with BRSV/BVDV2-wt or UI cells. Cells co-infected with BRSV/BVDV2-E 
produced 3.5, 5.4, 9.0, 3.9, 5.9, 7.7, and 13.0 times greater levels of IRF-7 mRNA 
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compared to cells co-infected with BRSV/BVDV2-wt at 2 HPI, 1, 2, 3, 5, 7, and 9 DPI, 
respectively (Fig. 2.6B). Co-infection of cells with BRSV/BVDV2-wt had decreased 
levels of IRF-7 mRNA compared to single infections with BVDV2-wt or BRSV. At 7 
and 9 DPI, BRSV reduced the IRF-7 mRNA levels in cells co-infected with BVDV2-E 
compared to BVDV2-E-infected cells (Fig. 2.6A and 2.6B). 
3.6. BVDV2-E induces the mRNA expression of IFN-β 
BT cells infected with BVDV2-E had significantly (P < 0.01) increased IFN-β 
mRNA production compared to BVDV2-wt-infected or UI cells. BVDV2-E-infected 
cells produced 3.0, 5.7, 8.5, 7.0, and 3.4 times greater levels of IFN-β mRNA compared 
to BVDV2-wt-infected cells at 2, 3, 5, 7, and 9 DPI, respectively. There was no 
significant difference in IFN-β mRNA levels between ncp BVDV2-wt and UI cells (Fig. 
2.7A). Cells co-infected with BRSV/BVDV2-E had significantly (P < 0.01) increased 
IFN-β mRNA production compared to cells co-infected with BRSV/BVDV2-wt or UI 
cells. Cells co-infected with BRSV/BVDV2-E produced 2.8, 5.2, 7.5, 3.1, and 2.2 times 
greater levels of IFN-β mRNA compared to cells co-infected with BRSV/BVDV2-wt at 
2, 3, 5, 7, and 9 DPI, respectively. In BRSV-infected cells, IFN-β mRNA production 
began increasing at 5 DPI and became significant (P < 0.01) at 7 and 9 DPI compared to 
BVDV2-wt-infected cells or UI cells. In co-infected cells, BVDV2-wt abolished the 
increased effect of BRSV and decreased the IFN-β mRNA to levels equivalent to those 
found in UI cells (Fig. 2.7B). BRSV did not reduce the IFN-β mRNA levels in cells co-
infected with BRSV/BVDV2-E or BRSV/BVDV2-wt compared to BVDV2-E- or 
BVDV2-wt-infected cells, respectively. Within 2 HPI, cells stimulated with poly I:C 
produced 49 times greater level of IFN-β mRNA compared to UI cells and viral infected 
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cells; however, there were no significant differences between cells stimulated with poly 
I:C and UI cells at any other time point evaluated (Fig. 2.7A and 2.7B). 
3.7. IFN-β and NF-κB luciferase activities in infected BT cells 
Using a dual-luciferase reporter assay, IFN-β luciferase activity in BT cells 
infected with BVDV2-E was 2.6, 2.6, and 2.3 times significantly (P < 0.05) greater than 
in cells infected with BVDV2-wt at 1, 2, and 5 DPI, respectively. The IFN-β luciferase 
activity in cells co-infected with BRSV/BVDV2-E was 2.5, 2.2, and 1.9 times 
significantly (P < 0.05) greater than in cells co-infected with BRSV/BVDV2-wt at 1, 2, 
and 5 DPI, respectively (Fig. 2.7C). No significant differences between treatment groups 
were observed at 3 DPI, as well as at 2 HPI, 7, and 9 DPI (Fig. 3.11). There were no 
significant differences in the IFN-β luciferase activity among cells infected with BRSV, 
BVDV2-wt, or co-infected with BRSV/BVDV2-wt at any time point evaluated. 
BVDV2-wt in BT cells co-infected with BRSV significantly (P < 0.05) increased 
NF-κB luciferase activity within 3 DPI compared to BRSV-infected or UI cells (Fig. 2.8). 
The NF-κB luciferase activity in cells infected with BVDV2-wt was 9.7, 12.7, and 6.9 
times significantly (P < 0.05) greater than cells infected with BVDV2-E at 5, 7, and 9 
DPI, respectively. The NF-κB luciferase activity in cells co-infected with 
BRSV/BVDV2-wt was 8.5 times significantly (P < 0.05) greater than cells co-infected 
with BRSV/BVDV2-E at both 5 and 7 DPI and 11.7 and 11.8 times greater than cells 
infected with BRSV alone at 5 and 7 DPI, respectively (Fig. 2.8). No significant 
differences between treatment groups were detected at 2 HPI, 1 DPI, and 2 DPI (Fig. 
3.12). 
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4. Discussion 
 Our findings of ncp BVDV2 inhibition of IFN-1 pathway signaling and the 
enhancement of BRSV replication demonstrates the important role of BVDV2 in single 
and co-infected cells. The importance of the BVDV2 Npro protein suggests a similar 
importance of the intact BVDV2 Npro in animals infected with BRDC. In vitro, ncp 
BVDV1 Npro mediates inhibition of IFN-1 production in host cells (Gil et al., 2006a; 
Hilton et al., 2006; Schweizer et al., 2006). In the present study, the BVDV2-wt isolate 
with a functional Npro was a poor inducer of IFN-1, while BVDV2-E, a mutant with a 
dysfunctional Npro fused with EGFP, induced a significant IFN-1 response in both 
MDBK and BT cells. These results are consistent with a previous report of a mutant type 
1 BVDV strain NADL with modified Npro fused with EGFP, which showed reduced 
antagonism of IFN-1 synthesis. It was determined that the IFN-1 response was dependent 
on Npro expression and independent of viral replication efficiency (Gil et al., 2006a). The 
increased production of IFN-1 by cells infected with BVDV2-E may have reduced viral 
replication to significantly lower levels, which suggests that the antagonism of IFN-1 
production enhances BVDV2 replication. These results are similar to a study where 
recombinant IFN-1 inhibited CSFV replication in different cell lines (Xia et al., 2005). 
BVDV2-wt strongly inhibited IFN-1 production in MDBK cells stimulated 48 HPI with 
poly I:C, while BVDV2-E-infected cells produced significantly greater amounts of IFN-1 
than cells infected with BVDV2-wt. These results demonstrate the role of an intact 
functional BVDV2 Npro in the antagonism of IFN-1 production in host cells and suggest 
that BVDV2-E is able to replicate effectively in the presence of IFN-1 but at lower levels. 
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In this study, IFN-1 inhibition was significantly greater in BT cells co-infected 
with BRSV and BVDV2-wt than in cells co-infected with BRSV and BVDV2-E or in 
cells infected with BRSV alone. The Npro product of BVDV interferes with the 
transcription and synthesis of IFN-1 by promoting the degradation of IRF-3 by 
proteosomal degradation (Hilton et al., 2006; Seago et al., 2007). It was reported that the 
insertion of EGFP within the amino end of Npro interferes with the protein’s ability to 
promote IRF-3 degradation. The structural integrity of the BVDV Npro amino terminus 
was important for IFN-1 suppression rather than the enzymatic activity of the protein (Gil 
et al., 2006a). In this study, results showed that cells co-infected with BRSV/BVDV2-wt 
exhibit greater IFN-1 inhibition than cells infected with BRSV alone. Inhibition of the 
IFN-1 response of cells with BVDV2-wt infection enhanced BRSV replication. The 
decrease in IFN-1 inhibition observed in cells co-infected with BRSV/BVDV2-E 
confirms the role of Npro on IFN-1 inhibition.  
 The BRSV titer and RNA levels significantly increased in BT cells co-infected 
with BRSV/BVDV2-wt compared to cells co-infected with BRSV/BVDV2-E or infected 
with BRSV alone. This increased BRSV replication was attributed to the synergistic 
action of BVDV2-wt and BRSV inhibition of IFN-1. These results are consistent with a 
previous study where the IFN-1 pathway signaling was inhibited by using a TBK-1 
inhibitor, which decreased the IFN-β mRNA expression and increased the viral mRNA 
expression of dengue virus serotype 2 (DENV2), a member of the family Flaviviridae 
(Zhang et al., 2013). The nonstructural BRSV proteins, NS1 and NS2, together inhibit the 
phosphorylation and transcriptional activity of IRF-3 resisting IFN-1 production (Bossert 
and Conzelmann, 2002; Bossert et al., 2003). In addition, the Npro protein of BVDV 
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inhibits the production of IFN-1 by targeting the IRF-3 for proteosomal degradation, 
resulting in the inhibition of IFN-1 transcription (Seago et al., 2007). Increases in BRSV 
titer and RNA levels did not occur in cells co-infected with BRSV/BVDV2-E compared 
to cells infected with BRSV alone, which is attributed to the diminished ability of 
BVDV2-E to inhibit IFN-1.  Similarly, in vivo, enhanced respiratory and digestive tract 
diseases have been reported with BRSV/BVDV co-infections compared to infection with 
either virus alone (Brodersen and Kelling, 1998, 1999). Brodersen and Kelling (1998; 
1999) showed that calves concurrently infected with BRSV and BVDV had more severe 
clinical signs of disease and extensive lung lesions, and shed virus in greater 
concentration for longer duration compared to calves infected with either virus alone 
(Brodersen and Kelling, 1998, 1999). BVDV2-wt, unlike BVDV2-E, enhances BRSV 
replication because of the intact BVDV2 Npro role in the antagonism of IFN production. 
Using a real-time Q-RT-PCR assay, we observed decreased effects of the BVDV2 
Npro protein on IFN-1 pathway signaling during single and co-infection with BRSV. 
Compared to intact BVDV2 Npro, the dysfunctional Npro had greatly increased mRNA 
levels of PKR, TBK-1, IRF-3, IRF-7, and IFN-β, while no significant differences in 
MAVS and NF-κB mRNA, as well as the mRNA of the protein that facilitates the IRF-3 
degradation, PIN-1, were observed. 
MAVS (IFN-β-promoter stimulator 1, IPS-1) is essential for IFN-1 production in 
viral infections through IRF-3 and NF-κB pathways. In the current study, BRSV, 
BVDV2-wt, and BVDV2-E did not affect MAVS mRNA expression. These results are 
consistent with a previous study reporting that MAVS was largely intact when HEC-1B 
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cells were infected with poliovirus, a virus that significantly reduced the IFN-β mRNA 
levels (Kotla and Gustin, 2015). The importance of MAVS in the IFN-1 pathway was 
reported in mammalian (feline) cells. During Sendai virus infection, inhibiting MAVS by 
using siRNA inhibited the IFN-β promoter activation. In contrast, MAVS over-
expression activated IRF-3 and NF-κB pathway signaling and induced IFN-β production 
(Wu et al., 2016). Our results showed no significant differences in MAVS mRNA among 
the different treatment groups at all time points compared to UI cells (Fig. 3.6A and 
3.6B), while the IFN-β mRNA levels and the IFN-1 production were significantly 
reduced in cells infected BVDV2-wt. These results indicate that the intact BVDV2 Npro 
antagonism of IFN-1 production does not appear to be mediated by MAVS mRNA 
expression inhibition. 
The IFN-induced double-stranded RNA-dependent protein kinase (PKR) is 
activated in response to dsRNA and a wide range of activators and cell stresses. 
Phosphorylated (activated) PKR can activate NF-κB, phosphorylate eIF2α, and induce 
apoptosis (García et al., 2006). In this study, BVDV2-wt increased PKR mRNA after two 
DPI, which is consistent with an in vivo study where both types of ncp BVDV, type 1 and 
2, increased PKR mRNA at 5 DPI in spleen and tracheo-bronchial lymph nodes of 
infected beef calves (Palomares et al., 2013). Although BVDV2-wt increased PKR 
mRNA, BVDV2-E increased PKR mRNA more rapidly and to greater levels suggesting 
an important role of ncp BVDV2 Npro protein in PKR inhibition. In contrast, it was 
determined that unlike cp BVDV, ncp BVDV1 inhibited the PKR signaling pathway 
resulting in enhanced protein synthesis and cell survival (Gil et al., 2006b). CSFV 
activates PKR which phosphorylates the eIF2α leading to apoptosis (Hsu et al., 2014). 
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Our study showed that BRSV and BVDV2-wt increased PKR mRNA to similar levels, 
while co-infection with BRSV and BVDV2-wt did not increase the PKR mRNA, which 
was attributed to the synergistic action of these two viruses. Minimal difference in BRSV 
cytopathic effects was observed between cells infected with BRSV and cells co-infected 
with BRSV and BVDV2-wt. Although the PKR mRNA levels in cells co-infected with 
BRSV and BVDV2-E were increased compared to cells infected with BRSV alone, the 
BRSV cytopathic effects were decreased in co-infected cells (data not shown). These 
results suggest that PKR is not essential for the cytopathic effects of BRSV. PKR detects 
viral dsRNA and initiates the antiviral stress granule (avSG) formation in the cytoplasm 
which triggers innate immunity. Removal of PKR diminished IFN production and 
enhanced viral replication (Onomoto et al., 2012). Secreted IFN-1 binds to IFN-1 
receptor on the neighboring cells triggering a variety of genes, including PKR, which can 
be induced by the IFN treatment (García et al., 2007). The increased PKR mRNA levels 
caused by BVDV2-E compared to BVDV2-wt may, in part, relate to the increased IFN-1 
production (feedback effect). The rapid increase in PKR mRNA observed within 2 HPI 
following BVDV2-E infection demonstrates an inhibitory role of intact Npro in PKR 
mRNA expression. 
TANK-binding kinase 1 (TBK-1, also known as NF-κB-activating kinase (NAK) 
or T2K) regulates the IRF-3 and NF-κB pathways. Activated TBK-1 phosphorylates the 
transcription factors IRF-3 and IRF-7 (Zhao, 2013). The NS3 protein of hepatitis C virus, 
a member of the BVDV family (Flaviviridae), binds to TBK-1 and inhibits the 
interaction between TBK-1 and IRF-3 leading to cellular antiviral response inhibition 
(Otsuka et al., 2005). In our study, TBK-1 mRNA levels were increased by BVDV2-E 
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while they were not changed in infections with BVDV2-wt and/or BRSV compared to UI 
cells. The lack of TBK-1 up-regulation in BVDV2-wt-infected cells was associated with 
the inhibition of the IRF-3/7 pathway signaling and decreased IFN-1 production, which 
may be associated with lack of IRF-3/7 phosphorylation. Whereas, BVDV2-E up-
regulated the TBK-1 and increased the IFN-1 production, which suggests a central role of 
BVDV2 Npro on TBK-1 regulation in the IRF-3/7 signaling pathway. Similar results were 
reported when HepG2 cells were treated with a TBK-1 inhibitor (BX795) and stimulated 
with poly I:C, which decreased the IFN-β mRNA expression and increased the DENV2 
viral mRNA expression (Zhang et al., 2013). Preventing the IRF-3/7 activation by 
inhibiting the TBK-1 mRNA expression suggests another role of intact Npro in the 
antagonism of IFN-1 production and immunosuppression associated with BVDV 
infection. 
The transcription factor, nuclear factor-κB (NF-κB), induces the expression of 
immune and inflammatory genes and IFN-1 production. To determine whether BRSV 
and/or BVDV2 can inhibit inflammatory reactions via inhibition of the NF-κB signaling 
pathway, we utilized a dual-luciferase reporter assay system. While there were no 
significant differences in the expression of NF-κB mRNA (Fig. 3.7A and 3.7B) among 
different infections at different time points, BVDV2-wt, unlike BVDV2-E, significantly 
increased NF-κB luciferase activity. Similar to our results, cp BVDV type 1 was able to 
induce the production of cytokines and modulate transcriptional factors, including IRF-7, 
in MDBK cells through activating NF-κB. The expression of the negative regulator of the 
immune response A20 (TNFAIP3), a target ubiquitin-editing enzyme of NF-κB, is 
mediated by the NF-κB pathway. Using the pharmacological inhibitor of NF-κB 
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signaling pathway (BAY-117085) blocked the BVDV type 1 activities (Fredericksen et 
al., 2015, 2016). The significantly increased BVDV2-wt activation of NF-κB suggests 
that the intact Npro antagonizes the IFN-1 production through a NF-κB-independent 
pathway. In cells infected with cp BVDV NADL, the Npro does not affect the NF-κB 
activation of gene expression (Chen et al., 2007). However, our results indicate that only 
the dysfunctional BVDV2 Npro did not affect the NF-κB activity suggesting a positive 
role of intact ncp BVDV2 Npro in the NF-κB activation. The increase in NF-κB activity 
and the decrease in IFN-1 production in cells infected with BVDV2-wt suggest that the 
IRF3/7 pathway is the main pathway of IFN-1 production that is reduced by intact 
BVDV2 Npro in single and co-infection with BRSV. It has been reported that respiratory 
syncytial virus (RSV) is a potent activator of NF-κB (Jamaluddin et al., 1998). This is in 
contrast to our results that showed that BRSV did not increase NF-κB luciferase activity. 
Our results of NF-κB activity and mRNA expression suggest a limited role of NF-κB 
pathway in IFN-1 production in BVDV2- and BRSV-infected BT cells. 
The mammalian interferon-regulatory factor (IRF) family includes nine members 
named from one to nine. They have different roles in the gene regulatory networks in the 
immune system. IRF-3 and IRF-7 are closely related to each other and are important 
cellular transcription factors targeting the IFN-1 gene and increasing the IFN-1 
production in infected cells. IRF-3 and IRF-7 monomers are activated into 
phosphorylated dimers and translocated to the nucleus of virus-infected cells (Taniguchi 
et al., 2001). Our results showed that BVDV2-wt and BRSV similarly increased the IRF-
7 mRNA levels. However, only BRSV induced the IRF-3 mRNA after 5 DPI, which may 
explain the increased IFN-1 production by BRSV compared to BVDV2-wt. BVDV-1 
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induced the IRF-7 production through activating NF-κB (Fredericksen et al., 2015). In 
our study, BVDV2-wt increased the mRNA levels of IRF-7 within 3 DPI and enhanced 
the NF-κB activity within 3 DPI, while the TBK-1 mRNA levels were not increased by 
BVDV2-wt-infection. These results suggest that BVDV2-wt increased the IRF-7 mRNA 
levels through NF-κB pathway. Compared to single infection, co-infection of cells with 
BRSV and BVDV-wt had reduced IRF-3 and IRF-7 mRNA levels indicating the role of 
BRSV and BVDV-wt in IRF-3 and IRF-7 inhibition and the synergistic interaction of 
these viruses. It has been reported that NS1 and NS2 proteins of BRSV mediate the 
inhibition of IRF-3 activation and IFN induction in infected MDBK cells (Bossert et al., 
2003). In our study, the dysfunctional Npro of BVDV2-E greatly induced IRF-3 mRNA 
levels within 2 DPI and IRF-7 mRNA levels within 2 HPI indicating the role of intact 
BVDV2 Npro in the antagonism of IFN-1 production. These results are consistent with 
studies previously reported showing that the Npro protein of Pestivirus directly interacts 
with the monomer and dimer forms of IRF-3 preventing the IFN production (Gottipati et 
al., 2016). BVDV Npro interacts with IRF-3 before the virus-induced phosphorylation of 
IRF-3 leading to polyubiquitination and proteasomal degradation of IRF-3 (Chen et al., 
2007).  Both cp and ncp BVDV inhibit the full function of IRF-3 but do not increase or 
decrease the nuclear uptake of IRF-7 (Baigent et al., 2004). Our results demonstrate the 
role of intact BVDV2 Npro in the inhibition of the IRF-3 and IRF-7 mRNA expression in 
order to antagonize the IFN production and increase the BRSV replication. 
We found that BVDV2-wt did not change the IFN-β mRNA levels compared to 
UI cells and no significant change in IFN-β luciferase activity was detected, which 
indicated the role of intact Npro in the antagonism of IFN-1. Similar to our results, other 
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studies have shown that the BVDV Npro prevents IFN-β mRNA production in infected 
cells (Chen et al., 2007; Hilton et al., 2006). We found that BVDV2-E greatly increased 
the IFN-β mRNA levels as well as the IFN-β luciferase activity. Our results are consistent 
with a study where cp BVDV with mutant Npro did not suppress the IFN production (Gil 
et al., 2006a). BRSV induced IFN-β mRNA after 5 DPI, which may explain the increased 
IFN-1 production in BRSV-infected cells. This BRSV-mediated increased IFN-β mRNA 
was abolished by BVDV-wt indicating the major role of intact BVDV2 Npro in 
immunosuppression. BRSV had no negative effect on the IFN-β mRNA levels when co-
infected with BVDV2-wt or BVDV2-E. These results demonstrate the importance and 
strength of IFN-1 antagonism by BVDV2-wt, which will increase the replication of 
BRSV. 
The peptidylprolyl isomerase (cis–trans peptidylprolyl isomerase, NIMA-
interacting 1, PIN-1) interacts with the phosphorylated IRF-3 in the nucleus to facilitate 
the IRF-3 degradation and terminate the action of IRF-3 (Saitoh et al., 2006). In our 
study, there were no significant effects of BVDV2-wt, BVDV2-E, and/or BRSV on the 
PIN-1 mRNA levels in different treatment groups (Fig. 3.8A and 3.8B), which is 
consistent with a study by Chen et al., 2007, which suggested that BVDV Npro induces 
IRF-3 degradation via a PIN-1-independent mechanism (Chen et al., 2007). While the 
intact BVDV2 Npro decreases IFN-β mRNA levels and the IFN-1 production, it has no 
impact on the PIN-1 mRNA levels. These results suggest that PIN-1 has no role in IFN 
antagonism during BVDV2 and/or BRSV infections. 
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 Infection with BVDV2-E having a dysfunctional Npro induced greater levels of 
IFN-1 than BVDV2-wt, confirming the role of the intact type 2 BVDV Npro in the 
antagonism of IFN-1 in BVDV2-infected cells. BVDV2-E induced mRNA expression of 
the IRF-3 pathway signals indicating the important inhibition of the IRF-3 pathway by 
intact BVDV2 Npro. In vitro, BVDV-wt, unlike BVDV2-E, decreased mRNA expression 
of the IRF-3 pathway signal in cells co-infected with BRSV/BVDV2-wt and enhanced 
BRSV replication. This enhancement of BRSV replication in vitro correlates with the in 
vivo increased pathogenicity of BRSV in calves co-infected with BVDV (Brodersen and 
Kelling, 1998). In vitro, infection of cells with ncp BVDV having a functional Npro 
interferes with IFN-1 production, yet in vivo BVDV induces a sustained IFN production 
in postnatal animals (Charleston et al., 2002). These findings may contribute to the 
understanding of the immunosuppressive effects of BVDV and the mechanism(s) 
involved in the increased pathogenicity of BRSV and other viral infections during co-
infection with ncp BVDV, which may lead to a better understanding of the BRDC. 
Understanding the role of BVDV and up-regulating the host’s immune response by use of 
a mutant BVDV while maintaining antigenicity should add to the development of a safer 
and more effective BVDV vaccine. 
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Figure legends 
Fig. 2.1. Genomic organization of BVDV2 isolates and IFN production. (A) Genomic 
organization and encoded proteins of BVDV2 NY93/c (BVDV2-wt) and BVDV2 NY93/c 
N-NPro 18 EGFP (BVDV2-E) isolates. The coding sequence of the EGFP was inserted into 
the BVDV2 NY93 genome between amino acids 18 and 19 of the Npro protein forming 
BVDV2-E. (B) MDBK cells infected with BVDV2-E synthesized significantly greater 
levels of IFN-1 compared to UI control cells or cells infected with BVDV2-wt. MDBK 
cells were infected with each BVDV2 isolate and cell lysates harvested 24 HPI, clarified 
by centrifugation, and pH adjusted to inactivate virus. Experimental samples were added 
to NCL1-Luc-ISRE-Hygro reporter cells and incubated for 8 h followed by cell lysis. 
Luciferase activity of the cell lysates was measured. (C) MDBK cells infected with 
BVDV2-E synthesized significantly greater levels of IFN-1 than cells infected with 
BVDV2-wt. MDBK cells were treated with poly I:C, mock-infected with media (UI) or 
infected with each of the BVDV2 isolates. The media and inoculum were replaced with 
fresh poly I:C in all plates at 48 HPI and incubated for an additional 20 h. Cells were then 
treated as in (B). (*) Groups are statistically different from the other groups at P < 0.05. 
Error bars represent standard error of the means (SEM). 
Fig. 2.2. BVDV2 Npro decreases IFN-1 production and increases BRSV replication in 
co-infected BT cells. (A) IFN-1 inhibition was significantly greater in BT cells co-
infected with BRSV/BVDV2-wt than in cells co-infected with BRSV/BVDV2-E or in 
cells infected with BRSV alone. IFN-1 inhibition was significantly greater in BT cells 
infected with BVDV2-wt compared to BVDV2-E. BT cells were infected with BRSV, 
BVDV2-wt, BRSV/BVDV2-wt, BVDV2-E or BRSV/BVDV2-E and after 48 h, media 
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was replaced with fresh media and incubation continued for 20 h. Cells were then treated 
as in Fig. 2.1B. (B) BRSV titers and RNA levels. The BRSV titer was significantly greater 
at 5 DPI in cells co-infected with BRSV/BVDV2-wt compared to cells infected with 
BRSV alone or co-infected with BRSV/BVDV2-E. BVDV2-wt, but not BVDV2-E, 
enhanced BRSV replication in BRSV co-infected BT cells. BT cells were infected with 
BRSV alone, BRSV/BVDV2-wt or BRSV/BVDV2-E. Cell lysates were harvested at 2, 6, 
12, and 24 HPI, and 2, 3, 5, 7, and 9 DPI. BRSV growth kinetics were determined using 
an enzyme-linked immunosorbent assay. BRSV RNA levels were quantified using Q-RT-
PCR. (*) Groups are statistically different from the other groups at P < 0.05. Error bars 
represent SEM. 
Fig. 2.3. BVDV2-E greatly induces PKR mRNA expression. BT cells were infected 
with BVDV2-wt, BVDV2-E, BRSV, or co-infected with BRSV/BVDV2-wt or 
BRSV/BVDV2-E at a m.o.i. of 0.05, or stimulated with poly I:C: (A) single infections and 
(B) co-infections. Cells were harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total RNA was 
extracted and PKR mRNA levels quantified using real-time Q-RT-PCR and normalized 
against two reference genes, GAPDH and RPS18. Results are represented as fold change 
expressed relative to UI control at 2 HPI. (*) Groups are statistically different from the 
other groups at P < 0.05. Error bars represent SEM. 
Fig. 2.4. ncp BVDV2 Npro is essential for TBK-1 inhibition. BT cells were infected, (A) 
single infections and (B) co-infections, and cells harvested and RNAs extracted as in Fig. 
2.3. The TBK-1 mRNA levels were quantified using Q-RT-PCR and normalized. Results 
are represented as in Fig. 2.3. (*) Groups are statistically different from the other groups at 
P < 0.05. Error bars represent SEM. 
76 
 
Fig. 2.5. ncp BVDV2 Npro reduces IRF-3 mRNA expression. BT cells were infected, 
(A) single infections and (B) co-infections, and cells harvested and RNAs extracted as in 
Fig. 2.3. The IRF-3 mRNA levels were quantified using Q-RT-PCR and normalized. 
Results are represented as in Fig. 2.3. (*) Groups are statistically different from the other 
groups at P < 0.05. Error bars represent SEM. 
Fig. 2.6. ncp BVDV2 Npro reduces IRF-7 mRNA expression. BT cells were infected, 
(A) single infections and (B) co-infections, and cells harvested and RNAs extracted as in 
Fig. 2.3. The IRF-7 mRNA levels were quantified using Q-RT-PCR and normalized. 
Results are represented as in Fig. 2.3. (*) Groups are statistically different from the other 
groups at P < 0.05. Error bars represent SEM. 
Fig. 2.7. ncp BVDV2 Npro is essential for IFN-β inhibition. BT cells were infected, (A) 
single infections and (B) co-infections, and cells harvested and RNAs extracted as in Fig. 
2.3. The IFN-β mRNA levels were quantified using Q-RT-PCR and normalized. Results 
are represented as in Fig. 2.3. (C) IFN-β luciferase activity. BT cells were transfected with 
IFN-β (firefly) and control (pRL Renilla Luciferase Reporter) vectors. After 24 h, cells 
were infected with BVDV2-wt, BVDV2-E, BRSV, or co-infected with BRSV/BVDV2-wt 
or BRSV/BVDV2-E, or stimulated with poly I:C. Cells were harvested at 2 HPI, 1, 2, 3, 5, 
7, or 9 DPI. The IFN-β was analyzed using a dual-luciferase reporter assay system. 
Results are represented as relative fold change expressions. No significant differences 
were detected at 2 HPI, 7 DPI, and 9 DPI (Fig. 3.11). (*) Groups are statistically different 
from the other groups at P < 0.05. Error bars represent SEM. 
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Fig. 2.8. NF-κB luciferase activity. BT cells were treated as in Fig. 2.7C using pGL4.32 
[luc2P/NF-κB-RE/Hygro] (firefly) and control (pRL Renilla Luciferase Reporter) vectors. 
Results are represented as in Fig. 2.7C. No significant differences were detected at 2 HPI, 
1 DPI, and 2 DPI (Fig. 3.12). (*) Groups are statistically different from the other groups at 
P < 0.05. Error bars represent SEM. 
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Fig. 2.1. Genomic organization of BVDV2 isolates and IFN production. 
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Fig. 2.2. BVDV2 Npro decreases IFN-1 production and increases BRSV replication in 
co-infected BT cells. 
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Fig. 2.3 (A). PKR mRNA expression in infected BT cells. 
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Fig. 2.3 (B). PKR mRNA expression in co-infected BT cells. 
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Fig. 2.4 (A). TBK-1 mRNA expression in infected BT cells. 
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Fig. 2.4 (B). TBK-1 mRNA expression in co-infected BT cells. 
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Fig. 2.5 (A). IRF-3 mRNA expression in infected BT cells. 
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                               Fig. 2.5 (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.5 (B). IRF-3 mRNA expression in co-infected BT cells. 
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Fig. 2.6 (A). IRF-7 mRNA expression in infected BT cells. 
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                Fig. 2.6 (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.6 (B). IRF-7 mRNA expression in co-infected BT cells. 
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                 Fig. 2.7 (A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.7 (A). IFN-β mRNA expression in infected BT cells. 
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                     Fig. 2.7 (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.7 (B). IFN-β mRNA expression in co-infected BT cells. 
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                 Fig. 2.7 (C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.7 (C). IFN-β luciferase activity. Results are represented as fold change expressed 
relative to UI at the 1 DPI time point. (Look at the extended graph: Fig. 3.11). 
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                    Fig. 2.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.8. NF-κB luciferase activity. Results are represented as fold change expressed 
relative to UI at the 3 DPI time point. (Look at the extended graph: Fig. 3.12). 
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CHAPTER 3: 
SUPPLEMENTARY DATA 
Introduction 
In this research, we used real-time Q-RT-PCR to evaluate the mRNA levels of 
cell signals in BT cells infected with BRSV, BVDV2-wt, or BVDV2-E, or co-infected 
with BRSV/BVDV2-wt or BRSV/BVDV2-E. Type I IFN production levels were 
evaluated and dual-luciferase reporter assays were used for some signals. The main 
findings of this study are published in Virology (Alkheraif et al., 2017). In this section, 
chapter 3, we are presenting some work that was critical for the real-time Q-RT-PCR 
assays and its normalization, as well as some other work that was used to convert the 
results of IFN response assays from luminescence reading (relative light units, RLU) to 
IFN units. Here also, we are providing some results, which were not included or were not 
shown in our published paper, 2017. 
For a gene expression study, it is a very crucial step to specify reliable reference 
genes. We determined that bovine GAPDH with bovine RPS18 are the most reliable 
reference genes to be used in our experiments with BT cells. The quantities of total RNA 
production increased as cell growth increased until they reached 100% confluency, when 
the production of total RNA started to decrease with time. Even though the dual-
luciferase reporter assay results indicated that BVDV2-wt in BT cells co-infected with 
BRSV significantly increased NF-κB luciferase activity compared to BRSV-infected or 
UI cells (Fig. 2.8), real-time Q-RT-PCR did not result in significant differences in the 
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NF-κB mRNA levels. Likewise, real-time Q-RT-PCR did not show significant 
differences in the mRNA expression of MAVS and PIN-1 among different infected and 
co-infected BT cells. BVDV2-E with BRSV in co-infected BT cells increased the 
production of IRF-3 protein at a higher level compared to other infections.  
Total RNA Production in Cells 
BT cells were infected when the confluency became 90%. There was no change in 
the confluency within the first two hours (2 H). Cells continued growing for 24 – 30 
hours (1 D) until they reached 100% confluency. Total RNA increased as cell growth 
increased. When the rate of cell growth decreased because of the limitation of space, the 
production of total RNA decreased. Cells treated with poly I:C produced more total RNA 
compared to infected or uninfected cells. (Fig. 3.1A, B, C). Also, the amount of total 
RNA was affected by the age (passage) of cells. With all infections or treatments, cells at 
passage # 20 (7 day-old) produced more RNA compared to passage # 23 and # 24. Cells 
at passage # 23 (9 day-old) produced more RNA than cells at passage # 24 (10 day-old). 
Younger cells produced more total RNA than older cells (Fig. 3.2A, B, C). 
RT-PCR and Q-RT-PCR 
RT-PCR is a very sensitive method for virus identification and differentiation. 
Quantitative RT-PCR (Q-RT-PCR) determines the total amount of viral RNA present in a 
sample (Menzo et al., 1992). RT-PCR is a quick diagnostic method compared to other 
methods such as virus isolation, plaque assay, or viral titration. The first amplification of 
extracted cp and ncp BVDV RNA was in 1990 using BVDV infected cell cultures and 
clinical samples from PI and acutely-infected calves. The amplified nucleic acid was 
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visualized using agarose gel electrophoresis and stained with ethidium bromide or 
hybridized with biotinylated probes. RT-PCR is specific and sensitive. RT-PCR can be 
used with different primer sets to distinguish between viruses and viral strains. It is 
possible to determine BVDV species in a sample using RT-PCR (Belák and Ballagi-
Pordány, 1991; Hertig et al., 1991; Schmitt et al., 1994; Schroeder and Balassu-Chan, 
1990; Tajima et al., 1995). Nevertheless, gel-based RT-PCR results can be compromised 
during nucleic acid amplification by sample contamination. 
A single tube, fluorogenic probe-based, real-time quantitative RT-PCR (Q-RT-
PCR), TaqMan RT-PCR, was developed to detect RNA of classical swine fever virus 
(McGoldrick et al., 1999; Ophuis et al., 2006). Q-RT-PCR is a rapid, economical, high 
volume, sensitive, and specific procedure to detect, quantify, and classify many viruses in 
samples. Q-RT-PCR has been used to quantify and classify BVDV in serum and tissue 
homogenate (Bhudevi and Weinstock, 2001; Mahlum et al., 2002). Using BioRad's 
iCycler iQ, real-time Q-RT-PCR was used to detect and quantify viral RNA of bovine 
respiratory syncytial virus (BRSV) in cell lysate harvested at different time points post-
infection. Real-time Q-RT-PCR was specific, rapid, efficient, and eliminated the post-
PCR processing steps compared to quantitative competitive RT-PCR (QC-RT-PCR) 
(Achenbach et al., 2004). QC-RT-PCR is an appropriate method for diagnosis of diseases 
and evaluation of the efficiency of vaccines (Boxus et al., 2005). Inter-run calibration is 
required whenever samples are analyzed in more than one run (Hellemans et al., 2007). 
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Determination of Q-RT-PCR Reference Genes 
For a real-time Q-RT-PCR gene expression study, it is a very important and 
crucial step to choose reference genes that are stably expressed amongst different 
treatment groups. Gene expression results need to be normalized against reference genes 
and the use of a minimum of two validated reference genes is highly recommended. 
However, across all gene expression studies, approximately 80% of them used only one 
reference gene. There are an abundance of reference genes, but β-actin (ACTB) and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH, also known as G3PDH) are 
commonly used. Only 15% of studies tested a panel of potential reference genes for the 
stability of expression before using them as reference genes (Chapman and Waldenström, 
2015; Sharan et al., 2015). The stability of reference genes cannot be evaluated by using 
only one reference gene. Using multiple reference genes produces data with greater 
reliability and evaluates the stability of these genes (Hellemans et al., 2007). We used a 
panel of 19 bovine genes, including 14 reference genes, and two total RNA samples from 
BT cells infected with BRSV collected at one and five DPI. We found two groups of 
reference genes, one of which included three reference genes, GAPDH, phosphoglycerate 
kinase 1 (PGK1), and RPS18, which can be used with each other. We evaluated those 
genes (Fig. 3.3, 3.4, and 3.5) and determined that GAPDH and RPS18 were the most 
reliable reference genes to use in combination. 
The mRNA expression of MAVS, NF-κB, and PIN-1 
Real-time Q-RT-PCR results showed no significant differences in the mRNA 
expression of some cellular signal genes among the different treatment groups at all time 
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points compared to UI cells. Those signals included MAVS, NF-κB, and PIN-1. BT cells 
were infected with BVDV2-wt, BVDV2-E, BRSV, or co-infected with BRSV/BVDV2-
wt or BRSV/BVDV2-E at a m.o.i. of 0.05, or stimulated with poly I:C. Cells were 
harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total RNA was extracted and gene mRNA 
levels quantified using real-time Q-RT-PCR and normalized against two reference genes, 
GAPDH and RPS18 (Fig. 3.6, 3.7, and 3.8). 
Type I IFN Reporter Gene Assay 
Reporter gene assays have been developed to measure type I IFN production. The 
Mx reporter gene assay uses a plasmid containing a human MxA promoter associated 
with chloramphenical acetyltransferase (CAT) cDNA. This plasmid is transfected into 
Madin-Darby Bovine Kidney (MDBK) cells. The IFN in test samples will stimulate the 
Mx promoter which results in CAT synthesis. CAT is measured using a commercial 
ELISA kit which reflects the amount of IFN in the test sample (Fray et al., 2001). In the 
luciferase reporter assay, the reporter cell line, NCL1-ISRE-Luc-Hygro, is used. These 
cells are bovine uterus cells transfected with a plasmid containing an IFN stimulated 
response element (ISRE) promoter with luciferase reporter gene. Test samples are added 
to these cells and type I IFN is quantified using a luciferase assay reagent (Gil et al., 
2006a). In addition to reporter gene assays, real-time reverse transcriptase polymerase 
chain reaction (Real-time RT-PCR) has been used to measure the transcription of IFN-
related RNA (Yamane et al., 2008). 
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Type I IFN Reporter Gene Assay Standard Curve 
A type I IFN standard curve was prepared using a 1:2 serial dilution of a type I 
IFN standard to convert relative light units (RLU, sample luminescence reading) to IFN 
units. We added 67.5 units to the wells of dilution –1, 33.75 units to the wells of dilution 
–2, until 0.033 units were added to the wells of the –12 dilution. We determined that the 
best dilutions to use were from –5 to –12 resulting in a straight line with R2 = 0.949, a 
slope 7994.9, and a constant 2498.9 in the following equation: Y = 7994.9X + 2498.9 
(Fig. 3.9). This equation was used for all of the type I IFN reporter gene assay results 
(Fig. 2.1A and 2.1B and Fig. 2.2A). 
IRF-3 Protein Production in Cells 
Bovine turbinate cells co-infected with BRSV/BVDV2-E produced IRF-3 protein 
at higher levels than cells infected with BRSV alone or with BVDV2-wt. Cells infected 
with BRSV/BVDV2-wt produced less IRF-3 protein compared to cells infected with 
BRSV alone or with BVDV2-E (Fig. 3.10). 
Cells co-infected with BRSV/BVDV2-E produced greater levels of IRF-3 mRNA 
compared to cells co-infected with BRSV/BVDV2-wt. Cells co-infected with 
BRSV/BVDV2-wt had IRF-3 mRNA levels equivalent to uninfected (UI) cells (Fig. 
2.5B). IRF-3 protein is a 48kDa protein. To check the effects of different infections on 
the IRF-3 protein levels, BT cell were infected with BRSV alone, BRSV/BVDV2-E, and 
BRSV/BVDV2-wt. Cells were incubated for four days, the protein was isolated, and 
western blotting was performed. The western blot membrane was incubated with 
primary, anti-IRF-3 antibody produced in rabbit (AV31992-50UG, SIGMA-ALDRICH, 
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dilution 1:2000), secondary antibodies, anti-Rabbit IgG, HRP-linked antibody (7074S, 
Cell Signaling, dilution 1:2400), and β-Actin antibody (4967S, Cell Signaling, dilution 
1:1000). 
Other Cellular Signal Proteins 
Western blotting was performed using antibodies against some other cellular 
signal proteins and phosphorylated proteins with different concentrations of skim dry 
milk or bovine serum albumin for blocking. Unfortunately, we were not successful in 
detecting these proteins. Antibodies included: anti-IRF-7 antibody produced in rabbit 
(SAB2101180-50UG, SIGMA-ALDRICH, dilution 1:1000), anti-phospho-IRF-3 
(pSer386) antibody produced in rabbit (SAB4504651, SIGMA-ALDRICH, dilution 1:500 
~ 1:1000), anti-phospho-IRF-3 (phospho-Ser396) antibody produced in rabbit (orb6225, 
biorbyt, dilution 1:100 ~ 1:500), and anti-phospho-PKR (pThr451) antibody produced in 
rabbit (cat. # PA1-26677, Thermo Scientific, dilution 1:1000).  
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  Fig. 3.1 (A). 
 
 
 
 
 
 
 
Fig. 3.1 (A). Total RNA production in infected BT cells. BT cells were infected with 
BVDV2-wt, BVDV2-E, or BRSV at a m.o.i. of 0.05, or stimulated with poly I:C. Cells 
were harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total RNA was extracted and quantified 
using a Nanodrop spectrophotometer. The experiment was replicated independently three 
times resulting in a randomized complete block design and the averages are represented. 
Error bars represent SEM. 
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  Fig. 3.1 (B). 
 
 
 
 
 
 
 
 
Fig. 3.1 (B). Total RNA production in co-infected BT cells. BT cells were infected 
with BRSV, co-infected with BRSV/BVDV2-wt or BRSV/BVDV2-E at a m.o.i. of 0.05, 
or stimulated with poly I:C. Cells were harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total 
RNA was extracted and quantified using a Nanodrop spectrophotometer. The experiment 
was replicated independently three times resulting in a randomized complete block 
design and the averages are represented. Error bars represent SEM. 
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                                              Fig. 3.1 (C). 
 
 
 
 
 
 
 
 Fig. 3.1 (C). Total RNA production in BT cells. BT cells were infected with BRSV or 
remained uninfected. Cells were harvested at 1 or 5 DPI. Total RNA was extracted and 
quantified using a Nanodrop spectrophotometer. 
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                              Fig. 3.2. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.2. Total RNA production with increasing BT cell passage number. (A) Cell 
passage # 20, (B) Cell passage # 23, and (C) Cell passage # 24. BT cells were infected and 
treated, and cells harvested and RNAs extracted as in Fig. 3.1 (A). 
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  Fig. 3.3 (A). 
 
 
 
 
 
 
Fig. 3.3 (A). GAPDH mRNA expression in infected BT cells. BT cells were infected 
with BVDV2-wt, BVDV2-E, or BRSV at a m.o.i. of 0.05, or stimulated with poly I:C. 
Cells were harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total RNA was extracted and 
GAPDH mRNA levels quantified using real-time Q-RT-PCR. Results are represented as 
fold change expressed relative to UI control at 2 HPI. Error bars represent SEM. 
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  Fig. 3.3 (B). 
 
 
 
 
 
Fig. 3.3 (B). GAPDH mRNA expression in co-infected BT cells. BT cells were infected 
with BRSV, co-infected with BRSV/BVDV2-wt or BRSV/BVDV2-E at a m.o.i. of 0.05, 
or stimulated with poly I:C. Cells were harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total 
RNA was extracted and GAPDH mRNA levels quantified using real-time Q-RT-PCR. 
Results are represented as fold change expressed relative to UI control at 2 HPI. Error bars 
represent SEM. 
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    Fig. 3.4 (A). 
 
 
 
 
 
 
 
 
Fig. 3.4 (A). PGK1 mRNA expression in infected BT cells. BT cells were infected with 
BVDV2-wt, BVDV2-E, or BRSV at a m.o.i. of 0.05, or stimulated with poly I:C. Cells 
were harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total RNA was extracted and PGK1 
mRNA levels quantified using real-time Q-RT-PCR. Results are represented as fold 
change expressed relative to UI control at 2 HPI. Error bars represent SEM. 
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  Fig. 3.4 (B). 
 
 
 
 
 
 
 
 
Fig. 3.4 (B). PGK1 mRNA expression in co-infected BT cells. BT cells were infected 
with BRSV, co-infected with BRSV/BVDV2-wt or BRSV/BVDV2-E at a m.o.i. of 0.05, 
or stimulated with poly I:C. Cells were harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total 
RNA was extracted and PGK1 mRNA levels quantified using real-time Q-RT-PCR. 
Results are represented as fold change expressed relative to UI control at 2 HPI. Error bars 
represent SEM. 
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   Fig. 3.5 (A). 
 
 
 
 
 
Fig. 3.5 (A). RPS18 mRNA expression in infected BT cells. BT cells were infected with 
BVDV2-wt, BVDV2-E, or BRSV at a m.o.i. of 0.05, or stimulated with poly I:C. Cells 
were harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total RNA was extracted and RPS18 
mRNA levels quantified using real-time Q-RT-PCR. Results are represented as fold 
change expressed relative to UI control at 2 HPI. Error bars represent SEM. 
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  Fig. 3.5 (B). 
 
 
 
 
 
Fig. 3.5 (B). RPS18 mRNA expression in co-infected BT cells. BT cells were infected 
with BRSV, co-infected with BRSV/BVDV2-wt or BRSV/BVDV2-E at a m.o.i. of 0.05, 
or stimulated with poly I:C. Cells were harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total 
RNA was extracted and RPS18 mRNA levels quantified using real-time Q-RT-PCR. 
Results are represented as fold change expressed relative to UI control at 2 HPI. Error bars 
represent SEM. 
 
109 
 
  Fig. 3.6 (A). 
 
 
 
 
 
Fig. 3.6 (A). MAVS mRNA expression in infected BT cells. BT cells were infected with 
BVDV2-wt, BVDV2-E, BRSV at a m.o.i. of 0.05, or stimulated with poly I:C. Cells were 
harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total RNA was extracted and MAVS mRNA 
levels quantified using real-time Q-RT-PCR and normalized against two reference genes, 
GAPDH and RPS18. Results are represented as fold change expressed relative to UI 
control at 2 HPI. Error bars represent SEM. 
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  Fig. 3.6 (B). 
 
 
 
 
 
Fig. 3.6 (B). MAVS mRNA expression in co-infected BT cells. BT cells were infected 
with BRSV, co-infected with BRSV/BVDV2-wt or BRSV/BVDV2-E at a m.o.i. of 0.05, 
or stimulated with poly I:C. Cells were harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total 
RNA was extracted and MAVS mRNA levels quantified using real-time Q-RT-PCR and 
normalized against two reference genes, GAPDH and RPS18. Results are represented as 
fold change expressed relative to UI control at 2 HPI. Error bars represent SEM. 
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  Fig. 3.7 (A). 
 
 
 
 
 
Fig. 3.7 (A). NF-κB mRNA expression in infected BT cells. BT cells were infected with 
BVDV2-wt, BVDV2-E, BRSV at a m.o.i. of 0.05, or stimulated with poly I:C. Cells were 
harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total RNA was extracted and NF-κB mRNA 
levels quantified using real-time Q-RT-PCR and normalized against two reference genes, 
GAPDH and RPS18. Results are represented as fold change expressed relative to UI 
control at 2 HPI. Error bars represent SEM. 
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  Fig. 3.7 (B). 
 
 
 
 
 
Fig. 3.7 (B). NF-κB mRNA expression in co-infected BT cells. BT cells were infected 
with BRSV, co-infected with BRSV/BVDV2-wt or BRSV/BVDV2-E at a m.o.i. of 0.05, 
or stimulated with poly I:C. Cells were harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total 
RNA was extracted and NF-κB mRNA levels quantified using real-time Q-RT-PCR and 
normalized against two reference genes, GAPDH and RPS18. Results are represented as 
fold change expressed relative to UI control at 2 HPI. Error bars represent SEM. 
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  Fig. 3.8 (A). 
 
 
 
 
 
 
Fig. 3.8 (A). PIN-1 mRNA expression in infected BT cells. BT cells were infected with 
BVDV2-wt, BVDV2-E, BRSV at a m.o.i. of 0.05, or stimulated with poly I:C. Cells were 
harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total RNA was extracted and PIN-1 mRNA 
levels quantified using real-time Q-RT-PCR and normalized against two reference genes, 
GAPDH and RPS18. Results are represented as fold change expressed relative to UI 
control at 2 HPI. Error bars represent SEM. 
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  Fig. 3.8 (B). 
 
 
 
 
 
Fig. 3.8 (B). PIN-1 mRNA expression in co-infected BT cells. BT cells were infected 
with BRSV, co-infected with BRSV/BVDV2-wt or BRSV/BVDV2-E at a m.o.i. of 0.05, 
or stimulated with poly I:C. Cells were harvested at 2 HPI, 1, 2, 3, 5, 7, or 9 DPI. Total 
RNA was extracted and PIN-1 mRNA levels quantified using real-time Q-RT-PCR and 
normalized against two reference genes, GAPDH and RPS18. Results are represented as 
fold change expressed relative to UI control at 2 HPI. Error bars represent SEM. 
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                                                        Fig. 3.9. 
 
 
 
 
 
Fig. 3.9. Type I IFN standard curve. NCL1-Luc-ISRE-Hygro reporter cells were treated 
with 1:2 serial dilution of recombinant human IFN standard using three wells for each 
dilution. Cells were incubated for 8 hours followed by cell lysis. Luciferase activity of the 
cell lysates was measured. 
 
 
X Y 
Units Reading 
4.219 39274 
2.109 14658 
1.055 8603 
0.527 4680 
0.264 5578 
0.132 4586 
0.066 5270 
0.033 4534 
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                                                              Fig. 3.10. 
                 ~ 70 kDa → 
       48 kDa (IRF-3) → 
 
 
 
 
Fig. 3.10. IRF-3 protein production in co-infected BT cells. BT cells co-infected with 
BRSV/BVDV2-E produced IRF-3 protein at higher levels than cells infected with BRSV 
alone or with BVDV2-wt. BT cells co-infected with BRSV/BVDV2-wt produced less 
IRF-3 protein compared to cells infected with BRSV alone or with BVDV2-E. Cells were 
infected and harvested at 4 DPI. Protein was isolated and quantified and western blotting 
was performed twice. SpectraTM Multicolor Broad Range Protein Ladder (Cat. # 26634, 
Thermo Scientific) was used. 
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                                 Fig. 3.11. 
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                                              Fig. 3.12. 
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CHAPTER 4: 
SUMMARY AND FUTURE DIRECTIONS 
The findings of this study confirm the role of the intact BVDV-2 Npro in the 
antagonism of type I IFN in BVDV2-infected cells. While intact Npro of BVDV prevents 
the production of type I IFN by suppressing levels of IRF-3 to avoid host antiviral 
responses, BVDV-1 and BVDV-2 with a dysfunctional Npro fused with EGFP, induced a 
significant type I IFN response in both MDBK and BT cells and increased the production 
of IRF-3 protein (Alkheraif et al., 2017; Gil et al., 2006a; Hilton et al., 2006; Horscroft et 
al., 2005). The importance of the BVDV-2 Npro protein suggests a similar importance of 
the intact BVDV-2 Npro in animals infected with BRDC. Immunosuppression during 
BVDV infection in animals may contribute to secondary bacterial and viral infections. 
Our findings determined that BVDV2-wt, unlike BVDV2-E, decreased type I IFN 
production and enhanced BRSV replication in BT cells.  
Our results showed that, compared to BVDV2-wt, BVDV2-E significantly up-
regulated IFN-β mRNA based on real-time Q-RT-PCR and significantly increased IFN-β 
activity based on a dual-luciferase reporter assay. However, although our finding showed 
that there were no significant differences in NF-κB mRNA, the dual-luciferase reporter 
assay showed that BVDV2-wt significantly increased NF-κB activity compared to 
BVDV2-E. Plasmids encoding bovine IRF-3, IRF-7, PKR, and TBK-1 genes will be used 
to investigate the activities of these signal proteins in infected or co-infected BT cells. It 
is expected that BVDV2-E will significantly increase the activities of these signals. Using 
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western blotting, we found that BT cells co-infected with BRSV/BVDV2-E produced 
IRF-3 protein at higher levels than cells infected with BRSV alone or with BVDV2-wt. 
Performing western blotting with the same antibodies and using protein extracted from 
BT cells infected with BVDV2-wt, BVDV2-E, or BRSV will be a good addition to 
compare the result of co-infected cells. This western botting can be performed at other 
different time points. 
Although BVDV is commonly associated with cattle, it has also been reported in 
pigs, deer, and other domesticated animals. In alpaca testicular cells, BVDV infection 
inhibited type I IFN response and replicated 3 – 4 logs lower compared to bovine cells 
(Samson et al., 2011). It was reported that the seroprevalence of BVDV was low in 
alpacas (Vicugna pacos) (Cockcroft et al., 2015; Dittmer et al., 2018). However, BVDV 
can be a primary acute pathogen in alpacas and change leukocyte subset populations, 
which may result in transient immunosuppression and contribute to secondary infections 
(Henningson et al., 2013; Topliff et al., 2017). Investigating the effects of BVDV Npro in 
alpaca cells may provide a better understanding of the BVDV virulence during its 
infection and mechanisms of enhanced disease from BRSV/BVDV2 co-infection. The 
mRNA of the cell signals, including MAVS, PKR, TBK-1, IRF-3, IRF-7, IFN, NF-κB 
and PIN-1, can by characterized in alpaca testicular cells infected with BRSV, BVDV2-
wt, or BVDV2-E or co-infected with BRSV/BVDV2-wt or BRSV/BVDV2-E. Evaluating 
the type I IFN production and BRSV replication in alpaca cells during co-infection with 
BRSV/BVDV2-wt or BRSV/BVDV2-E will add to the understanding of the role of 
BVDV Npro during co-infection in alpaca cells. Likewise, similar studies may be 
evaluated using bison cells.  
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Inhibiting type I IFN induction cell signals 
Using inhibitors of the type I IFN induction cell signals that were induced to 
greater levels in cells infected with BVDV2-E compared to BVDV2-wt we can determine 
the significance of these signals in disease pathogenesis during BVDV infections. The 
pharmacological inhibitor of the NF-κB signaling pathway (BAY-117085) (Fredericksen 
et al., 2015) can be used to ensure that the increased IRF-7 observed in cells infected with 
BVDV2-E was independent of the NF-κB signaling pathway. Unlike BRSV and 
BVDV2-wt, BVDV2-E increased the mRNA of TBK-1. An inhibitor of TBK-1 (BX795) 
(Zhang et al., 2013) can be used to determine if TBK-1 is essential to the increase of type 
I IFN and its mRNA expression during BVDV2-E infection. If the TBK-1 inhibitor 
abolished the IFN increase, this would confirm that the type I IFN was increased through 
the TBK-1 IRF-3 pathway.  
Characterize attenuation and immunogenicity of genetically-modified BVDV 
To determine the impact of Npro on attenuation of virulence in vivo, the 
attenuation of virulence of noncytopathic BVDV-2 mutant will be confirmed clinically 
and pathologically by experimental inoculation of calves. Following BVDV2-wt, 
BVDV2-E, and BRSV single and/or co-infections, calves will be observed daily and 
clinical signs (respiration rate, dyspnea, and general condition) will be assigned 
numerical values based on a scoring system. Calves will be euthanatized nine days post-
infection. Systematic necropsy will be performed to collect tissues, and all gross 
abnormalities will be recorded at necropsy by a pathologist. Postmortem analyses will 
include determination of the extent of lesions, viral titers, viral RNA levels, and antigen 
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distribution in lymphoid organs. Virulence will be assessed on the basis of pathologic 
changes (lymphocytolysis, lymphodepletion), viral titers and BVDV RNA, viral antigen 
distribution in target cells of lymphoid organs and clinical signs (inappetence and 
dyspnea) in infected calves compared to control animals. Assessment of induction of host 
innate and adaptive immune responses to the attenuated BVDV mutant will be achieved 
by measuring type I INF and antibody responses as well as by assessing protective 
immunity in challenge-exposed calves (Henningson et al., 2013). We expect to confirm 
that attenuation of virulence correlates with a dysfunctional Npro.  
Overall, it is expected that the proposed research will provide detailed insight into 
influences on viral function, virulence and immunity. We expect to show that BVDV Npro 
enhances virulence and modulates innate immune responses to BRSV infection. This 
understanding will be beneficial for the development of safer and more effective BVDV 
vaccines. 
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APPENDIX A: 
MATERIALS 
Cell Culture Solutions 
Dulbecco’s Modified Eagle Medium (DMEM)-High Glucose 
To prepare 6 liters: 
 
 
 
 
Adjust pH to 6.8 ~ 6.9 using 6 M HCl. 
Filter sterilize with 0.2 µm Supor® membrane filter into 500-ml bottles. 
Use LB plates to test for bacteria and fungi.  
Seal lids with parafilm and store at 4 ºC. 
Equine Serum 
Hyclone, Logan, UT. 
Fetal Bovine Serum 
Hyclone, Logan, UT.  
Calcium and Magnesium-Free Phosphate-Buffered Saline (CMF-PBS) 
To prepare 6 liters: 
 
 
 
 
 
 
 
Adjust pH to 7.2 using 6 M HCl. 
Filter sterilize with 0.2 µm Supor® membrane filter into 500-ml bottles. 
Use LB plates to test for bacteria and fungi.  
Seal lids with parafilm and store at 4 ºC. 
Ultrapure water (UPW, upH2O) 6 liters 
DMEM 80.24 grams 
NaHCO3 22.2 grams 
upH2O 6 liters 
NaCl 48 grams 
KCl 2.4 grams 
NaHCO3 5.25 grams 
Glucose (dextrose) 15 grams 
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1X Trypsin-EDTA 
0.5% Trypsin-EDTA.  
To prepare a liter: 
 
 
 
Add phenol red to adjust color to light pink. 
Filter sterilize with 0.2 µm Supor® membrane filter into 100-ml bottles. 
Use LB plates to test for bacteria and fungi.  
Store at –20 ºC. 
Cell Freezing Media 
To prepare 101 ml: 
 
 
 
 
 
 
Filter sterilize with 0.2 µm Supor® membrane filter. 
Store at 4 ºC. 
Poly I:C 
Polyinosinic-Polycytidylic acid [Poly(I)-Poly(C); Poly (I:C)] sodium salt: 
P0913-10MG, ten milligrams lyophilized powder. 
Lot# 082M4029V, Amersham Biosciences, Piscataway, NJ, USA. 
Store at –20 °C. 
Preparing Poly I:C stock (2 mg/ml) 
Add 5 ml PBS to the tube that contains the 10 mg Poly I:C powder. 
Swirl and pass through a 26-gauge needle several times. 
Aliquot 0.5 ml Poly I:C into 2-ml tubes. 
Store at –80 °C for up to 3 years. 
Preparing 100 µg/ml Poly I:C 
To prepare 36 ml of 100 µg/ml Poly I:C. 
Poly I:C stock (2 mg/ml): 1.8 ml 
2% HS DMEM 34.2 ml 
Discard unused portion. 
CMF-PBS 0.9 liter 
10X Trypsin-EDTA 0.1 liter 
Dimethyl sulfoxide (DMSO)  8 ml 
Glycerol  8 ml 
Equine or fetal bovine serum 15 ml 
DMEM 70 ml 
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Ampicillin Solution (10 mg/ml) 
To prepare 10 ml (Ampicillin, Sodium Salt): 
0.1 g (100 mg) Ampicillin + 10 ml upH2O = 10 ml of 10 mg/ml → 10 µg/µl. 
Filter the solution through 0.22 µm filter, using a syringe. 
Store Ampicillin at 4 °C for up to one month, or freeze at –20 °C. 
Luria-Bertani (LB) Media 
To prepare a liter: 
upH2O 1 liter 
Bacto tryptone 10 grams 
Bacto yeast extract 5 grams 
NaCl 10 grams 
Adjust pH to 7.0 using 6 M HCl. 
Pour into bottles. 
Autoclave for 20 minutes.  
Store at 4º C. 
Luria-Bertani (LB) Plates 
To prepare a liter: 
upH2O 1 liter 
Bacto tryptone 10 grams 
Bacto yeast extract 5 grams 
NaCl 10 grams 
Adjust pH to 7.0 using 6 M HCl. 
Then add: 
Bacto agar 15 grams 
Autoclave for 20 minutes. 
Cool to 50 ºC. 
Add antibiotic if needed 
Pour approximately 20 ml into each 90-mm plate. 
Leave plates uncovered in the laminar flow hood for 30 minutes to solidify. 
Store at 4 ºC.  
70% Ethanol for Total RNA Extraction 
Prepare: 
Absolute ethanol 2.1 ml 
Nuclease-free water 0.9 ml 
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Immunoperoxidase Staining (ELISA) Solutions* 
Phosphate Buffered Saline (PBS), 0.01M            
 To prepare 6 liters: 
 
 
 
Adjust pH to 7.6 using 6 M HCl. 
Fixation Buffer (PBS/20% Acetone) 
To prepare a liter: 
  
 
Binding Buffer 
To prepare a liter: 
 
 
 
Wash Buffer 
To prepare 5 liters: 
 
 
 
Substrate Buffer (Acetate Buffer 0.05M, pH 5.0) 
Prepare: 
 
 
 
 
Mix: 
 
 
 
Adjust pH to 5.0.  
3-Amino-9-Ethyl-Carbozole (AEC) Solution 
To prepare a 4 mg/ml stock solution: 
N,N-dimethylformamide 100 ml 
AEC 400 mg 
Using aluminum foil, wrap bottle to protect from light. 
* Store all the immunoperoxidase staining solutions at room temperature. 
upH2O 6 liters 
Na2HPO4 12 grams 
NaH2PO4  1.08 grams 
NaCl 51 grams 
PBS 0.8 liter 
Acetone 0.2 liter 
PBS 1 liter 
NaCl 29.5 grams 
Tween 20 0.1 ml 
PBS 5 liters 
Tween 20 2.5 ml 
upH2O 200 ml 
Solution A 
Acetic acid 1.156 ml 
 
upH2O 500 ml 
Solution B 
 Sodium acetate 6.8 grams 
Solution A 148 ml 
One liter of substrate buffer Solution B 352 ml 
upH2O 500 ml 
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Agarose Gel Electrophoresis Solutions* 
0.5X TBE (Working Solution) 
To prepare a liter: 
5X TBE 100 ml 
upH2O 900 ml 
5X TBE Buffer 
(Tris base, Boric acid, and EDTA) 
To prepare a liter of 5X TBE: 
upH2O 1 liter 
Tris base 54 grams 
Boric acid 27.5 grams 
0.5M EDTA (pH 8.0) 20 ml 
Ethidium Bromide 
To prepare a 10 mg/ml stock solution: 
Sterile upH2O 10 ml 
Ethidium bromide 100 mg 
Using aluminum foil, wrap bottle to protect from light. 
* Store all the agarose gel electrophoresis solutions at room temperature. 
Interferon (IFN) Response Assay Solutions 
PBS with 0.1% BSA 
To prepare 50 ml of stock solution: 
CMF-PBS 50 ml 
Bovine serum albumin (BSA) 50 mg 
Store at 4 ºC. 
(1 mg BSA/ml PBS solution = 0.1% BSA solution)  
1X Reporter Lysis Buffer with 1 mg BSA/ml 
Prepare a 1.25 mg BSA/ml H2O stock solution: 
Sterile upH2O 40 ml 
Bovine serum albumin (BSA) 50 mg 
Store at 4 ºC. 
(1.25 mg BSA/ml H2O solution = 0.125% BSA solution) 
To prepare a 1X reporter lysis buffer with 1 mg BSA/ml solution: 
1.25 mg BSA/ml upH2O stock solution 2 ml 
5X reporter lysis buffer 0.5 ml 
Discard unused buffer after assay. 
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1X Passive Lysis Buffer 
To prepare 5 ml: 
Sterile upH2O 4 ml 
5X Passive Lysis Buffer 1 ml 
Discard unused buffer after assay. 
Western Blotting Solutions 
RIPA Buffer 
To prepare 250 ml of stock solution:  
 
 
 
 
 
 
 
* To prepare Tris base 0.5 M: add 6.057 grams Tris base to 100 ml upH2O. 
Adjust the pH to 8, using HCl. 
Store RIPA buffer at 4 °C. 
10% Ammonium Persulfate (10% APS) 
Prepare:  
Ammonium persulfate, 98% 1 gram 
upH2O 10 ml 
Vortex. 
Prepare 0.5 ml/tube aliquots in 1.5-ml tubes. 
Store at –20 °C. 
Bis Tris 3.5X Buffer 
Bis tris (C8 H19 N O5). 
To make 1M (molar concentration), add 209.24 grams to one liter upH2O. 
Prepare:  
To have: Molar Bis tris upH2O 
 1M 209.24 grams 1 L 
1X 0.357M (357mM) 74.73 grams 1 L 
1X 0.357M (357mM) 14.95 grams 200 ml 
3.5X 1.25M (1250mM) 52.32 grams 200 ml 
3.5X 1.25M (1250mM) 13.08 grams 50 ml 
Adjust the pH to 6.5 – 6.8, using HCl.  
Store at 4 °C for up to 6 months. 
NaCl      2.1915 grams  
Triton X-100 2.5 ml 1% final 
Sodium deoxycholate 1.25 grams 0.5% final 
 Sodium dodecyl sulfate (SDS) 0.25 grams 0.1% final 
Tris base 0.5 M (pH 8)* 25 ml 50mM final 
upH2O 222.5 ml Up to 250 ml 
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1M Sodium Bisulfite Buffer (as Antioxidant) 
Sodium bisulfite (NaHSO3). 
Prepare:  
To have: Molar Sodium bisulfite upH2O 
1X 1M 104.07 grams Up to 1 L 
1X 1M 2.6 grams Up to 25 ml 
Store at 4 °C for up to 2 months. 
NuPAGE: MOPS SDS Running Buffer (20X) 
Prepare:  
 
 
 
 
 
 
 
Store at 4 °C for up to 6 months. 
To make 1 liter of 1X MOPS SDS Running Buffer 
Use 950 ml upH2O + 50 ml of 20X buffer = 1 L. 
Add 5 ml of the antioxidant, 1M Sodium Bisulfite buffer. 
The pH of the 1X buffer is 7.7. 
Do not use acid or base to adjust the pH. 
Store at 4 °C. It may be used for up to 5 times. 
NuPAGE: Transfer Buffer (20X) 
Prepare:  
 
 
 
 
 
 
Store at 4 °C for up to 6 months. 
To make 1 liter of 1X Transfer Buffer 
Use 950 ml upH2O + 50 ml of 20X buffer = 1 liter. 
Add 5 ml of the antioxidant, 1M Sodium Bisulfite buffer. 
The pH of the 1X buffer is 7.2. 
Do not use acid or base to adjust the pH. 
Store at 4 °C. It may be used for up to 5 times. 
 to make 500 ml to make 250 ml For 1X Buffer 
MOPS 104.6 grams 52.3 grams 50mM final 
Tris base 60.6 grams 30.3 grams 50mM final 
SDS 10  grams 5 grams 0.1% final 
EDTA 3.7224 grams 1.8612 grams 1mM final 
upH2O Up to 500 ml Up to 250 ml  
 to make 150 ml to make 250 ml For 1X Buffer 
Bicine 12.24 grams 20.4 grams 25mM final 
Bis tris 15.7 grams 26.17 grams 25mM final 
EDTA 1.117 grams 1.8612 grams 1mM final 
upH2O Up to 150 ml Up to 250 ml  
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Western Blotting 8% gel 
Prepare:  
 
 
 
 
 
 
 
 
 
8% gel needs to be prepared and poured immediately at room temperature. 
Allow to solidify for 20 – 30 minutes. 
Then, prepare and pour the stacking gel. 
Insert a 10-well comb. 
Allow to solidify for 20 – 30 minutes. 
TBS Buffer (10X) 
Preparing Tris Buffer Saline (10X) 
 
 
 
 
 
Adjust pH to 7.5 with HCl. 
Store at 4 °C for up to 3 months. 
TBS-T Solution 
To prepare Tris Buffer Saline with 0.1% Tween® 20 (TBS-T): 
 
 
 
 
 
Store at 4 °C for one week only. 
Blocking Solution (TBS-T with 5% Milk or BSA) 
Using skim dry milk or bovine serum albumin (BSA):  
 
 
 
 
 8% for 2 Gels Stacking 
Bis tris 3.5X buffer 2. 84 ml 1 ml 
30% acrylamide 2. 68 ml 0. 46 ml 
upH2O 4. 48 ml 2. 04 ml 
Mix well… then add: 
10% APS 50 µl 40 µl 
TEMED 14 µl 20 µl 
Use (Pour)  ~ 4.5 ml for each ~ 1.5 ml for each 
 to make 1 L to make 500 ml For 1X Buffer 
NaCl  87.7 grams 43.85 grams 150mM final 
Tris base 12.114 grams 6.057 grams 100mM final 
upH2O Up to 1 L Up to 500 ml  
 to make 1 L to make 500 ml 
upH2O 900 ml 450 ml 
TBS (10X) 100 ml 50 ml 
Tween® 20 1 ml 0.5 ml 
 for two gels for four gels 
TBS-T 10 ml 20 ml 
Milk or BSA 0.5 gram 1 gram 
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APPENDIX B: 
METHODS 
Cell Culture Methods 
The following methods were used with three cell lines: 
1. MDBK (Madin-Darby Bovine Kidney) cells: 
Cell density is approximately 3.5×107 cells in a 100% confluent 75 cm2 flask, and 
3×106 cells in a 100% confluent well of 6-well plate. 
2. BT (Bovine Turbinate) cells: 
Cell density is approximately 4×106 cells in a 100% confluent 75 cm2 flask, and 
3×105 cells in a 100% confluent well of 6-well plate.   
3. NCL1-ISRE-Luc-Hygro (modified bovine uterus) cells: 
This reporter cell line has an ISRE (IFN Stimulated Response Element) gene 
coupled with a luciferase reporter gene and hygromycin antibiotic resistance gene. Use 6 
µl of Hygromycin B (50 mg/ml solution) per ml of culture media to maintain selection. 
Cell density is approximately 6×106 cells in a 100% confluent 75 cm2 flask. 
Establishing a Cell Culture from a Frozen Stock 
- Mix 27 ml DMEM with 3 ml HS in a 75 cm2 tissue culture flask. 
- Prevent ice crystal formation by thawing cells in cryovial (ampule) rapidly in a 37 ºC 
water-bath to prevent cell lysis. 
- Add cells to tissue culture flask with media. 
- Incubate at 37 ºC with 5% CO2. After 24 hours, change media. 
Cell Culture Maintenance 
- Discard the old media. 
- Rinse cells twice with 10 ml CMF-PBS. 
- Add 5 ml 0.05% trypsin-EDTA to cells, swirl, remove all but 1 ml, and allow cells to 
separate for 3 minutes (8 minutes for MDBK cells). 
- Tap flask to dislodge cells. 
- Resuspend cells using 10 ml of DMEM/10%HS. 
- Add 0.5 – 3 ml of cell suspension to 25 ml 10%HS/DMEM/75-cm2 flask (35 ml/162-
cm2 flask).  
- Incubate at 37 ºC with 5% CO2. 
- Pass cells every week or at least twice a month.  
Preparing a Frozen Stock of Cells 
- Discard the old media. 
- Rinse cells twice with 10 ml CMF-PBS. 
- Add 5 ml 0.05% trypsin-EDTA to cells, swirl, remove all but 1 ml, and allow cells to 
separate for 3 minutes (8 minutes for MDBK cells). 
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- Tap flask to dislodge cells. 
- Resuspend cells in 5 ml freezing media and pipette up and down. 
- Aliquot each 1 ml into a 2 ml cryovial.  
- Wrap in cotton, place in styrofoam container and freeze at –80 ºC. 
- After 24 hours, place cryovials in a box at –80 ºC. 
Testing for Bacteria and Fungi 
To ensure that there is no contamination in materials, cells, and viruses, spread a 
0.2 ml sample onto an LB plate and incubate at 37 ºC for bacteria and another 0.2 ml 
sample onto another LB plate and incubate at room temperature for fungi, for two weeks. 
Virus-Work Methods 
Preparation of Virus Stocks 
- Use 90% confluent MDBK-cell flasks for BVDV2 isolates. Use 90% confluent BT-cell 
flasks for BRSV236-652. 
- Calculate the virus needed using the following formula: 
Cells per flask × # of flask × % confluency × m.o.i. 
                                TCID50 
- Add virus inoculum to 2%HS/DMEM to have a final volume of 5 ml for each flask.  
- Rinse flask twice with 10 ml DMEM. 
- Add 5 ml virus inoculum/flask. 
- Incubate at 37 ºC with occasional rocking for 90 minutes. 
- Add 20 ml 2%HS/DMEM/75-cm2 flask (30 ml/162-cm2 flask). 
- Incubate at 37 ºC with 5% CO2 for 4 days for ncp BVDV2 isolates, and until CPE 
(Cytopathic Effects) for BRSV 236-652 (8 – 10 days). 
- Freeze flasks at –80 ºC for at least 24 hours. Then thaw on ice. 
- Pellet the virus if needed (see "Purified Pelleted Virus Stock"), or aliquot 0.5 – 2 ml 
into 2-ml cryovials, and store at –80 ºC. 
- Titer the virus. 
Purified Pelleted Virus Stock 
- Using the infected flasks from previous protocol "Preparation of virus stocks".  
- Thaw flasks on ice and transfer supernatant into 50 ml conical tubes. 
- Centrifuge for 30 minutes at 2,000×g (~3,000 rpm) at 4 ºC. 
- Transfer supernatant into autoclaved ultracentrifuge tubes, making sure to transfer 
exactly the same amount into each balanced tube. 
- Centrifuge for 2 hours at 25,000 rpm at 4 ºC using Beckman Ultracentrifuge. 
- Pour off supernatant carefully and put the tubes up side down on paper towels. 
- Re-suspend viral pellet with 0.5 ml DMEM, pipette up and down to mix. 
- Use the same 0.5 ml DMEM to re-suspend the second tube. 
- Aliquot 100 µl into four and 50 µl into two 2-ml cryovials. Store at –80 ºC. 
- Titer the pelleted virus.  
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Virus Titration 
1. Preparation of 96-well flat bottomed plate: 
- Use MDBK cells for BVDV isolates, and BT cells for BRSV. 
- Rinse flask twice with 10 ml CMF-PBS. Add 5 ml 0.05% trypsin-EDTA, swirl to cover 
cells and remove all but 1 ml. 
- Allow cells to incubate at room temperature for 5 minutes, tap flask to dislodge cells.  
- Re-suspend cells using 10 ml of 3%HS/DMEM. 
- Seed 2×104 MDBK cells/well, or 1×104 BT cells/well. 
- Incubate at 37 ºC with 5% CO2 overnight. 
2. Preparation of viral ten-fold serial dilution and inoculation of cells in plates: 
- Prepare 5 ml tubes with 0.9 ml DMEM (or 0.45 ml DMEM for Pelleted Virus Stock). 
- Add 0.1 ml stock virus into tube # –1 (or 50 µl pelleted virus stock), vortex. 
- Transfer 0.1 ml (or 50 µl pelleted virus) from tube # –1 to tube # –2, vortex, repeat 
from tube # –2 to –3… etc. Add 50 µl of dilution –1 into each well of row # 1, and 50 
µl of dilution –2 into row # 2, etc. 
- Add 50 µl DMEM into each well of N.C. (Negative control) row. 
- Incubate at 37 ºC with 5% CO2 for 4 days for BVDV, or 7 days for BRSV. 
- Fix the plates. 
Fixation 
- Shake media off plates into a biohazard bag. 
- Dry plates for 10 – 20 minutes in a hood. 
- Add 0.1 ml fixation buffer (PBS/20% acetone) per well. 
- Incubate for 10 – 15 minutes at room temperature. 
- Shake the fixation buffer off. 
- Allow plates to dry overnight up side down. 
- Detect viral antigen using Immunoperoxidase Staining. 
Immunoperoxidase Staining (ELISA) 
- Use fixed dry plates. 
- Re-hydrate wells with 100 µl binding buffer/well for 2 – 4 minutes. 
1. mAb (primary monoclonal antibody) **: 
- Use anti-BVDV mAb 348 for BVDV isolates, and 8G12 for BRSV. 
- Make a 1:1000 dilution of mAb in binding buffer.  
- Shake the binding buffer off plates. 
- Add 50 µl of the diluted mAb/well. 
- Incubate at 37 ºC for 1 hour. 
2. Biotinylated Horse anti-mouse IgG (secondary antibody) **: 
- Make a 1:200 dilution of IgG in binding buffer with 60% chicken serum.  
- Shake the mAb off plates. 
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- Wash plate three times:   Shake off. 
                                      Add 100 µl wash buffer/well. 
                                      Shake off. Repeat three times. 
                                            Drain on a towel. 
- Add 50 µl of the diluted IgG/well. 
- Incubate at 37 ºC for 1 hour. 
3. HRP-Streptavidin **: 
- Make a 1:500 dilution of HRP in binding buffer.  
- Shake the IgG off plates. 
- Wash plate three times with wash buffer. 
- Add 50 µl of the diluted HRP/well. 
- Incubate at 37 ºC for 1 hour. 
Preparing a 3% H2O2 (Hydrogen peroxide) solution: 
0.9 ml substrate buffer + 0.1 ml 30% H2O2 
Use same day. 
4. AEC (3-Amino-9-Ethyl-Carbozole) **: 
- Use glassware with AEC always. 
- For each 96-well plate, mix 5 ml substrate buffer with 20 µl 3% H2O2. 
- Then add 0.3 ml AEC slowly while swirling the mixture. 
- Shake the HRP off plates. 
- Wash plate three times with wash buffer. 
- Add 50 µl of the AEC/well. Incubate at room temperature for 2 – 4 minutes. 
- When stained wells appear reddish brown color, shake off, rinse three times with tap 
water to stop the reaction. 
- Let plate dry overnight, look for labeled viral antigen under the microscope and 
calculate the titer. 
 
**See "table 1" for exact quantities/plate. 
Growth Kinetics Assay 
- Calculate the amount of virus needed at a m.o.i. of 0.01 using the following formula: 
Cells per well × # of wells × % confluency × m.o.i. 
                                TCID50 
- Dilute viruses in DMEM to have a final volume of 1 ml/well. 
- Use 90% confluent MDBK cell 6-well plates for BVDV2 isolates. 
- Use two plates for each time-point.  
- Infect two wells with 1 ml/well of BVDV2 NY93, BVDV2-NY93/c, or BVDV2-
NY93/c-EGFP, or add DMEM as negative control.  
- Incubate at 37 ºC with occasional rocking for 2 hours. 
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- Remove the inoculum and rinse with 1 ml DMEM. 
- Add 3 ml 2%HS/DMEM/well. 
- Freeze the two plates of the first time-point (2 hours). 
- Incubate the remaining time-points at 37 ºC with 5% CO2 for 1.5, 3, 6, 9, 12, 18, 24, 48, 
72, 96 hours.   
- Freeze plates of each time-point at –80 ºC for at least 24 hours. 
- Thaw on ice. 
- Aliquot 0.2 – 1 ml into four 2 ml cryovials and store at –80 ºC. 
- Titer the viruses at each time-point. 
Growth Kinetics of Concurrent Infections 
- BVDV2-NY93 with BRSV (or BVDV2-NY93/c-EGFP with BRSV):  
- Calculate the amount of virus needed at a m.o.i. of 0.6 for BVDV2-NY93, BVDV2-
NY93/c N-Npro 18 EGFP, and BRSV using the following formula: 
Cells per well × # of wells × % confluency × m.o.i. 
                                TCID50 
- Dilute viruses in 2%HS/DMEM to have a final volume of 1 ml/well. 
- Use 90% confluent BT cell 6-well plates. 
- Use two plates for each time-point. Infect two wells with 1 ml/well of BRSV, BVDV2-
NY93 (or BVDV2-NY93/c-EGFP), or BVDV2-NY93 with BRSV (or BVDV2-
NY93/c-EGFP with BRSV), or add 2%HS/DMEM as negative control.  
- Incubate at 37 ºC with occasional rocking for 90 minutes. 
- Remove the inoculum and rinse with 1 ml DMEM. 
- Add 3 ml 2%HS DMEM/well. 
- Incubate at 37 ºC with 5% CO2 for 1.5, 6, 12, 24, and 48 hours, and 3, 5, 7, and 9 days.   
- Freeze plates of each time-point at –80 ºC for at least 24 hours. 
- Thaw on ice and mix the two wells of each virus to have 6 ml. 
- Aliquot 0.2 – 3 ml into five 2 ml cryovials and store at –80 ºC. 
- Titer the viruses at each time-point. 
- Extract the mRNAs and perform real-time RT-PCR. 
RT-PCR Methods 
RNA Extraction (Using Trizol® LS Reagent) 
- Add 0.25 ml of the sample (cell-culture supernatant that has virus) into a 1.5 ml tube 
and add 0.75 ml Trizol LS reagent (the volume ratio should be 1:3). Pipette up and 
down to mix and lyse the cells. 
  [Note: Trizol LS reagent is very dangerous and harmful to eyes and skin]. 
- Incubate at room temperature for 5 minutes.  
- Add 0.2 ml chloroform into each tube. 
- Cap tubes securely and shake vigorously for 15 seconds. 
- Incubate samples at room temperature for 15 minutes. 
- Centrifuge samples at no more than 12,000×g for 15 minutes at 2 – 8 °C. 
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- Now, there are three phases: clear aqueous phase at the top, white phase (like a 
membrane) as inter-phase, and phenol phase at the bottom. 
- Transfer the upper aqueous phase to a clean 1.5-ml tube. 
- Add 0.5 ml isopropyl alcohol (Isopropanol). 
- Incubate at room temperature for 10 minutes. 
- Centrifuge at no more than 12,000×g for 10 minutes at 2 – 8 °C. The RNA pellet may 
not be visible. 
- Pour off the supernatant carefully. 
- Add 1 ml 75% ethanol in DEPC-treated water (3 parts absolute ethanol + 1 part DEPC-
treated water). 
- Vortex samples and store at –80 °C.  
RT-PCR Primers 
For BVDV, the forward primer: 5’ CAT GCC CAT AGT AGG AC 3’; and the 
reverse primer: 5’ CCA TGT GCC ATG TAC AG 3’ (Integrated DNA Technologies, 
Inc., Coralville, IA). 
For EGFP, the forward primer: 5’ GTG AGC AAG GGC GAG GAG CTG 3’; 
and the reverse primer: 5’ CTT GTA CAG CTC GTC CAT GCC GAG AG 3’ (Integrated 
DNA Technologies, Inc., Coralville, IA). 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Pellet the RNA: 
- Using the extracted RNA in 1 ml 75% ethanol in DEPC. 
- Centrifuge at 9,000×g for 10 minutes at 2 – 8 °C, and pour off the ethanol. 
- Dry for 15 minutes in a speed-vac. 
- Add 10 µl of DEPC-treated water and pipette up and down. 
- Incubate at 55 °C for 15 minutes and on ice for a minute. 
RT-PCR: 
- Using thin-walled PCR tubes… 
# of  samples one 
Reverse primer (2 pmol/µl) 1 µl 
10mM dNTP Mix 1 µl 
DEPC-treated water  8 µl 
RNA sample 2 µl 
Final volume  12 µl 
- Using PCR machine: perform the following cycle: 
1 = 65 °C for 5:00 minutes 
2 = 4.0 °C       for 1:00 minute 
3 = END  
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- Add 8 µl of the following mixture to each RNA sample: 
# of  samples one 
5X First strand Buffer 4 µl 
0.1 M DTT 1 µl 
RNase Inhibitor (10 U/µl) 2 µl 
Superscript III RT 1 µl 
From last step 12 µl 
Final volume 20 µl 
- Perform the following cycle: 
1 = 56 °C for 1 hour 
2 = 70 °C for 15:00 minutes 
3 =  4 °C forever 
4 = END  
- Now, the complementary DNA (cDNA) is formed. 
- Add 2 µl cDNA to 48 µl of the following mixture: 
# of  samples one 
10X PCR Buffer (- MgCl2) 5 µl 
50mM MgCl2 1.5 µl 
10mM dNTP Mix 1 µl 
Upstream primer (50 pmol/µl) 1 µl 
Downstream primer (50 pmol/µl) 1 µl 
Taq Polymerase 0.4 µl 
DEPC-treated water  38.1 µl 
cDNA 2 µl 
Final volume 50 µl 
- Perform the following cycle: 
1 = 94 °C for  2 minutes 
2 = 94 °C for 10 seconds 
3 = 50 °C for 15 seconds 
4 = 72 °C for 30 seconds 
5 = Go to 2, 30 times 
6 = 72 °C for 10 minutes 
7 =  4 °C forever 
8 = END  
 
- Store at –20 °C, until performing an agarose gel electrophoresis.  
138 
 
Agarose Gel Electrophoresis 
- To prepare a 1% agarose gel for a small gel apparatus, add 0.4 g of agarose to 40 ml of 
0.5X TBE buffer. 
- Microwave, cool, pour, and allow to solidify for 20 minutes. 
- Mix 10 µl of RNA samples or 1KB ladder with 2 µl dye and load into wells of the gel. 
- Run for approximately 90 minutes at 82V (voltage).  
- Stain with 15 µl ethidium bromide (10 mg/ml) in 0.5X TBE buffer for 15 minutes. 
- Destain in new 0.5X TBE buffer for 15 minutes. 
- Visualize gel under ultraviolet light. 
Viral RNA Extraction 
(Using QIAamp® Viral RNA Mini kit, spin protocol, Cat. # 52904, Qiagen, Valencia, 
CA). 
- Pipette 560 µl prepared buffer AVL (containing carrier RNA) into a 1.5-ml tube. 
- Add 140 µl of the sample (cell-culture supernatant that has virus). 
- Pulse-vortex for 15 seconds. 
- Incubate at room temperature for at least 10 minutes, then briefly centrifuge. 
- Add 560 µl of absolute (96 – 100%) ethanol (for molecular biology use). 
- Pulse-vortex for 15 seconds, then briefly centrifuge. 
- Apply 630 µl of the solution into a QIAamp Mini spin column (in a 2-ml tube), close 
lid. 
- Centrifuge at 6,000×g (8,000 rpm) for 1 minute. 
- Place the column into a new 2-ml tube. 
- Apply the remaining 630 µl of the solution into the column, and repeat the last step.  
   [At this step, the RNA is binding to the silica-gel-based membrane of the column]. 
- Apply 500 µl of buffer AW1 (wash buffer), close lid. 
- Centrifuge at 8,000 rpm for 1 minute to wash the contaminants away (first wash). 
- Place the column into a new 2-ml tube.  
- Apply 500 µl of buffer AW2 (wash buffer), close lid. 
- Centrifuge at full speed (14,000 rpm) for 3 minutes to wash the contaminants away 
(second wash).  
- Place the column into a new 1.5-ml tube. 
- Centrifuge at full speed for 1 minute. 
- Place the column into a new 1.5-ml tube. 
- Open the column and apply 60 µl of AVE, close lid. 
- Incubate at room temperature for 1 minute. 
- Centrifuge at 8,000 rpm for 1 minute to elute the RNA from the membrane into the 1.5-
ml tube. 
- Label the tubes and discard the columns. 
- The RNA is stable for one year at –20 ºC or –80 ºC.  
- Perform real-time RT-PCR. 
139 
 
Real-time RT-PCR Primers and Probe 
For BVDV, the forward primer: 5’-GGGNAGTCGTCARTGGTTCG-3’; the 
reverse primer: 5’-GTGCCATGTACAGCAGAGWTTTT-3’; and probe: 5’-6-FAM-
CCAYGTGGACGAGGGCAYGC-TAMRA-3’. The BVDV probe was labeled with a 
fluorescent reporter molecule (6-carboxy-fluorescein, 6-FAM) at the 5’ end and with a 
quencher molecule (6-carboxy-tetra-methyl-rhodamine, TAMRA) at the 3’ end. Primers 
and probe were based on sequences of the 5’ UTR (Mahlum et al., 2002).  
For BRSV, the forward primer: 5’-GCA-ATG-CTG-CAG-GAC-TAG-GTA-
TAA-T-3’; the reverse primer: 5’-ACA-CTG-TAA-TTG-ATG-ACC-CCA-TTC-T-3’; 
and probe: 5’-/5HEX/-ACC-AAG-ACT-TGT-ATG-ATG-CTG-CCA-AAG-CA-
/31ABkFQ/-3’. The BRSV probe was labeled with a fluorescent reporter molecule 
(hexachlorofluorescein, HEX) at the 5’ end and with a quencher molecule (31ABkFQ) at 
the 3’ end. Primers and probe were based on conserved regions of the published 
sequences of the BRSV N gene (Boxus, 2005) (Integrated DNA Technologies, Inc., 
Coralville, IA). 
Stock solutions of primers and probes are 100 µM/L (100 pmol/µl). 
Real-Time RT-PCR 
(Using BIO-RAD's iCycler iQ™). 
- Prepare a table that shows which wells of the 96-well Real-time RT-PCR plate will be 
used. Use two wells for each RNA sample. 
- Dilute the appropriate primers and probe of each virus in RNase-free water. 
- Prepare the master mix for the RNA of BVDV2: 
# of reactions Pre reaction 
2X QuantiTect Probe RT-PCR Mix 12.5 µl 
Forward Primer (1:8 dilution) 1 µl 
Reverse Primer (1:8 dilution) 1 µl 
Probe (1:13.5 dilution) 1 µl 
QuantiTect RT Mix 0.25 µl 
RNase-Free Water 4.25 µl 
Final Volume 20 µl 
- Prepare the master mix for the RNA of BRSV 236-652: 
# of reactions Pre reaction 
2X QuantiTect Probe RT-PCR Mix 12.5 µl 
Forward Primer (1:10 dilution) 1 µl 
Reverse Primer (1:10 dilution) 1 µl 
Probe (1:20 dilution) 1 µl 
QuantiTect RT Mix 0.25 µl 
RNase-Free Water 4.25 µl 
Final Volume 20 µl 
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- Apply 20 µl of the master mix into each well. 
- Add 5 µl of RNA sample. 
- Using BIO-RAD's iCycler iQ™, Optical System Software: 
- For the mRNA of BVDV2, define FAM as fluorophore and perform this cycle:  
Cycle 1 1X One step 50 ºC For 30 minutes 
Cycle 2 1X One step 95 ºC For 15 minutes 
Cycle 3 40X Step 1 95 ºC For 15 seconds 
Step 2 55 ºC For 30 seconds 
Data collection and Real-time analysis enabled 
Step 3 72 ºC For 30 seconds 
Cycle 4 1X One step 4 ºC HOLD 
- For the mRNA of BRSV236-652, define HEX as fluorophore and perform this cycle:  
Cycle 1 1X One step 50 ºC For 30 minutes 
Cycle 2 1X One step 95 ºC For 15 minutes 
Cycle 3 45X Step 1 94 ºC For 15 seconds 
Step 2 59 ºC For 60 seconds 
Data collection and Real-time analysis enabled 
Cycle 4 1X One step 4 ºC HOLD 
- Copy the data and make a graph. 
Interferon (IFN) Response Assay Methods 
Interferon Expression Assay 
BVDV2-NY93, BVDV2-NY93/c, and BVDV2-NY93/c-EGFP:  
- Dilute viruses and poly I:C in 2%HS/DMEM to a final volume of 1 ml/well. 
- Use 10 wells of three 90% confluent MDBK cell 6-well plates. 
- Infect two wells with 1 ml/well of BVDV2-NY93, BVDV2-NY93/c, or BVDV2-
NY93/c-EGFP, or add 2%HS/DMEM as negative control or poly I:C (100 µg/ml) as 
positive control.  
- Incubate at 37 ºC with occasional rocking for 90 minutes. 
- Add 2 ml 2%HS/DMEM/well. 
- Incubate at 37 ºC with 5% CO2 for 24 hours. 
- Freeze plates at –80 ºC for at least 24 hours. 
- Thaw on ice and place the cell lysate in 15-ml tubes. 
- Centrifuge at 2,000×g for 30 minutes at 4 ºC. 
- Transfer to new 15-ml tubes. 
- Adjust pH to 2 with 2M HCl and test strips. 
- Incubate at 4 ºC for 24 hours to inactive the viruses. 
- Adjust pH to 7 with 2M NaOH and test strips. 
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Testing samples: 
- Use 20 wells of three NCL1-ISRE-Luc-Hygro cell 12-well plates, which are seeded and 
incubated for 12 hours. 
- Replace media of NCL1-ISRE-Luc-Hygro cell wells with 0.5 ml of each sample, using 
two wells for each sample. 
- Incubate at 37 ºC with 5% CO2 for 8 hours. 
- Discard test sample, wash NCL1-ISRE-Luc-Hygro cells twice with 1 ml CMF-PBS. 
- Apply 100 µl of 1X passive lysis buffer, and harvest the cells using scraper. 
- Transfer cell debris and liquid into 1.5-ml tubes, vortex for 15 seconds. 
- Centrifuge at 12,000×g at 4 ºC for 2 minutes. 
- Transfer the supernatant to new 1.5-ml tubes. 
- Store at –80 ºC for at least 24 hours. 
- Perform luciferase assay. 
IFN Standard Curve 
Preparing 1:2 serial dilution of recombinant human IFN standard (Bio-source PHC 
4045): 
- Apply 200 µl of PBS with 0.1% BSA to 12 tubes (–1 to –12 tubes). 
- Mix 5.4 µl of recombinant human IFN standard stock (100 units/µl, total 540 units) 
with 194.6 µl of PBS with 0.1% BSA to have 200 µl, vortex. 
- Mix the 200 µl from last step (540 units) with the 200 µl of –1 tube, vortex, and then 
transfer 200 µl from –1 (270 units) to –2 tubes… until –12 tube. 
- Now each tube has 200 µl. 
- Add 1.8 ml DMEM to each tube to be 2 ml in each tube. 
- Now, every 0.5 ml of –1 tube includes 67.5 units, every 0.5 ml of –2 tube includes 
33.75 units, and every 0.5 ml of –12 tube includes 0.032959 units. 
- Replace media of NCL1-ISRE-Luc-Hygro cell wells with 0.5 ml of each dilution 
sample, using three wells for each dilution sample (total 36 wells). 
- Incubate and harvest just like previously described with other NCL1-ISRE-Luc-Hygro 
cell plates. 
Luciferase Assay 
- Using samples in 1X passive lysis buffer. 
- Use opaque luminometer (dark) 96-well plate. 
Preparing 1:50 serial dilution of Purified Luceferase standard: 
- Apply 98 µl of 1X Reporter Lysis Buffer to 10 tubes (–1 to –10 tubes). 
- Add 2 µl of Purified Luceferase standard to –1 to have 100 µl, vortex. 
- Transfer 2 µl from –1 to –2 tubes until –10 tube. 
- Equilibrate luciferase assay reagent and samples to room temperature. 
- Leave the first two wells of the plate empty, and apply 20 µl/well from each sample 
into two wells. Use three wells for IFN standard curve samples. Use one well for 
Purified Luceferase standard dilution. 
- Use FluoStar Optima luminometer, set to inject 100 µl luciferase assay buffer/well, and 
measure luminescence. 
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Interferon Inhibition Assay of Concurrent Infection 
BVDV2-NY93 with BRSV & BVDV2-NY93/c-EGFP with BRSV:  
- Dilute viruses and poly I:C in 2%HS/DMEM to a final volume of 1 ml/well. 
- Use 14 wells of four 90% confluent BT cell 6-well plates. 
- Infect two wells with 1 ml/well of BRSV, BVDV2-NY93, BVDV2-NY93 with BRSV, 
BVDV2-NY93/c-EGFP, or BVDV2-NY93/c-EGFP with BRSV, or add 2%HS/DMEM 
as negative control or poly I:C (100 µg/ml) as positive control.  
- Incubate at 37 ºC with occasional rocking for 90 minutes. 
- Add 2 ml 2%HS/DMEM/well. 
- Incubate at 37 ºC with 5% CO2 for 48 (or 72) hours. 
- Wash wells with 1 ml DMEM, and replace with 3 ml fresh 2%HS/DMEM/well for one 
well for each, and replace with 3 ml fresh poly I:C in 2%HS/DMEM/well (50 µg/ml) 
for the another well of each. 
- Incubate at 37 ºC with 5% CO2 for 20 hours. 
- Freeze plates at –80 ºC for at least 24 hours. 
- Thaw on ice and place the cell lysate in 15-ml tubes. 
- Centrifuge at 2,000×g for 30 minutes at 4 ºC, transfer to new 15-ml tubes. 
- Adjust pH to 2 with 2M HCl and test strips. 
- Incubate at 4 ºC for 24 hours to inactive the viruses. 
- Adjust pH to 7 with 2M NaOH and test strips. 
- Now, there are 14 different samples. 
Testing samples: 
- Use 28 wells of four NCL1-ISRE-Luc-Hygro cell 12-well plates, which are seeded and 
incubated for 12 hours. 
- Replace media of NCL1-ISRE-Luc-Hygro cell wells with 0.5 ml of each sample, using 
two wells for each sample. 
- Incubate at 37 ºC with 5% CO2 for 8 hours. 
- Discard test sample, wash NCL1-ISRE-Luc-Hygro cells twice with 1 ml CMF-PBS. 
- Apply 100 µl of 1X passive lysis buffer, and harvest the cells using scraper. 
- Transfer cell debris and liquid into 1.5-ml tubes. 
- Vortex for 15 seconds. 
- Centrifuge at 12,000×g at 4 ºC for 2 minutes. 
- Transfer the supernatant to new 1.5-ml tubes. 
- Store at –80 ºC for at least 24 hours. 
- Perform luciferase assay. 
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Cellular Gene mRNA Extraction and Real-time Q-RT-PCR: 
BT cells were infected and harvested. Total RNA was extracted from cell lysates. The 
cellular gene mRNA levels were quantified using real-time Q-RT-PCR. 
Preparing 49 Flasks of BT Cells 
- Using six 150 cm2 flasks of NVSL-BT cells. 
- Wash twice, trypsinize, re-suspend with 500 ml DMEM in one flask. 
- Each flask has about 8 million BT cells. Total about 48 million. 
- Pour 10 ml cells (≈ 1 million cells) into each 75 cm2 flask. 
- Add 15 ml media into each flask. 
- After three days, the confluency became 90% (% confluency = 0.9). 
Viral Inoculation 
- Calculate the amount of virus needed at a m.o.i. of 0.05 using the following formula: 
Cells per well × # of flasks × % confluency × m.o.i. 
                                TCID50 
- Dilute viruses in DMEM to have a final volume of 5 ml/flask. 
- Label flasks for seven time-points. Seven flasks for each time-point.  
- Infect seven flasks with 5 ml/flask of BVDV2-wt, BVDV2-E, BRSV, BRSV and 
BVDV2-wt, or BRSV and BVDV2-E at a m.o.i. of 0.05, stimulated with 5 ml/flask of 
poly I:C (100 µg/ml), or treated with 5 ml/flask of media as UI control. 
- Incubate at 33 ºC for 2 hours. 
- Discard the inoculum and rinse with 10 ml DMEM. 
- Add 25 ml 2%HS/DMEM/flask. 
- Harvest and lyse cells in the seven flasks for the first time-point (2 hour). 
- Incubate other time-point flasks at 33 ºC for 1, 2, 3, 5, 7, or 9 Days. 
- Harvest and lyse cells at other time-point flasks using RLT buffer (Qiagen). 
Harvest (Trypsinize and Collect) Cells 
- Completely discard the medium and wash with 10 ml PBS. 
- Add 5 ml of 0.25% trypsin and remove 4.5 ml of it. 
- After cells detach (5 – 10 minutes), tip the flask 2 – 3 times and add 4 ml DMEM. 
- Transfer the 5 ml cells from each flask into a new 15-ml tube.  
- Centrifuge the 15-ml tubes at 3000×g for 10 minutes and discard the supernatant.  
- Centrifuge at 1000×g for 2 minutes and discard the rest of the supernatant. 
- To disrupt the cells, add 0.75 ml of buffer Plus RLT/15-ml tube, pipet to mix. 
- Homogenize the lysate by passing lysate at least 5 times through a 21-gauge needle (0.8 
mm diameter). Do not reuse needle or syringe.  
- Transfer the 0.75 ml lysate into a new 1.5-ml tube 
- Store lysates at –20 °C. 
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Total RNA Extraction and gDNA Elimination 
Using RNeasy Plus Mini Kit (Cat. # 74134, Qiagen, Valencia, CA, USA). 
This kit includes gDNA Eliminator Mini Spin Columns specially designed to effectively 
remove genomic DNA (gDNA) contamination. 
- Use 2 columns for each sample (total = 14 columns for each time-point). 
- Thaw samples to room temperature. 
- Transfer 0.35 ml of the sample to each of the 2 “gDNA Eliminator Mini Spin Columns” 
(uncolored) placed in 2-ml collection tubes. 
- Centrifuge for 30 seconds at (or more than) 8000×g (10000 rpm), discard the columns.  
- Save the flow-through within the 2-ml tube. This step removes the genomic DNA. 
- Add 0.35 ml of 70% ethanol: mix well by pipetting. Do not centrifuge. 
- Transfer the 0.7 ml (700 µl) to a new “RNeasy Mini Spin Column” (pink) placed in a 2-
ml collection tube, close lid. 
- Centrifuge for 15 seconds at (or more than) 8000×g (10000 rpm). 
- Discard the flow-through and reuse the 2-ml tube. 
- Add 0.7 ml buffer RW1 to the column, close lid. 
- Centrifuge for 15 seconds at (or more than) 8000×g (10000 rpm) to wash the 
membrane. 
- Discard the flow-through and reuse the 2-ml tube. 
- Add 0.5 ml buffer RPE to the column, close lid. 
- Centrifuge for 15 seconds at (or more than) 8000×g (10000 rpm) to wash the membrane 
for the second time. 
- Discard the flow-through and reuse the 2-ml tube. 
- Add 0.5 ml buffer RPE to the column, close lid. 
- Centrifuge for 2 minutes at (or more than) 8000×g (10000 rpm) to wash (third time) 
and dry the membrane. 
- Discard the flow-through and the 2-ml tube. 
- Transfer the column into a new 2-ml tube, close lid. 
- Centrifuge at full speed (17,000×g) for 1 minute to dry column completely.  
- To elute the RNA, place the column in a new 1.5-ml tube, add 50 µl RNase-free water 
directly to the membrane, close lid. 
- Centrifuge for 1 minute at (or more than) 8000×g (10000 rpm). 
- Repeat the last step using another 50 µl RNase-free water. 
- Discard the columns, label the RNA tubes. 
- Mix the total RNAs of the two columns of each sample in one of them to have 200 µl 
RNA sample. 
- Using the Nanodrop, analyze the purified RNA for quantity. 
- Dilute RNA samples to be 20 ng/µl using nuclease-free water. 
- Aliquot the diluted RNAs (20 ng/µl) into labeled ten 0.6-ml tubes. 
- Aliquot 45 μl/tube. 
- Store the RNAs at –80 °C. 
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Common RNA Sample (Inter-Run Calibration) for Real-time Q-RT-PCR 
- BT cells were passed into three 162 cm2 flasks with 10% HS DMEM.  
- Incubate at 37 ºC with 5% CO2. 
- Three days later, the cell monolayer became 100% confluent. 
- Cells were harvested and lysed as described previously. 
- Total RNA was extracted using twelve columns of RNeasy Plus Mini Kit (Cat. # 
74134, Qiagen). 
- Mix the total RNA from the twelve columns of each sample into one of them to have 
1200 µl. 
- Using the Nanodrop, analyze the purified RNA for quantity. 
- Dilute common RNA sample to 40 ng/µl using nuclease-free water. 
- Aliquot the diluted RNA (40 ng/µl) into labeled ten 0.6-ml tubes. 
- Aliquot 100 μl/tube. 
- More than 80 tubes of common RNA sample. 
- Store the RNAs at –80 °C. 
- This common RNA sample needs to be diluted before use to 20 ng/µl by adding 100 µl 
nuclease-free water before using. 
- Used common RNA sample tube should not be used again. Each tube must be 
discarded when it is thawed. 
Determination of the Appropriate Two Reference Genes 
Preparing BRSV samples at two time-points: 
- Two flasks of 75 cm2 of BT cells 90% confluency were used. 
- Cells were infected with BRSV at a m.o.i. of 0.05. 
- Incubate at 33 ºC with 5% CO2 for 2 hours. 
- Discard the inoculum and rinse with 10 ml DMEM. 
- Add 25 ml 2%HS/DMEM/flask. 
- Incubate at 33 ºC with 5% CO2. 
- Cells were harvested and lysed at two time-points: 1 and 5 days. 
- Total RNA was extracted using RNeasy Plus Mini Kit (Cat. # 74134, Qiagen).  
- Using the Nanodrop, analyze the purified RNA for quantity. 
- RNA was diluted to 20 ng/µl using nuclease-free water. 
- Aliquot 280 μl/tube (three tubes). 
- Store RNA at –80 °C. 
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Real-time Q-RT-PCR for determination of the two reference genes: 
Use a prime PCR Custom 96-well plate with 19 genes (Cow B96 reference plate, 20X, 
Bio-Rad, Hercules, CA, USA). This plate includes forward and reverse primes for 19 
cow genes. One half (columns # 1 - 6) of this plate will be used with BRSV sample at one 
day and the other half will be used with BRSV sample at 5 days. 
   Product:  
   Plate Name: 
   Concentration: 
   Purification: 
   Format: 
   Item: 
   Instrument: 
   Quantity: 
PrimePCR Custom Plate 96 Well, 19 genes 
Cow B96 Reference Plate, Cow 
20× 
Desalted 
96-wells × 20µl reactions 
10025217 
CFX96 
3 
 1 2 3 4 5 6 7 8 9 10 11 12 
A ACTB ACTB ACTB RPL13A RPL13A RPL13A ACTB ACTB ACTB RPL13A RPL13A RPL13A 
B AMBP AMBP AMBP RPLPO RPLPO RPLPO AMBP AMBP AMBP RPLPO RPLPO RPLPO 
C G6PD G6PD G6PD RPS18 RPS18 RPS18 G6PD G6PD G6PD RPS18 RPS18 RPS18 
D G3PDH G3PDH G3PDH TBP TBP TBP G3PDH G3PDH G3PDH TBP TBP TBP 
E GUSB GUSB GUSB TFRC TFRC TFRC GUSB GUSB GUSB TFRC TFRC TFRC 
F HMBS HMBS HMBS YWHAZ YWHAZ YWHAZ HMBS HMBS HMBS YWHAZ YWHAZ YWHAZ 
G HPRT1 HPRT1 HPRT1 gDNA RQ1 RQ2 HPRT1 HPRT1 HPRT1 gDNA RQ1 RQ2 
H PGK1 PGK1 PGK1 PCR RT  PGK1 PGK1 PGK1 PCR RT  
Using EXPRESS One-Step SYBR® GreenER™ Kit for one-step qRT-PCR using 
EXPRESS SYBR® GreenER™ qPCR SuperMixes (Cat. # 11784-200, Invitrogen, 
Carlsbad, CA, USA). 
- Prepare the master mix: 
- Apply 20 µl of the (1040 µl) master mixture into each well (48 wells + 4) of each half 
of the 96-well plate. 
- Using C1000 Touch™ Thermal Cycler (Bio-Rad): 
# of reactions Per reaction 52 + 52 = 104 
EXPRESS  SYBR® GreenER™ qPCR SuperMix Universal 10 µl 1040 µl 
EXPRESS SuperScript® Mix for One-Step SYBR® GreenER™ 0.5 µl 52 µl 
RNase-Free Water 4.1 µl 426.4 µl 
ROX Reference Dye (25μM) 0.4 µl 41.6 µl 
 BRSV Samples (Day 1 or 5)  5 µl  
Sub-Total  20 µl 1560 µl 
Mix 780 µl with 260 µl of BRSV samples Day 1. 
Mix 780 µl with 260 µl of BRSV samples Day 5. 
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- The protocol:  
Cycle 1 1X One step 50 ºC For 15 minutes 
Cycle 2 1X One step 95 ºC For 2 minutes 
Cycle 3 40X Step 1 95 ºC For 15 seconds 
Step 2 60 ºC For 60 seconds 
+ Plate Read 
Cycle 4 1X One step 4 ºC HOLD 
- Copy the data and determine reference genes. 
- Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and bovine ribosomal protein 
S18 (RPS18) were chosen as endogenous controls to normalize all gene expression 
results. 
Real-time Q-RT-PCR of Cellular Signals 
The cellular genes (MAVS, PKR, TBK-1, NF-κB, IRF-3, IRF-7, IFN-β, and PIN-1) were 
detected using commercially available primer and probe sets specific for bovine genes 
(TaqMan Gene Expression Assays, Applied Biosystems, Foster City, CA, USA). Three 
wells were used for each sample. Therefore, two plates (plate 1 and 2) were used for each 
gene. 
Step 1: designing the Real-time Q-RT-PCR plates: 
- Plate # 1: See table 2. 
- Plate # 2: See table 3. 
- One well was used with water instead of RNA sample as negative control.  
- One well was used for common RNA sample with the gene of the plate as positive 
control.  
- Two wells were used with common RNA sample and the gene of the plate, but without 
reverse transcriptase (No-RT) as negative control.  
- The reading of No-RT wells should be at least 35 cycles or no reading, indicating no 
detection of gDNA contamination. 
- Three wells were used as inter-run calibration, using the common RNA sample with 
GAPDH on every single plate for all signals. Wells are H5, H6, and H7. 
- Five wells were used for standard curve using dilution (0 to dilution – 4) of common 
RNA sample with GAPDH on every single plate for all signals. Wells are H8, H9, H10, 
H11, and H12. 
- For other genes, use primers and probes of the gene instead of GAPDH in all wells 
except wells on row # H from column 5 to 12. 
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Step 2: The protocol: 
Cycle 1 1X One step 50 ºC For 15 minutes 
Cycle 2 1X One step 95 ºC For 2 minutes 
Cycle 3 40X Step 1 95 ºC For 15 seconds 
Step 2 60 ºC For 60 seconds 
+ Plate Read 
Cycle 4 1X One step 4 ºC HOLD 
Step 3: Mix the master mixtures: 
- Using 0.4 μl ROX/reaction: 
- The plate should be kept in the ice box → cover the plate. 
- Add 5 µl from each sample into its labeled three wells. 
- Cover the plate. Take it to the real-time qRT-PCR machine. 
- Leave the cover on the plate in the machine. 
Step 4: result calculation: 
The ∆Cq value was calculated by normalizing each sample to the average of GAPDH and 
RPS18 using the equation ∆Cq = Cq (target gene) – Cq ((GAPDH + RPS18) / 2). Then, 
∆∆Cq was calculated by subtracting the ∆Cq of the control (UI at 2 HPI) sample from the 
∆Cq of each experimental and control sample using the equation ∆∆Cq = ∆Cq (a 
normalized sample) – ∆Cq (the control sample). Lastly, the relative values to the control 
sample were calculated by using the formula 2–(∆∆Cq), where the control sample = 2–(0) = 
20 = 1.  
# of reactions Per reaction 190 reactions 
EXPRESS SuperScript® qPCR SuperMix Universal 10 µl 1900 µl  
EXPRESS SuperScript® Mix for one-Step qPCR (RT)   
RNase-Free Water 1.6 µl 304 µl 
ROX Reference Dye (25μM) 0.4 µl 76 µl 
 GAPDH Primers and Probe (TaqMan® Gene Expression Assays)  1 µl 190 µl 
Sub-Total  13 µl 2470 µl 
In 0.5-ml tube, mix 65 µl (for 5 wells) of the master mixtures with 10 µl water = 75 µl 
→ two No-RT reactions (Wells # 3-H and 4-H) for each plate. 
The rest will be enough for about 180 wells (2340 µl). 
# of reactions Per reaction 180 reactions 
Master mixtures 13 µl 2340 µl 
EXPRESS SuperScript® Mix for one-Step qPCR (RT) 2 µl 360 µl 
Total  15 µl 2700 µl 
Apply 15 µl of the master mixture into labeled wells on the two 96-well plates. 
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Genomic DNA Extraction from BT Cells 
Using DNeasy Blood & Tissue Kit, (Cat. # 69504, QIAGEN). 
Step 1: Preparing the BT cells 
- Use a 75 cm2 flask of NVSL-BT cells. 
- Wash twice with 12 ml of PBS. 
- Use 5 ml trypsin and remove it. 
- Incubate for 5 – 8 minutes in the 37 °C incubator. 
- Re-suspend cells with 2.6 ml PBS and transfer 1.3 ml (~ 2 million) cells to tube # 1. 
- Add new 1.3 ml PBS to the flask, mix. 
- Transfer 1.3 ml (~ 1 million) cells to tube # 2. 
- Add new 1.3 ml PBS to the flask, mix. 
- Transfer 1.3 ml (~ 0.5 million) cells to tube # 3. 
- At room temperature, centrifuge the three tubes at 2,000 rpm for 5 minutes to make cell 
pellets. 
Step 2: Preparing the mixtures 
- Remove the supernatant. Re-suspend the cell pellets with 200 µl PBS. 
- Add 20 µl of proteinase K. 
- Add 200 µl of Buffer AL. 
- Mix thoroughly by vortexing for 5 seconds. 
- Incubate in 56 °C water bath for 10 minutes. 
- Then, add 200 µl of absolute ethanol (99%). 
- Mix thoroughly by vortexing for 5 seconds. 
Step 3: Extract the genomic DNA 
- Use three columns of kit # 69504 (QIAGEN) and label them as # 1 – 3. 
- Transfer the mixtures (620 µl) to the columns. 
- Centrifuge the three columns at 8,000 rpm for 1 minute. 
- Discard the flow-through and collection tubes. 
- Transfer the columns to new 2-ml tubes. 
- Add 500 µl Buffer AW1. 
- Centrifuge the three columns at 8,000 rpm for 1 minute. 
- Discard the flow-through and collection tubes. 
- Transfer the columns to new 2-ml tubes. 
- Add 500 µl Buffer AW2. 
- Centrifuge the three columns at 14,000 rpm for 3 minutes. 
- Discard the flow-through and collection tubes. 
- Transfer the columns to new 1.5-ml tubes. 
- Add 100 (not 200) µl Buffer AE. 
- Incubate for 1 minute. 
- Centrifuge the three columns at 8,000 rpm for 1 minute. 
- Close the 1.5-ml tubes (A set) which include the eluate DNA (high concentration of 
DNA). Label the three tubes. 
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- Transfer the columns to new 1.5-ml tubes. 
- Add 100 (not 200) µl Buffer AE. 
- Incubate for 1 minute. 
- Centrifuge the three columns at 8,000 rpm for 1 minute. 
- Close the 1.5-ml tubes (B set) which include the eluate DNA (low concentration of 
DNA). Label the three tubes. 
Step 4: Measuring the quantity 
- Using the Nanodrop, analyze the genomic DNA for quantity. 
- Use the sample type: “DNA-50”. 
- Use B set tubes to dilute the DNA in A set tubes to prepare tubes with 100 ng/µl DNA. 
- Store at –20 °C. 
- Genomic DNA was sent to the “Active Motif” company to make plasmids, including: 
IRF-3, IRF-7, PKR, TBK1, and ACTB. 
Plasmid Clones 
Plasmids for different genes were received from different labs and companies. Plasmids 
were amplified in E. coli DH5α in our lab to make a stock for each plasmid. 
NF-kB plasmid: pGL4.32[luc2P/NF-κB-RE/Hygro] Vector (Promega, Cat. # E8491). 
 
Using Escherichia coli (DH5α) bacteria (Invitrogen, Cat. # 18265-017, store at –80 °C).  
Day 1. 
- Thaw the bacteria on ice. Do not touch the bottom of the bacteria tube.  
- Leave the bacteria on ice for 10 – 15 minutes to thaw. 
- Put a new 15-ml tube on ice. 
- The plasmid concentration should not be more than 50 ng within 1 – 5 µl. 
- Dilute the plasmid to 20 ng/µl. 
- Transfer 60 µl of bacteria to the 15-ml tube. 
- Add 2.5 µl (50 ng) plasmid and gently mix one time. 
- Incubate the bacteria on ice for 30 minutes. 
- Re-freeze the unused bacteria using dry ice with 70% ethanol. Store at –80 °C. 
- Heat shock: at 42 °C for 30 – 40 seconds. 
- This “heat shock” will increase the diameter of the pores to allow the plasmids to go 
inside the bacteria. 
- Then incubate the bacteria on ice for 2 minutes to close the pores. 
- Add 940 µl of LB broth (with no ampicillin). 
- Do not tighten the lid of the 15-ml tube to allow air exchange. You can replace the lid 
with foil. 
- Incubate the tube at 37 °C with shaking at 225 RPM for one hour in a shaking 
incubator. 
- After the one-hour incubation, the LB broth should change from very clear to slightly 
cloudy (turbid).  
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- After this point, do not put the bacteria on ice. 
- Incubate six LB plates with Ampicillin (an antibiotic) for an hour at 37 °C. 
- Use two plates with 30 µl of bacteria per plate, two plates with 50 µl, and two plates 
with 100 µl. 
- Mix 60 µl of bacteria with 140 µl new LB broth for the 30 µl of bacteria plates. 
- Mix 100 µl of bacteria with 100 µl new LB broth for the 50 µl of bacteria plates. 
- Incubate them at 37 °C for 10 minutes upside up, then for 14 hours (overnight) upside 
down with or without CO2. 
- Store the rest of the 1 ml bacteria at 4 °C for one week. 
Day 2. After 14 hours 
- Mix 10 ml LB broth with 100 µl Ampicillin (10µg/µl). [Final: 100 µg/ml]. 
- Aliquot it into four 12-ml tubes (2.5 ml/tube).  
- Take (pick) one colony using a pipette tip, and put the tip inside the tube with broth. 
- The best colony is a large one and separated from other colonies. 
- Note: small colonies may not have the plasmid. 
- Incubate the tube at 37 °C with shaking at 260 – 300 RPM for 7 – 8 hours in a shaking 
incubator. 
- After 7 – 8 hours: 
- Mix 56 ml LB broth with 560 µl Ampicillin (10 µg/µl).  
- Aliquot it into four 125-ml flasks (14 ml/flask).  
- Add 28 µl bacteria from one 12-ml tube into one flask. Use one flask with each tube 
(dilution 1:500). 
- Incubate the flasks at 37 °C with shaking at 260 – 300 RPM for 18 hour (overnight) in a 
shaking incubator. 
Day 3. After 18 hours 
Use the Wizard Plus Minipreps DNA Purification System (Promega, Cat. # A7100). 
- Transfer the 14 ml of each flask into 15-ml tube on ice. 
- Centrifuge the four 15-ml tube at 3000 RPM for 15 minutes at 4 °C. 
- Pour off the supernatant (media) completely or use vacuum. 
-  Resuspend the cell pellet in 400 μl of cell resuspension solution.  
- Transfer the resuspended cells to a 1.5-ml tube. 
- Add 400 μl of cell lysis solution and mix well by inverting the tube several times.  
- Incubate for 3 – 5 minutes for efficient lysis. 
- Add 400 μl of neutralization solution and mix by inverting the tube several times. 
- Centrifuge the lysate at 10,000×g for 6 minutes. 
- Using a laboratory vacuum manifold, prepare four Wizard® Miniprep Columns (syringe 
barrels with minicolumns). 
- Pipet 1 ml of the resuspended resin into each barrel with minicolumn. 
- Transfer all of the cleared lysate from 1.5-ml tubes to the miniprep column. 
- Apply the vacuum. 
- Add 2 ml of the Column Wash Solution (with ethanol). 
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- Apply the vacuum. 
- Dry the resin by continuing to draw a vacuum for 30 seconds, but not longer. 
- Discard the syringe and transfer the minicolumns to new 1.5-ml tubes. 
- Centrifuge the minicolumn at 10,000×g for 2 minutes to remove any residual column 
wash solution. 
- Transfer the minicolumns to new 1.5-ml tubes. 
- Add 50 μl of nuclease-free water to each minicolumn and wait for 1 minute. 
- Centrifuge the tubes (with minicolumns) at 10,000×g for 20 seconds to elute the 
plasmids. 
- Discard the minicolumns. 
- Using the Nanodrop, analyze the plasmid (DNA) for quantity. 
- Label the tubes and store at –20 °C. 
Western Blotting 
Cell Harvesting from 75 cm2 Flasks 
- Completely discard media. 
- Wash once with 10 ml PBS. 
- Add 5 ml of 0.25% trypsin and remove 4 ml of it. 
- (Optional) you can incubate at 37 °C. 
- After cells detach (5 – 10 minutes) add 9 ml media (2% HS). 
- Transfer 5 ml/tube into two 15-ml tubes on ice.  
- Centrifuge the tubes at 2000 rpm (1900×g) 4 °C for 5 minutes. 
- Completely discard the supernatant. 
- Prepare RIPA with 1% Halt protease inhibitors. 
- Homogenize samples for 5 seconds. Clean between samples with 70% alcohol swab. 
- Transfer the samples into 1.5-ml tubes and label them. 
- Store for at least 15 minutes to break bubbles at –80 °C or until they are needed. 
- Take proteins (samples) out of the freezer on ice to thaw. 
- Centrifuge the protein at 10,000 rpm (9,500×g) 4 °C for 5 minutes. 
- Place on ice. 
Protein Quantification 
- In a 15-ml tube, prepare 50:1 ratio reagent A&B from BCA Pierce Kit (Pierce® BCA 
Protein Assay Kit (Prod # 23225, Lot # NC171236, Thermo scientific). 
- Pour 200 µl of reagent mixture in each well of the 26 wells of a 96-well plate. 
- Load 2 µl of each sample and standard (Albumin) into each well. 
- Tap the plates gently to mix. 
- Incubate at 37 °C for 20 minutes in dry or humid incubator with gentle shaking. 
- Read the protein concentrations on the plate reader. 
4x NUPAGE (LDS Sample buffer (4X), 10 ml, Cat. # NP0007): 
Using DTT: DL-1,4-Dithiothiothreitol, for molecular biology, 1M solution in water 
(code: 426380100, 10 ml, Acros Organics). 
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- Mix 3 volume of sample + 1 volume of NUPAGE + 1x of DTT (20x). 
- Pour 85 µl of sample into 1.5-ml tube. 
- Add 34.3 µl of the mixture [85 + 34.3 = 119.3 µl]. 
- Discard the Debris (cell membranes). 
- Vortex and spin for 1 second. 
- Incubate samples at 70 °C for 10 minutes to denaturing proteins. 
- Place samples on ice immediately for 10 – 20 minutes. 
- Store at –80 °C for years. 
Preparing the Western Gels 
Using Pierce® ECL Western Blotting Substrate (Prod # 32106, Lot # OC182119, Thermo 
scientific). 
- Use clean and dry glass plates (spacer plate and short plate). Place them in the clamp 
and then on the casting stander with gasket. 
- Fill with ultrapure water (upH2O) to make sure that there is no leaking. 
- Discard the water. 
- Dry plates by using filter paper. 
- Mark a line 2 cm from the top of the short plate. 
- Prepare the gel (8%). 
- Pour the gel until the line. 
- Add isopropanol on the gel to make the top of the gel equal. 
- Allow to solidify for 20 – 30 minutes. 
- Use filter paper to remove isopropanol. 
- Pour the stacking gel. 
- Insert a 10-well comb. 
- Allow to solidify for 20 – 30 minutes. 
- Remove the comb. 
- Incubate the protein sample on ice for 30 minutes.  
- Centrifuge the samples at 10,000 rpm at 4 °C for 5 minutes, then on ice. 
When the gel is solidified: 
- Put the solidified gel within the two glass plates on the “electrode assembly.” Then in 
the Mini tank. 
- Fill the tank with 1X running buffer with sodium bisulfite as antioxidant (5 mM final). 
- Wash wells with the running buffer to make sure they are clean. 
- Load 10 µl ladder in the first well, samples in their wells, and RIPA in the empty wells. 
Use the same amount of samples (proteins). 
- Cover the Mini tank with the lid. 
- Contact to the electrophoresis device. 
- Start with 80 volts (Amps max). 
- Once the samples reach the line between the upper and lower gels, and they are 
migrating in an even, well defined, and compact band, you can increase the voltage to 
100 and then to 120 volts. 
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Transferring the Proteins from the Gel to the Membrane (Wet Transfer) 
- Cut PVDF membrane (6×9 cm) and label. 
- Treat it with methanol for 1 – 10 minutes (recycle methanol for 
one month only). 
- Use a small tray with some of 1X Transfer buffer. 
- Place one filter paper.  
- Place the membrane onto the filter paper. 
- Discard the well section of the gel (stacking gel). 
- Remove the gel from the glass onto the membrane. 
- Remove the air bubbles from between the gel and the membrane.  
- Place another filter paper onto the gel. 
- Incubate at room temperature for 5 minutes. 
- Assemble the sandwiches and place it into the tank. 
- Fill the tank with transfer buffer,  
- Add the ice box. 
- Incubate them in for 10 – 20 minutes. 
- Transfer with stirring. 
- Use 63 volts for 2 hours at room temperature or 22 volts overnight in cool room. 
- The gel sandwich (wet transfer) order (look at the table): 
    -Black ← black - sponge - filter- Gel - membrane - filter - sponge - Clear → Red+ 
Membrane Incubation with Antibodies 
1. Block the membrane: 
The membrane needs to be blocked before adding the antibodies. Use the same solution 
recommended by the primary antibody datasheet. 
- Wash membrane three times for 5 minutes/each with TBS-T. 
-  In plastic bag, put 5 ml of blocking solution and the membrane. 
- Put the bag on rocker for 2 hours. Or overnight in cool room. 
- Wash three times for 5 minutes/each with TBS-T. 
- Wash the bag with upH2O. 
2. Incubation with the primary antibody: 
Use primary antibody (e.g. β-Actin, # 4967S, from Cell Signaling). 
- Use 5% BSA in TBS-T. 
- Use 1:1000 dilution = 10 µl antibody with 10 ml 5% BSA in TBS-T solution. 
- Using the same plastic bag, add diluted antibody and the membrane. 
- Put the bag on rocker overnight in cool room. 
- Then, wash three times for 5 minutes/each with TBS-T. 
- Wash the bag with upH2O. 
– 
Black 
sponge 
filter paper 
gel 
PVDF membrane 
filter paper 
sponge 
Clear 
+ 
155 
 
3. Incubation with the secondary antibody: 
Use secondary antibody (e.g. β-Actin, cat. # 7074S, from Cell Signaling). 
- Use 5% BSA in TBS-T. 
- Use 1:2400 dilution = 5 µl antibody with 12 ml 5% BSA in TBS-T solution. 
- Using the same plastic bag, add 6 ml of diluted antibody and the membrane. 
- Put the bag on rocker for 2 hours at room temperature. 
- Then, wash three times for 5 minutes/each with TBS-T. 
- Wash the bag with upH2O. 
Developing the Membrane 
Use Pierce ECL Western Blotting Substrate (Prod # 32106, Lot # OC182119, Thermo 
scientific). 
- Just before leaving to the scanning machine (VersaDoc), Mix 0.5 ml of reagent # 1 with 
0.5 ml of reagent # 2. 
- Take the membranes in the washing buffer to the scanning machine. 
- Take the first membrane out of the washing buffer and transfer to an empty tray. 
- Apply the developing solution to the membrane at least 5 times and then transfer the 
solution back to its tube. 
- Put the developed membrane in the scanning machine (VersaDoc). 
- To check that the membrane is in the right place, click on “Preview”. 
- Change the time: 10, 20, 30, 40, 50, 60, 70, 80 seconds. 
- Click on “Acquire”, name the file, and wait. 
- When you see the image, click on “file”, then Transfer to your file. 
- In the end, use your flash memory (USP) to transfer your result to your computer. 
Image J 
Use the Image J program to calculate the density of the bands: 
- Open the program. 
- File → Open → then, open you file. 
- Choose your first band and locate it. 
- Label the first band as # 1 by clicking “analyze” then “Gels” then “Select First Lane”. 
- Use the arrows to locate the second band. 
- Label the second band as # 2 by clicking “analyze” then “Gels” then “Select Next 
Lane”. 
- Use the arrows to locate the third band. 
- Label the third band as # 3 by clicking “analyze” then “Gels” then “Select Next Lane”. 
- When you end, click “analyze” then “Gels” then “Plot Lanes”. 
- Make lines between the background and the rest. 
- Use the ‘Wand Tool” to calculate the bands. 
- Transfer the results to Excel and make your figure. 
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